Bon Natural Life Limited (BON) F-119 Nov 242024 FY Registration statement (foreign)Financial data

Company Profile

Cover

Cover	12 Months Ended
Cover	Sep. 30, 2023
Entity Addresses [Line Items]
Document Type	F-1
Amendment Flag	false
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2024
Entity Registrant Name	Bon Natural Life Limited
Entity Central Index Key	0001816815
Entity Incorporation, State or Country Code	E9
Entity Address, Address Line One	C601, Gazelle Valley
Entity Address, Address Line Two	No.69 Jinye Road
Entity Address, Address Line Three	Xi’an Hi-tech Zone
Entity Address, City or Town	Xi’an
Entity Address, Country	CN
City Area Code	+ 0086
Local Phone Number	29-88346301
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Business Contact [Member]
Entity Addresses [Line Items]
Entity Address, Address Line One	500 Fifth Ave
Entity Address, Address Line Two	Suite 938
Entity Address, City or Town	New York
Entity Address, Postal Zip Code	10110
City Area Code	(646)
Local Phone Number	861-7891
Contact Personnel Name	The Crone Law Group P.C.

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)		Sep. 30, 2023		Sep. 30, 2022
CURRENT ASSETS
Cash		$ 112,751		$ 840,861
Short-term investments		65
Accounts receivable, net		4,602,466		6,784,307
Inventories, net		987,287		1,722,120
Advance to suppliers, net		15,117,191		4,091,990
Acquisition deposit		1,000,000		1,000,000
Prepaid expenses and other current assets		2,355,293		277,509
TOTAL CURRENT ASSETS		24,183,464		14,716,787
Property, plant and equipment, net		21,064,043		21,624,437
Intangible assets, net		995,227		366,167
Right-of-use lease assets, net		312,067		546,690
Deferred tax assets, net		1,335		2,768
TOTAL ASSETS		46,556,136		37,256,849
CURRENT LIABILITIES
Short-term loans		2,509,890		2,424,587
Current portion of long-term loans		419,610		2,135,979
Accounts payable		1,404,937		214,585
Due to related parties		83,380
Taxes payable		2,718,687		1,239,708
Deferred revenue		106,514		188,745
Accrued expenses and other current liabilities		2,140,900		114,431
Finance lease liabilities, current				26,285
Operating lease liability, current		227,297		230,182
TOTAL CURRENT LIABILITIES		9,611,215		6,647,338
Long-term loans		871,368		189,813
Finance lease liabilities, noncurrent
Operating lease liability, noncurrent		91,720		327,202
TOTAL LIABILITIES		10,574,303		7,164,353
COMMITMENTS AND CONTINGENCIES
EQUITY
Ordinary shares, ($0.001 par value, 270,000,000 shares authorized, 1,173,867 and 839,623 shares issued and outstanding as of September 30, 2023 and 2022, respectively)	[2]	1,174	[1]	840
Additional paid in capital		18,088,056		15,711,450
Statutory reserve		2,372,871		1,804,116
Retained earnings		18,703,996		14,676,769
Accumulated other comprehensive income		(3,681,445)		(2,631,171)
TOTAL BON NATURAL LIFE LIMITED SHAREHOLDERS’ EQUITY		35,484,652		29,562,004
Non-controlling interest		497,181		530,492
TOTAL SHAREHOLDERS’ EQUITY		35,981,833		30,092,496
TOTAL LIABILITIES AND EQUITY		46,556,136		37,256,849
Related Party [Member]
CURRENT ASSETS
Accounts receivable, net		3,500,000
Due from related parties		8,411
CURRENT LIABILITIES
Due to related parties		$ 83,380		$ 72,836

[1]Retroactively restated to reflect the Company’s 1-for-10 1-for-10

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Apr. 11, 2024	Mar. 09, 2024	Jun. 17, 2020	Mar. 31, 2024	Sep. 30, 2023	Jan. 17, 2023	Sep. 30, 2022	Jun. 24, 2020	Dec. 11, 2019
Statement of Financial Position [Abstract]
Ordinary shares, par value		$ 0.001			$ 0.001		$ 0.001		$ 0.0001
Ordinary shares, shares authorized		270,000,000			270,000,000		270,000,000		500,000,000
Ordinary shares, shares issued			1,550,000		1,173,867	275,000	839,623	516,667
Ordinary shares, shares outstanding				1,413,867	1,173,867	275,000	839,623	516,667
Reverse stock split, description	1-for-10	1-for10	1-for-3 shares

Consolidated Statements of Inco

Consolidated Statements of Income and Comprehensive (Loss) Income - USD ($)	6 Months Ended				12 Months Ended
	Mar. 31, 2024		Mar. 31, 2023		Sep. 30, 2023		Sep. 30, 2022		Sep. 30, 2021
Income Statement [Abstract]
REVENUE	$ 10,183,553		$ 14,149,967		$ 29,522,353		$ 29,908,561		$ 25,494,564
COST OF REVENUE	(7,215,116)		(9,432,619)		(20,682,326)		(20,484,996)		(18,382,637)
GROSS PROFIT	2,968,437		4,717,348		8,840,027		9,423,565		7,111,927
OPERATING EXPENSES
Selling expenses	(103,096)		(136,164)		(293,719)		(218,822)		(138,530)
General and administrative expenses	(1,890,452)		(1,465,955)		(2,329,198)		(2,239,967)		(1,323,726)
Research and development expenses	(890,384)		(129,995)		(298,469)		(424,558)		(249,050)
Total operating expenses	(2,883,932)		(1,732,114)		(2,921,386)		(2,883,347)		(1,711,306)
INCOME FROM OPERATIONS	84,505		2,985,234		5,918,641		6,540,218		5,400,621
OTHER INCOME (EXPENSES)
Interest income	161		8,732		9,419		1,392		3,207
Interest expense	(143,747)		(178,557)		(238,224)		(446,884)		(417,266)
Unrealized foreign transaction exchange gain (loss)	(2,747)		8,452		35,008		18,831		(45,124)
Government subsidies	61,081		11,916		25,415		1,306,627		449,972
Income from short-term investments							20,343		565
Other income	49,683		(223,044)		(195,279)		68,922		38,409
Total other income (expenses) , net	(35,569)		(372,501)		(363,661)		969,231		29,763
INCOME BEFORE INCOME TAX PROVISION	48,936		2,612,733		5,554,980		7,509,449		5,430,384
INCOME TAX PROVISION	(90,734)		(510,077)		(1,002,298)		(1,267,025)		(820,931)
NET INCOME	(41,798)		2,102,656		4,552,682		6,242,424		4,609,453
Less: net income (loss) attributable to non-controlling interest	(31,279)		(17,104)		(43,300)		4,936		18,650
NET INCOME ATTRIBUTABLE TO BON NATURAL LIFE LIMITED	(10,519)		2,119,760		4,595,982		6,237,488		4,590,803
OTHER COMPREHENSIVE INCOME (LOSS)
Total foreign currency translation adjustment	367,971		1,071,621		(1,040,285)		(2,855,701)		612,806
TOTAL COMPREHENSIVE INCOME	326,173		3,174,277		3,512,397		3,386,723		5,222,259
Less: foreign currency translation adjustment attributable to non-controlling interest	126,222		(17,104)		9,989		(2,309)		2,483
COMPREHENSIVE INCOME ATTRIBUTABLE TO BON NATURAL LIFE LIMITED	$ 199,951		$ 3,191,381		$ 3,502,408		$ 3,389,032		$ 5,219,776
EARNINGS PER SHARE
Basic	$ (0.03)	[1]	$ 2.36	[1]	$ 5.03	[2],[3]	$ 7.47	[2],[3]	$ 6.94	[2],[3]
Diluted	$ (0.03)	[1]	$ 2.34	[1]	$ 5	[2],[3]	$ 7.43	[2],[3]	$ 6.85	[2],[3]
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING
Basic	1,285,702	[1]	891,831	[1]	913,960	[2],[3]	836,077	[2],[3]	661,583	[2],[3]
Diluted	1,285,702	[1]	897,924	[1]	919,811	[2],[3]	839,606	[2],[3]	670,624	[2],[3]

[1]Retroactively restated to reflect the Company’s 1-for-10 1-for-10 1-for-10

Consolidated Statements of In_2

Consolidated Statements of Income and Comprehensive (Loss) Income (Parenthetical)	Apr. 11, 2024	Mar. 09, 2024	Jun. 17, 2020
Income Statement [Abstract]
Reverse stock split, description	1-for-10	1-for10	1-for-3 shares

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity - USD ($)		Common Stock [Member]		Additional Paid-in Capital [Member]	Statutory Reserve [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total Shareholders Equity [Member]	Noncontrolling Interest [Member]	Total
Balance at Sep. 30, 2020		$ 580		$ 5,251,205	$ 579,922	$ 5,072,672	$ (388,102)	$ 10,516,277	$ 506,732	$ 11,023,009
Balance, shares at Sep. 30, 2020	[1]	580,000
Issuance of ordinary shares in initial public offerings, net		$ 253		9,822,097				9,822,350		9,822,350
Issuance of ordinary shares in initial public offerings, net, shares	[1]	253,000
Amortization of share-based compensation				422,221				422,221		422,221
Amortization of stock options				44,910				44,910		44,910
Appropriation to statutory reserve					470,799	(470,799)
Net income (loss)						4,590,803		4,590,803	18,650	4,609,453
Foreign currency translation adjustment							610,323	610,323	2,483	612,806
Balance at Sep. 30, 2021		$ 833		15,540,433	1,050,721	9,192,676	222,221	26,006,884	527,865	26,534,749
Balance, shares at Sep. 30, 2021	[1]	833,000
Amortization of share-based compensation				170,883				170,883		170,883
Appropriation to statutory reserve					753,395	(753,395)
Net income (loss)						6,237,488		6,237,488	4,936	6,242,424
Foreign currency translation adjustment							(2,853,392)	(2,853,392)	(2,309)	(2,855,701)
Non-cash exercise of warrants		$ 6		(6)
Non cash exercise of warrants, shares	[1]	5,223
Exercise of stock options		$ 1		140				141		$ 141
Exercise of stock options, shares		1,400	[1]							1,400	[2]
Balance at Sep. 30, 2022		$ 840		15,711,450	1,804,116	14,676,769	(2,631,171)	29,562,004	530,492	$ 30,092,496
Balance, shares at Sep. 30, 2022	[1],[3]	839,623
Net income (loss)						2,119,760		2,119,760	(17,104)	2,102,656
Foreign currency translation adjustment							1,071,621	1,071,621		1,071,621
Issuance of ordinary shares in a private placement, net		$ 275		2,199,725				2,200,000		2,220,000
Issuance of ordinary shares in a private placement, shares	[3]	275,000
Balance at Mar. 31, 2023		$ 1,115		17,946,175	1,804,116	16,796,529	(1,559,550)	34,988,384	513,387	35,501,771
Balance, shares at Mar. 31, 2023	[3]	1,114,623
Balance at Sep. 30, 2022		$ 840		15,711,450	1,804,116	14,676,769	(2,631,171)	29,562,004	530,492	30,092,496
Balance, shares at Sep. 30, 2022	[1],[3]	839,623
Amortization of share-based compensation				131,092				131,092		131,092
Appropriation to statutory reserve					568,755	(568,755)
Net income (loss)						4,595,982		4,595,982	(43,300)	4,552,682
Foreign currency translation adjustment							(1,050,274)	(1,050,274)	9,989	(1,040,285)
Exercise of stock options		$ 2		(2)
Exercise of stock options, shares		2,244	[1]							2,244	[2]
Issuance of ordinary shares in a private placement, net		$ 275		2,027,269				2,027,544		$ 2,027,574
Issuance of ordinary shares in a private placement, shares	[1]	275,000
Issuance of ordinary shares for services		$ 57		218,247				218,304		218,304
Issuance of ordinary shares for services, shares	[1]	57,000
Balance at Sep. 30, 2023		$ 1,174		18,088,056	2,372,871	18,703,996	(3,681,445)	35,484,652	497,181	35,981,833
Balance, shares at Sep. 30, 2023	[1],[3]	1,173,867
Net income (loss)						(10,519)		(10,519)	(31,279)	(41,798)
Foreign currency translation adjustment							210,470	210,470	157,501	367,971
Balance at Mar. 31, 2024		$ 1,414		$ 19,097,652	$ 2,372,871	$ 18,693,477	$ (3,470,975)	$ 36,694,439	$ 623,403	$ 37,317,842
Balance, shares at Mar. 31, 2024	[3]	1,413,867

[1]Retroactively restated to reflect the Company’s 1-for-10 1-for-10

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Shareholders' Equity (Parenthetical)	Apr. 11, 2024	Mar. 09, 2024	Jun. 17, 2020
Statement of Stockholders' Equity [Abstract]
Reverse stock split, description	1-for-10	1-for10	1-for-3 shares

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities
Net income	$ 4,552,682	$ 6,242,424	$ 4,609,453
Adjustments to reconcile net income to cash provided (used in) by operating activities
Allowance for doubtful accounts		116	2,948
Depreciation and amortization	954,517	218,526	228,547
Inventory reserve recovery	(5,812)	(138,354)	(312,532)
Deferred income tax	1,411	19,012	29,109
Amortization of operating lease right-of-use assets	228,552	150,978	58,147
Amortization of stock-based compensation	131,092	170,883	44,910
Issuance of ordinary shares for services	218,304
Unrealized foreign currency exchange loss (gain)	(35,008)	(18,831)	45,124
Gain on disposal of property and equipment		(725)
Changes in operating assets and liabilities:
Accounts receivable	2,081,376	(1,300,942)	(89,543)
Inventories	721,371	(157,709)	(209,011)
Advance to suppliers, net	(11,510,450)	(407,022)	(399,262)
Prepaid expenses and other current assets	(2,170,541)	(265,446)	2,642
Accounts payable	833,547	(141,927)	(969,414)
Operating lease liabilities	(232,147)	(147,812)	(49,648)
Taxes payable	1,561,946	(3,632,922)	410,716
Deferred revenue	(80,176)	(875,295)	684,030
Accrued expenses and other current liabilities	2,097,424	97,925	(33,092)
Net cash (used in) provided by operating activities	(651,912)	(187,121)	4,053,124
Cash flows from investing activities
Purchase of short-term investments	(67)	(5,097,816)	(2,159,920)
Proceeds upon redemption of short-term investments		6,776,385	470,082
Purchase of property and equipment	(61,906)	(27,695)	(51,878)
Proceeds from sales of property and equipment		1,613
Capital expenditures on construction-in-progress	(460,125)	(4,708,138)	(4,432,941)
Purchase of intangible assets	(669,190)		(269,088)
Proceeds of borrowings to related parties	5,623
Payment of acquisition deposit			(1,000,000)
Net cash used in investing activities	(1,185,665)	(3,055,651)	(7,443,745)
Cash flows from financing activities
Net proceeds from issuance of ordinary shares	2,027,544		11,271,480
Proceeds from exercise of stock options		140
Proceeds from short-term loans	2,879,809	2,631,890	1,257,225
Proceeds from long-term loans	1,132,803	578,343	1,245,871
Repayment of short-term loans	(2,728,836)	(40,780)	(2,563,433)
Repayment of long-term loans	(2,143,046)	(637,147)	(2,522,101)
(Repayment of) proceeds from borrowings from related parties	13,482	(96,969)	(2,262,378)
(Repayment of) proceeds from third party loans			(721,484)
(Repayment of) principal from finance lease	(26,509)	(173,961)	169,153
Payment for deferred initial public offering costs			(521,651)
Net cash provided by financing activities	1,155,247	2,261,516	5,352,682
Effect of changes of foreign exchange rates on cash	(45,780)	(81,750)	(111,300)
Net (decrease) increase in cash	(728,110)	(1,063,006)	1,850,761
Cash, beginning of year	840,861	1,903,867	53,106
Cash, end of year	112,751	840,861	1,903,867
Supplemental disclosure of cash flow information
Cash paid for interest expense	238,224	446,884	417,266
Cash paid for income tax	478,683	2,290,393	2,411
Supplemental disclosure of non-cash investing and financing activities
Amortization of share-based compensation for initial public offering services			422,221
Exercise of options	2
Right-of-use assets obtained in exchange for operating lease obligations		546,323	257,564
Unpaid purchase of property and equipment	$ 403,318

ORGANIZATION AND BUSINESS DESCR

ORGANIZATION AND BUSINESS DESCRIPTION	12 Months Ended
ORGANIZATION AND BUSINESS DESCRIPTION	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND BUSINESS DESCRIPTION	NOTE 1 – ORGANIZATION AND BUSINESS DESCRIPTION Business Bon Natural Life Limited (“Bon Natural” or the “Company”), through its wholly-owned subsidiaries, is engaged in the research and development, manufacturing and sales of functional active ingredients extracted from natural herb plants which are widely used by manufacturer customers in the functional food, personal care, cosmetic and pharmaceutical industries. The Company sells its products to customers located in both Chinese and international markets. Organizations Bon Natural Life Limited was incorporated as an exempted company with limited liability under the laws of the Cayman Islands on December 11, 2019 Bon Natural owns 100 Bon Natural owns 100 Xi’an Cell and Molecule Information Technology Limited. (“Xi’an CMIT”) was formed on April 9, 2020, as a Wholly Foreign-Owned Enterprise (“WFOE”) in the People’s Republic of China (“PRC”). Bon Natural, Tea Essence, and Xi’an CMIT are currently not engaging in any active business operations and merely acting as holding companies. BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 1 – ORGANIZATION AND BUSINESS DESCRIPTION (continued) Prior to the reorganization described below, Mr. Yongwei Hu, the chairman of the board of directors and the chief executive officer of the Company, was the controlling shareholder of Xi’an App-Chem Bio(Tech) Co., Ltd. (“Xi’an App-Chem”), an entity incorporated on April 23, 2006 in accordance with PRC laws. Xi’an App-Chem owns 100 In addition, Xi’an App-Chem also owns majority of the equity interest in the following two entities: Xi’an Dietary Therapy Medical Technology Co., Ltd (“Xi’an DT”) was incorporated on April 24, 2015 in accordance with PRC laws, with 75 51 100 100 On September 27, 2021, the Company disposed Balikun to a third party for RMB 1.00 Xi’an App-Chem, together with its subsidiaries are collectively referred to as the “Bon Operating Companies” below. Reorganization A reorganization of our legal structure (“Reorganization”) was completed on May 28, 2020. The reorganization involved the incorporation of Bon Natural Life, Tea Essence and Xi’an CMIT, and entering into certain contractual arrangements between Xi’an CMIT, the shareholders of Bon Operating Companies and the Bon Operating Companies. Consequently, the Company became the ultimate holding company of Tea Essence, Xi’an CMIT and Bon Operating Companies. BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 1 – ORGANIZATION AND BUSINESS DESCRIPTION (continued) On May 28, 2020, Xi’an CMIT entered into a series of contractual arrangements with the shareholders of the Bon Operating Companies. These agreements include, Exclusive Service Agreement, Share Pledge Agreement, Proxy Agreement, Exclusive Option Agreement, Powers of Attorney, Spousal Consent Letter, and Loan Agreement intended to guarantee the exercise of the Exclusive Option Agreements and Spouse Consents (collectively the “VIE Agreements”). Pursuant to the VIE Agreements, Xi’an CMIT has the exclusive right to provide to the Bon Operating Companies consulting services related to business operations including technical and management consulting services. The VIE Agreements are designed to provide Xi’an CMIT with the power, rights, and obligations equivalent in all material respects to those it would possess as the sole equity holder of each of the Bon Operating Companies, including control rights and the rights to the assets, property, and revenue of each of the Bon Operating Companies. As a result of our direct ownership in Xi’an CMIT and the VIE Agreements, we believe that the Bon Operating Companies should be treated as Variable Interest Entities (“VIEs”) under the Statement of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 810 Consolidation and we are regarded as the primary beneficiary of our VIEs. We treat our VIEs as our consolidated entities under U.S. GAAP. The Company, together with its wholly owned subsidiaries and its VIEs, is effectively controlled by the same shareholders before and after the Reorganization and therefore the Reorganization is considered as a recapitalization of entities under common control. The consolidation of the Company, its subsidiaries, and its VIEs has been accounted for at historical cost and prepared on the basis as if the aforementioned transactions had become effective as of the beginning of the first period presented in the accompanying consolidated financial statements. Upon the completion of the Reorganization, the Company has subsidiaries in countries and jurisdictions in the PRC and Hong Kong. On September 8, 2021, Xi’an Youpincui Biotechnology Co., Ltd (“Xi’an Youpincui”) was formed as a Wholly Foreign-Owned Enterprise (“WFOE”) in the PRC. Tea Essence owns 100 On June 28, 2021, the Company closed its initial public offering (“IPO”) of 220,000 0.001 50.00 33,000 0.001 50.00 totaled 12.65 11.3 1-for-10 Terminating the VIE agreements for corporate restructuring Due to PRC legal restrictions on foreign ownership in companies that engage in online sales China, the Company originally carried out its business through Xi’an App-Chem, a domestic PRC company holding a value-added telecommunications license, through a variable interest entity structure, because foreign investment in the value-added telecommunication services industry in China is extensively regulated and subject to numerous restrictions. However, the Company’s online sales have historically generated minimal revenues. On September 28, 2021, the Company’s Board of Directors approved a restructuring of the Company’s corporate structure to terminate the original VIE contractual agreements, to convert Xi’an App-Chem from a PRC domestic company into a Sino-foreign joint venture, and to transfer 100 BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 1 – ORGANIZATION AND BUSINESS DESCRIPTION (continued) Details of the subsidiaries of the Company as of September 30, 2023 were set out below: SCHEDULE OF SUBSIDIARIES COMPANY Name of Entity Date of Incorporation Place of Incorporation % of Ownership Principal Activities Bon Natural Life December 11, 2019 Cayman Islands Parent, 100 Investment holding Bon Natural Life U.S.A. February 7, 2023 U.S.A. 100 Investment holding Tea Essence January 9, 2020 Hong Kong 100 Investment holding Xi’an CMIT April 9, 2020 Xi.an City, PRC 100 WFOE, Investment holding Xi’an Youpincui September 8, 2021 Xi.an City, PRC 100 WFOE, Investment holding PRC Subsidiaries: Xi’an App- Chem Bio (Tech) April 23, 2006 Xi’an City, PRC 100 General administration and sales of the Company’s products to customers Xi’an YH September 15, 2009 Xi’an City, PRC 91 Research and development of product Bon Operating Companies (owned by Xi’an App-Chem) App-Chem Health April 17, 2006 Tongchuan City, PRC 100 Registered owner of land with an area of 12,904.5 square meters, no other business activities App-Chem Ag-tech April 19, 2013 Dali County, PRC 100 Product manufacturing App-Chem Guangzhou April 27, 2018 Guangzhou City, PRC 100 Raw material purchase Tongchuan DT May 22, 2017 Tongchuan City, PRC 100 Product manufacturing Xi’an DT April 24, 2015 Xi’an City, PRC 75 Research and development of product Tianjin YHX September 16, 2019 Tianjin City, PRC 51 Raw material purchase Gansu BMK March 11, 2020 Jiuquan City, PRC 100 Product manufacturing Bozhou DT March 9, 2023 Bozhou City, PRC 100 Product manufacturing BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Sep. 30, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The accompanying consolidated financial statements include the financial statements of the Company, and its wholly owned subsidiaries. All inter-company balances and transactions are eliminated upon consolidation. Non-controlling interests Non-controlling interests represent minority shareholders’ 25 49 Uses of estimates In preparing the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“US GAAP”), management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates are based on information as of the date of the consolidated financial statements. Significant estimates required to be made by management include, but are not limited to, the allowance for estimated uncollectible receivables, realizability of advance to suppliers, inventory valuations, useful lives of property, plant and equipment, intangible assets, the recoverability of long-lived assets, provision necessary for contingent liabilities, fair value of stock-based compensation, revenue recognition and realization of deferred tax assets. The inputs into the Company’s judgments and estimates consider the economic implications of COVID-19 on the Company’s critical and significant accounting estimates. Actual results could differ from those estimates. Risks and Uncertainties The main operation of the Company is located in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by political, economic, and legal environments in the PRC, as well as by the general state of the PRC economy. The Company’s results may be adversely affected by changes in the political, regulatory and social conditions in the PRC. Although the Company has not experienced losses from these situations and believes that it is in compliance with existing laws and regulations including its organization and structure disclosed in Note 1, this may not be indicative of future results. The development and commercialization of natural and healthy extracts and compounds products is highly competitive, and the industry currently is characterized by rapidly changing technologies, significant competition and a strong emphasis on intellectual property. The Company may face competition with respect to its current and future pharmaceutical product candidates from major pharmaceutical companies in China. Since March 2023, the Company has recovered from the COVID-19 pandemic. However, the Company’s operations may be further affected by the ongoing outbreak of COVID-19 pandemic, A COVID-19 resurgence could negatively affect the execution of customer contracts, the collection of customer payments, or disruption of the Company’s supply chain. The continued uncertainties associated with COVID-19 may cause the Company’s revenue and cash flows to underperform in the next 12 months. The extent of the future impact of COVID-19 is still highly uncertain and cannot be predicted as of the date the Company’s consolidated financial statements are released. Cash Cash includes currency on hand and deposits held by banks that can be added or withdrawn without limitation. The Company maintains most of its bank accounts in the PRC. Cash balances in bank accounts in PRC are insured by the PRC regulation and are not insured by the Federal Deposit Insurance Corporation (see Note 16) Accounts receivable, net The Company determines the adequacy of reserves for doubtful accounts based on individual account analysis and historical collection trend. The Company establishes a provision for doubtful receivables when there is objective evidence that the Company may not be able to collect amounts due. The allowance is based on management’s best estimate of specific losses on individual exposures, as well as a provision on historical trends of collections. Actual amounts received may differ from management’s estimate of credit worthiness and the economic environment. Delinquent account balances are written-off against the allowance for doubtful accounts after management has determined that the collection is not probable, Nil Nil 99,528 13,004 13,337 BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) Advances to Suppliers, net Advances to suppliers consist of balances paid to suppliers for inventory raw materials and construction materials associated with the Company’s construction-in-progress projects that have not been provided or received. Advances to suppliers are reviewed periodically to determine whether their carrying value has become impaired. The Company considers the assets to be impaired if the collectability of the advance becomes doubtful. The Company uses the aging method to estimate the allowance for unrealizable balances. In addition, at each reporting date, the Company generally determines the adequacy of allowance for doubtful accounts by evaluating all available information, and then records specific allowances for those advances based on the specific facts and circumstances. As of September 30, 2023 and 2022, no Inventories, net Inventories are stated at net realizable value using weighted average method. Costs include the cost of raw materials, freight, direct labor and related production overhead. Any excess of the cost over the net realizable value of each item of inventories is recognized as a provision for diminution in the value of inventories. Net realizable value is the estimated selling price in the normal course of business less any costs to complete and sell products. The Company evaluates inventories on a quarterly basis for its net realizable value adjustments, and reduces the carrying value of those inventories that are obsolete or in excess of the forecasted usage to their estimated net realizable value based on various factors including aging, expiration dates, as applicable, taking into consideration historical and expected future product sales. The Company recorded inventory reserve of $ 1,079 6,869 Short-term investments The Company’s short-term investments consist of wealth management financial products purchased from PRC banks, which can be redeemed at any time. The banks invest the Company’s fund in certain financial instruments including money market funds, bonds or mutual funds, with floating interest rates. The carrying values of the Company’s short-term investments approximate fair value because of their short-term maturities. The interest earned is recognized in the consolidated statements of income and comprehensive income over the contractual term of these investments. As of September 30, 2023 and 2022, short-term investments consisted of the following: SCHEDULE OF SHORT-TERM INVESTMENT September 30, 2023 September 30, 2022 Beginning balance $ - $ 1,703,314 Add: purchase wealth management financial products 65 5,097,816 Less: proceeds received upon maturity of short-term investments - (6,776,385 ) Foreign currency translation adjustments - (24,745 ) Ending balance of short-term investments $ 65 $ - BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) Investment income generated from short-term investments amounted to Nil 20,343 565 Fair value of financial instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy prioritizes the inputs used to measure fair value. The hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: ● Level 1 — inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. ● Level 2 — inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted market prices for identical or similar assets in markets that are not active, inputs other than quoted prices that are observable and inputs derived from or corroborated by observable market data. ● Level 3 — inputs to the valuation methodology are unobservable. Unless otherwise disclosed, the fair value of the Company’s cash, short-term investment, accounts receivable, inventories, advance to suppliers, prepaid expenses and other current assets, accounts payable, short-term bank loans, accrued expenses and other current liabilities, taxes payable and due to related parties, approximate the fair value of the respective assets and liabilities as of September 30, 2023 and 2022 based upon the short-term nature of the assets and liabilities. The Company believes that the carrying amount of long-term loans approximates fair value at September 30, 2023 and 2022 based on the terms of the borrowings and current market rates as the rates of the borrowings are reflective of the current market rates. Property, plant and equipment, net Property, plant and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization of property and equipment is provided using the straight-line method over their expected useful lives, as follows: SCHEDULE OF USEFUL LIVES OF PROPERTY, PLANT AND EQUIPMENT Useful life Buildings 20 Machinery and equipment 5 10 Automobiles 8 Office and electric equipment 3 5 Expenditures for maintenance and repairs, which do not materially extend the useful lives of the assets, are charged to expense as incurred. Expenditures for major renewals and betterments which substantially extend the useful life of assets are capitalized. The cost and related accumulated depreciation of assets retired or sold are removed from the respective accounts, and any gain or loss is recognized in the consolidated statements of income and comprehensive income in other income or expenses. Construction-in-Progress (“CIP”) Construction-in-progress represents property and buildings under construction and consists of construction expenditures, equipment procurement, and other direct costs attributable to the construction. Construction-in-progress is not depreciated. Upon completion and ready for intended use, construction-in-progress is reclassified to the appropriate category within property, plant and equipment. BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) Intangible assets, net The Company’s intangible assets primarily include two land use rights. A land use right in the PRC represents an exclusive right to occupy, use and develop a piece of land during the contractual term of the land use right. The cost of a land use right is usually paid in one lump sum at the date the right is granted. The prepayment usually covers the entire period of the land use right. The lump sum advance payment is capitalized and recorded as land use right and then charged to expense on a straight-line basis over the period of the right, which is normally 50 The Company acquired the first land use right of 4.1 acres located at Tongchuan City, Shaanxi Province of China at cost of approximately $ 0.2 8.2 0.3 Impairment of long-lived Assets Long-lived assets, such as property, plant and equipment, land use rights and long-term investment, are reviewed for impairment when events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. Recoverability of a long-lived asset or asset group to be held and used is measured by a comparison of the carrying amount of an asset or asset group to the estimated undiscounted future cash flows expected to be generated by the asset or asset group. If the carrying value of an asset or asset group exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount that the carrying value exceeds the estimated fair value of the asset or asset group. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. Assets to be disposed are reported at the lower of carrying amount or fair value less costs to sell, and are no longer depreciated. No Leases ASC 842 requires that lessees recognize ROU assets and lease liabilities calculated based on the present value of lease payments for all lease agreements with terms that are greater than twelve months. ASC 842 distinguishes leases as either a finance lease or an operating lease that affects how the leases are measured and presented in the statement of operations and statement of cash flows. For operating leases, the Company calculated ROU assets and lease liabilities based on the present value of the remaining lease payments as of the date of adoption. There were no changes in the Company’s capital lease portfolio, which are now titled “finance leases” under ASC 842. Upon the adoption of the new guidance on October 1, 2020, the Company recognized operating lease right of use assets and operating lease liabilities of approximately $ 0.2 BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) Foreign Currency Translation The functional currency for Bon Natural is the U.S Dollar (“US$”). Tea Essence uses Hong Kong dollar as its functional currency. However, Bon Natural, and Tea Essence currently only serve as the holding companies and did not have active operations as of September 30, 2023. The Company operates its business through its subsidiaries in the PRC as of September 30, 2023. The functional currency of the Company’s subsidiaries is the Chinese Yuan (“RMB”). The Company’s consolidated financial statements have been translated into US$. Assets and liabilities accounts are translated using the exchange rate at each reporting period end date. Equity accounts are translated at historical rates. Income and expense accounts are translated at the average rate of exchange during the reporting period. The resulting translation adjustments are reported under other comprehensive income. Gains and losses resulting from the translations of foreign currency transactions and balances are reflected in the results of operations. The RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into US$ at the rates used in translation. The following table outlines the currency exchange rates that were used in creating the consolidated financial statements: SCHEDULE OF CURRENCY EXCHANGE RATES September 30, 2023 September 30, 2022 September 30, 2021 Period-end spot rate US$ 1 7.2960 US$ 1 7.1135 US$ 1 6.4580 Average rate US$ 1 7.0533 US$ 1 6.5532 US$ 1 6.5095 Revenue recognition To determine revenue recognition for contracts with customers, the Company performs the following five steps : (i) identify the contract(s) with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable that a significant future reversal will not In accordance to ASC 606, the Company recognizes revenue when it transfers its goods and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange. The Company accounts for the revenue generated from sales of its products to its customers, in which the Company is acting as a principal in these transactions, is subject to inventory risk, has latitude in establishing prices, and is responsible for fulfilling the promise to provide customers the specified goods. All of the Company’s contracts have single performance obligation as the promise is to transfer the individual goods to customers, and there are no other separately identifiable promises in the contracts. The Company’s revenue streams are recognized at a point in time when title and risk of loss passes and the customer accepts the goods, which generally occurs at delivery. The Company’s products are sold with no right of return and the Company does not provide other credits or sales incentive to customers. The Company’s sales are net of value added tax (“VAT”) and business tax and surcharges collected on behalf of tax authorities in respect of product sales. BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) Contract Assets and Liabilities Payment terms are established on the Company’s pre-established credit requirements based upon an evaluation of customers’ credit. The Company did not have contract assets as of September 30, 2023 and 2022. The Company’s contract liability primarily relates to unsatisfied performance obligations when payment has been received from customers before the Company’s products are delivered, and are recorded as deferred revenue on the consolidated balance sheets. Costs of fulfilling customers’ purchase orders, such as shipping, handling and delivery, which occur prior to the transfer of control, are recognized in selling, general and administrative expense when incurred. Deferred revenue amounted to $ 106,514 188,745 1,096,101 133,533 1,080,178 403,399 Disaggregation of Revenues The Company disaggregates its revenue from contracts by product types, as the Company believes it best depicts how the nature, amount, timing and uncertainty of the revenue and cash flows are affected by economic factors. The Company’s disaggregation of revenues for the years ended September 30, 2023, 2022 and 2021 are disclosed in Note 18 of the consolidation financial statements. Research and development expenses The Company expenses all internal research and development costs as incurred, which primarily comprise employee costs, internal and external costs related to execution of studies, including manufacturing costs, facility costs of the research center, and amortization and depreciation to intangible assets and property, plant and equipment used in the research and development activities. For the years ended September 30, 2023, 2022 and 2021, research and development expense were approximately $ 298,469 424,558 249,050 Selling, General and Administrative Expenses Selling expenses represents primarily costs of payroll, benefits, commissions for sales representatives and advertising expenses. General and administrative expenses represent primarily payroll and benefits costs for administrative employees, rent and operating costs of office premises, depreciation and amortization of office facilities, professional fees and other administrative expenses. Advertising expense Advertising expenses primarily relate to promotion of the Company’s brand name and products through outdoor billboards and social media such as Weibo and WeChat. Advertising expenses are included in selling expenses in the consolidated statements of income and comprehensive income. Advertising expenses amounted to $ 11,344 41,578 25,397 Government subsidies Government subsidies primarily relate to local government’s cash award to High and New Technology Enterprises (“HNTEs”) to encourage entrepreneurship and stimulate local economy. Such awards are granted on a case-by-case basis by local government. The Company’s subsidiary, Xi’an App-chem was approved as a HNTE and received government subsidy in the form of export sales refund and cash awards based on annual financial performance. BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) The Company recognizes government subsidies as other operating income when they are received because they are not subject to any past or future conditions, there are no performance conditions or conditions of use, and they are not subject to future refunds. Government subsidies received and recognized as other operating income totaled $ 25,415 1,306,627 449,972 Income taxes The Company accounts for current income taxes in accordance with the laws of the relevant tax authorities. Deferred income taxes are recognized when temporary differences exist between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period including the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. An uncertain tax position is recognized only if it is “more likely than not” that the tax position would be sustained in a tax examination. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the period incurred. As of September 30, 2023, the Company had income tax payable of $ 1,041,862 The Company’s subsidiaries in China are subject to the income tax laws of the PRC. No significant income was generated outside the PRC for the years ended September 30, 2023, 2022 and 2021. As of September 30, 2023 and 2022, all of the Company’s tax returns of its PRC subsidiaries remain open for statutory examination by PRC tax authorities. Value added tax (“VAT”) Sales revenue represents the invoiced value of goods, net of VAT. The VAT is based on gross sales price and VAT rates range up to 17% (starting from May 1, 2018, VAT rate was lowered to 16%, and starting from April 1, 2019, VAT rate was further lowered to 13%) 1,338,800 For export sales, VAT is not imposed on gross sales price, and the VAT related to purchasing raw materials is refunded after the export is completed. BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) Employee Defined Contribution Plan The Company’s subsidiaries in the PRC participate in a government-mandated multi-employer defined contribution plan pursuant to which pension, work-related injury benefits, maternity insurance, medical insurance, unemployment benefit and housing fund are provided to eligible full-time employees. The relevant labor regulations require the Company’s subsidiaries in the PRC to pay the local labor and social welfare authorities monthly contributions based on the applicable benchmarks and rates stipulated by the local government. The contributions to the plan are expensed as incurred. Employee social security and welfare benefits included as expenses in the accompanying consolidated statements of income and comprehensive income amounted to $ 93,190 80,150 54,189 Share Based Compensation The Company accounts for share-based payment awards exchanged for services at the estimated grant date fair value of the award. The Company issued 57,000 63,333 Nil 3,600 2,244 2,960 3,750 1-for-10 The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. Expected Term - The expected term of options represents the period that the Company’s stock-based awards are expected to be outstanding based on the simplified method, which is the half-life from vesting to the end of its contractual term. Expected Volatility - The Company computes stock price volatility over expected terms based on its historical common stock trading prices. Risk-Free Interest Rate - The Company bases the risk-free interest rate on the benchmark interest rate for loans from financial institutions provided by the People’s Bank of China with an equivalent remaining term. Expected Dividend - The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models. BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) Earnings per Share The Company computes earnings per share (“EPS”) in accordance with ASC 260, “Earnings per Share” (“ASC 260”). ASC 260 requires companies with complex capital structures to present basic and diluted EPS. Basic EPS is measured as net income divided by the weighted average common shares outstanding for the period. Diluted presents the dilutive effect on a per share basis of potential common shares (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. For the years ended September 30, 2023, 5,851 3,529 3,600 10,120 The following table sets forth the computation of basic and diluted earnings per share for the years ended September 30, 2023, 2022 and 2021: SCHEDULE OF EARNINGS PER SHARE 2023 2022 2021 For the Years ended September 30, 2023 2022 2021 Numerator: Net income attributable to ordinary shareholders $ 4,595,982 $ 6,237,488 $ 4,590,803 Denominator: Weighted-average number of ordinary shares outstanding – basic * 913,960 836,077 661,583 Outstanding options * 5,851 3,529 3,597 Outstanding warrants * - - 5,444 Potentially dilutive shares from outstanding options and warrants * 5,851 3,529 9,041 Weighted-average number of ordinary shares outstanding – diluted * 919,811 839,606 670,624 Earnings per share – basic * $ 5.03 $ 7.47 $ 6.94 Earnings per share – diluted * $ 5.00 $ 7.43 $ 6.85 * Retroactively restated to reflect the Company’s 1-for-10 Comprehensive income Comprehensive income consists of two components, net income and other comprehensive income (loss). The foreign currency translation gain or loss resulting from translation of the financial statements expressed in RMB to US$ is reported in other comprehensive income (loss) in the consolidated statements of income and comprehensive income. Statement of Cash Flows In accordance with ASC 230, “Statement of Cash Flows”, cash flows from the Company’s operations are formulated based upon the local currencies. As a result, amounts related to assets and liabilities reported on the consolidated statements of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) Recent Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), which requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost. ASU 2016-13 was subsequently amended by ASU 2018-19, ASU 2019-04, ASU 2019-05, ASU 2019-10 and ASU 2020-02. For public entities, ASU 2016-13 and its amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. For all other entities, this guidance and its amendments will be effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early application will be permitted for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is currently evaluating the effects of the guidance on the Company’s consolidated financial statements and related disclosures. In October 2020, the FASB issued ASU 2020-10, “Codification Improvements to Subtopic 205-10, presentation of financial statements”. The amendments in this Update improve the codification by ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to financial statements is codified in the disclosure section of the codification. That reduce the likelihood that the disclosure requirement would be missed. ASU 2020-10 is effective for the Company for annual and interim reporting periods beginning January 1, 2022. Early application of the amendments is permitted for any annual or interim period for which financial statements are available to be issued. The amendments in this Update should be applied retrospectively. An entity should apply the amendments at the beginning of the period that includes the adoption date. The Company is currently evaluating the impact of this new standard on Company’s consolidated financial statements and related disclosures. BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

LIQUIDITY

LIQUIDITY	12 Months Ended
LIQUIDITY	Sep. 30, 2023
Liquidity
LIQUIDITY	NOTE 3— LIQUIDITY As reflected in the Company’s consolidated financial statements, the Company is currently constructing two new manufacturing plants. As of September 30, 2023, the Company had future minimum capital expenditure commitment on its construction-in-progress (“CIP”) project of approximately $ 5.0 2.7 In assessing its liquidity, management monitors and analyzes the Company’s cash on-hand, its ability to generate sufficient revenue sources in the future, and its operating and capital expenditure commitments. In June 2021, the Company closed its initial public offering and received net proceeds of approximately $ 11.3 2.0 As of September 30, 2023, the Company had cash on hand of $ 112,751 4.6 3.5 75.8 3.8 2.5 0.4 0.9 1.7 Based on the current operating plan, management believes that the above-mentioned measures, including cash on hand of $ 112,751 , 2.0 proceeds from 1.7

ACCOUNTS RECEIVABLE, NET

ACCOUNTS RECEIVABLE, NET	12 Months Ended
ACCOUNTS RECEIVABLE, NET	Sep. 30, 2023
Credit Loss [Abstract]
ACCOUNTS RECEIVABLE, NET	NOTE 4 — ACCOUNTS RECEIVABLE, NET Accounts receivable, net, consists of the following: SCHEDULE OF ACCOUNTS RECEIVABLE, NET September 30, 2023 September 30, 2022 Accounts receivable $ 4,615,470 $ 6,797,644 Less: allowance for doubtful accounts (13,004 ) (13,337 ) Accounts receivable, net $ 4,602,466 $ 6,784,307 BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 4 — ACCOUNTS RECEIVABLE, NET (continued) The Company’s accounts receivable primarily includes balance due from customers when the Company’s products are sold and delivered to customers. Approximately $ 3.5 75.8 The following table summarizes the Company’s accounts receivable and subsequent collection by aging bucket: SCHEDULE OF ACCOUNTS RECEIVABLE AND SUBSEQUENT COLLECTION BY AGING BUCKET Accounts Receivable by aging bucket Balance as of September 30, 2023 Subsequent collection % of subsequent collection Less than 3 months $ 4,603,299 $ 3,487,207 75.8 % From 4 to 6 months - - - % From 7 to 9 months - - - % From 10 to 12 months - - - % Over 1 year 12,171 - - % Total gross accounts receivable 4,615,470 3,487,207 75.8 % Allowance for doubtful accounts (13,004 ) Accounts Receivable, net $ 4,602,466 $ 3,487,207 75.8 % Allowance for doubtful accounts movement is as follows: SCHEDULE OF ALLOWANCE FOR DOUBTFUL ACCOUNTS September 30, 2023 September 30, 2022 Beginning balance $ 13,337 $ 14,691 Additions - - Write-off uncollectible balance - - Foreign currency translation adjustments (334 ) (1,354 ) Ending balance $ 13,004 $ 13,337

INVENTORIES, NET

INVENTORIES, NET	12 Months Ended
INVENTORIES, NET	Sep. 30, 2023
Inventory Disclosure [Abstract]
INVENTORIES, NET	NOTE 5 – INVENTORIES, NET Inventories, net, consist of the following: SCHEDULE OF INVENTORIES September 30, 2023 September 30, 2022 Raw materials $ 12,715 $ 677,042 Finished goods 975,651 1,051,947 Inventory valuation allowance (1,079 ) (6,869 ) Total inventory, net $ 987,287 $ 1,722,120

ADVANCES TO SUPPLIERS, NET

ADVANCES TO SUPPLIERS, NET	12 Months Ended
ADVANCES TO SUPPLIERS, NET	Sep. 30, 2023
Advances To Suppliers Net
ADVANCES TO SUPPLIERS, NET	NOTE 6 – ADVANCES TO SUPPLIERS, NET Advances to suppliers, net, consist of the following: SCHEDULE OF ADVANCES TO SUPPLIERS Schedule of Advances to suppliers: September 30, 2023 September 30, 2022 Raw materials purchase $ 6,406,488 $ 3,654,520 Construction of the CIP 6,716,009 2,105 Machinery and equipment 1,918,860 - Others 75,834 435,365 Less: allowance for doubtful accounts - - Advances to suppliers, net $ 15,117,191 $ 4,091,990 September 30, 2022 advance to supplier balance has been fully realized by March 2023. For the balance as of September 30, 2023, approximately $ 2.8 18.7 BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

ACQUISITION DEPOSIT

ACQUISITION DEPOSIT	12 Months Ended
ACQUISITION DEPOSIT	Sep. 30, 2023
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
ACQUISITION DEPOSIT	NOTE 7— ACQUISITION DEPOSIT On July 6, 2021, the Company entered into a consulting agreement with a New York based consulting firm (“the consulting firm”), pursuant to which, the consulting firm will help the Company to (i) identify appropriate business partner candidates in New York or California in order to jointly establish a research and development center in the United States for future new product development; (ii) find opportunities to establish business relationship with U.S based companies with OEM demand and utilize the Company’s manufacturing strength and capability to manufacture healthcare ingredient products for U.S companies under the OEM arrangement and (iii) help the Company to purchase or lease appropriate commercial facilities in the U.S., etc. The consulting firm will be compensated with $ 30,000 1.5 1.0 Due to recent COVID-19 resurgence in Xi’an City and government mandatory quarantine and city lockdown, on January 20, 2022, the Company and the consulting firm signed a supplemental agreement to lower down the required deposit from original $ 1.5 1.0 As of September 30, 2023, the consulting firm has delivered a potential acquisition target to the Company, which is a small R&D firm developing anti-aging formulas. The consulting firm is now helping the Company to perform due diligence work and the Company is now negotiating the detailed terms with this acquisition target. The intended acquisition is expected to be completed around December 2024. The Company may, at its discretion, terminate the consulting agreement and request for a full refund of the deposit anytime if the due diligence work fails or the final acquisition terms not reached by both parties.

PROPERTY, PLANT AND EQUIPMENT,

PROPERTY, PLANT AND EQUIPMENT, NET	12 Months Ended
PROPERTY, PLANT AND EQUIPMENT, NET	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT, NET	NOTE 8— PROPERTY, PLANT AND EQUIPMENT, NET Property, plant and equipment, net, consists of the following: SCHEDULE OF PROPERTY, PLANT, AND EQUIPMENT September 30, 2023 September 30, 2022 Buildings $ 11,621,665 $ 967,530 Machinery, equipment and furniture 6,207,931 1,866,760 Motor Vehicles 210,201 201,537 Construction-in-progress (“CIP”) (1) 5,582,213 20,274,698 Subtotal 23,622,010 23,310,525 Less: accumulated depreciation (2,557,967 ) (1,686,088 ) Property, plant and equipment, net $ 21,064,043 $ 21,624,437 Depreciation expense was $ 945,507 210,916 219,906 (1) Construction-in-progress (“CIP”) represents direct costs of construction incurred for the Company’s manufacturing facilities. On August 16, 2017, the Company’s subsidiary, Xi’an App-Chem Bio (Tech) Co.,Ltd. started to construct a new manufacturing plant in Tongchuan City (“Tongchuan Project”), Shaanxi Province, with total budget of RMB 95.0 13.4 114.0 16.0 10,678,336 4,305,847 BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 8— PROPERTY, PLANT AND EQUIPMENT, NET (continued) On May 10, 2021, a subsidiary of the Company’s Xi’an App-Chem, Gansu Baimeikang Bioengineering Co., Ltd. obtained a land use right and started to construct a new manufacturing plant in Yumen City (“Yumen Project”), Gansu Province, with an initial budget of RMB 40.0 5.6 200.00 As of September 30, 2023, the Company has spent approximately $ 5.6 6.7 1.9 5.0 As of September 30, 2023, future minimum capital expenditures on the Company’s the CIP project are estimated as follows: SCHEDULE OF FUTURE MINIMUM CAPITAL EXPENDITURES ON THE CONSTRUCTION-IN-PROGRESS Years ending September 30, Yumen 2024 $ 5,000,000 2025 - 2026 - 2027 - Total $ 5,000,000

INTANGIBLE ASSETS, NET

INTANGIBLE ASSETS, NET	12 Months Ended
INTANGIBLE ASSETS, NET	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS, NET	NOTE 9 – INTANGIBLE ASSETS, NET Intangible assets, net mainly consist of the following: SCHEDULE OF INTANGIBLE ASSETS September 30, 2023 September 30, 2022 Land use rights $ 1,067,134 $ 430,985 Less: accumulated amortization (71,907 ) (64,818 ) Land use rights, net $ 995,227 $ 366,167 Amortization expenses were $ 9,010 7,610 8,641 SCHEDULE OF AMORTIZATION EXPENSES Years ending September 30, Amortization expense 2024 $ 21,649 2025 21,649 2026 21,649 2027 21,649 2028 21,649 Thereafter 886,982 Total $ 995,227 BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DEBT

DEBT	12 Months Ended
DEBT	Sep. 30, 2023
Debt Disclosure [Abstract]
DEBT	NOTE 10— DEBT The Company borrowed from PRC banks, other financial institutions and third-parties as working capital funds. As of September 30, 2023 and 2022, the Company’s debt consisted of the following: (a) Short-term loans: SCHEDULE OF SHORT-TERM LOANS September 30, 2023 September 30, 2022 China Construction Bank (“CCB’) (1) $ 42,785 $ 34,765 Shanghai Pudong Development Bank (“SPD Bank”) (2) 1,370,614 1,405,777 China Construction Bank (3) 137,061 140,578 Beijing Bank (4) 822,368 843,467 Industrial and Commercial Bank of China (5) 137,061 - Total short-term loans $ 2,509,890 $ 2,424,587 (1) On January 13, 2022, Tongchuan DT entered into another loan agreement with China Construction Bank (“CCB’) to borrow RMB 247,300 34,765 as working capital for one year, with maturity date on January 13, 2023 3.8525 On December 30, 2022, the Company’s subsidiary, Tongchuan DT entered into a loan agreement with CCB to borrow RMB 312,159 42,785 as working capital for one year, with maturity date on December 30, 2023 3.95 (2) On December 6, 2021, the Company’s subsidiary, Xi’an App-Chem, obtained an approval of line of credit from Shanghai Pudong Development Bank (“SPD Bank”) for a maximum of RMB 15.0 2.1 10.0 1.4 5.0 January 10, 2023 A third-party Xi’an Financial Guarantee Co., Ltd. provided guarantee to this loan and the Company paid $15,260 for the guarantee service. In addition, the Company pledged its 100% ownership interest in App-Chem Health and certain free patent owned by the Company as collateral to guarantee this loan 5.0 0.7 On January 16, 2023, the Company’s subsidiary, Xi’an App-Chem, obtained an approval of line of credit from SPD Bank for a maximum of RMB 10.0 1.4 10.0 1.4 4.3 A third-party Xi’an Financial Guarantee Co., Ltd. provided guarantee to this loan and the Company paid $15,260 for the guarantee service. In addition, the Company pledged its 100% ownership interest in App-Chem Health and certain free patent owned by the Company as collateral to guarantee this loan BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 10— DEBT(continued) (3) On May 18, 2022, Xi’an App-Chem’s subsidiary, Tianjin YHX, entered into a loan agreement with China Construction Bank to borrow RMB 1.0 140,578 as working capital for one year, with maturity date on May 18, 2023 3.96 On May 15, 2023, Xi’an App-Chem’s subsidiary, Tianjin YHX, entered into a loan agreement with China Construction Bank to borrow RMB 1.0 137,061 as working capital for one year, with maturity date on May 15, 2024 3.80 (4) On June 23, 2022, the Company’s subsidiary, Xi’an App-Chem, entered into a loan agreement with Beijing Bank to borrow RMB 6.0 0.8 5.22 June 22, 2023 100 On May 11, 2023, the Company’s subsidiary, Xi’an App-Chem, entered into a loan agreement with Beijing Bank to borrow RMB 6.0 0.8 5.17 May 10, 2024 100 (5) On March 14, 2023, Xi’an App-Chem’s subsidiary, Tianjin YHX, entered into a loan agreement with Industrial and Commercial Bank of China (“ICBC”) to borrow RMB 1.0 137,061 as working capital for one year, with maturity date on March 13, 2024 3.70 (b) Long-term loans: SCHEDULE OF LONG -TERM LOANS September 30, 2023 September 30, 2022 Xi’an High-Tech Emerging Industry Investment Fund Partnership (6) $ 44,747 $ 1,082,449 Webank Co., Ltd. (7) 209,133 262,813 China Resources Shenzhen International Investment Trust (8) 22,844 179,237 Huaxia Bank (9) 603,070 590,426 Qishang Bank (10) 411,184 210,867 Total 1,290,978 2,325,792 Less: current portion of long-term loans (419,610 ) (2,135,979 ) Total long-term loans $ 871,368 $ 189,813 (6) On June 26, 2017, the Company’s subsidiary, Xi’an App-Chem, entered into a loan agreement with third-party Xi’an High-tech Emerging Industries Investment Fund Partnership (the “Lender”) to borrow RMB 8.0 1.2 as working capital for three years, with maturity date on June 25, 2020 3.8 BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 10— DEBT (continued) The loan matured on June 25, 2020 and not repaid on time due to COVID-19 impact. The Company has negotiated with the Lender to extend the loan repayment date to December 25, 2022 in accordance with a COVID-19 relief notice issued by local government, with adjusted interest rate of 4.75% per annum during the period from June 26, 2020 to June 25, 2021, and 5.225% per annum during the period from June 26, 2021 to December 31, 2023 7.3 1.1 0.3 0.05 (7) On February 10, 2022, Xi’an App-Chem, entered into two loan agreements with Shenzhen Qianhai WeBank Co., Ltd, to borrow an aggregate of RMB 1.51 212,808 as working capital for two years, with maturity date on February 12, 2024 8.1 623,333 85,435 On June 20, 2021, Xi’an App-Chem’s subsidiary, Tianjin YHX, entered into a loan agreement with Shenzhen Qianhai WeBank Co., Ltd, to borrow RMB 620,000 96,005 as working capital for 24 months, with maturity date on June 20, 2023 14.4 On March 14, 2022, Tianjin YHX, entered into another loan agreement with Shenzhen Qianhai WeBank Co., Ltd, to borrow RMB 90,000 12,652 as working capital for 24 months, with maturity date on March 20, 2024 15.39 On January 12, 2023, Tianjin YHX, entered into another loan agreement with Shenzhen Qianhai WeBank Co., Ltd, to borrow RMB 150,000 20,559 as working capital for 24 months, with maturity date on January 20, 2025 13.77 On August 23, 2023, Tianjin YHX, entered into another loan agreement with Shenzhen Qianhai WeBank Co., Ltd, to borrow RMB 500,000 68,531 as working capital for 24 months, with maturity date on August 20, 2025 14.76 250,000 34,265 On September 15, 2023, Tianjin YHX, entered into another loan agreement with Shenzhen Qianhai WeBank Co., Ltd, to borrow RMB 27,000 3,701 as working capital for 24 months, with maturity date on September 15, 2025 14.76 13,500 34,265 BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 10— DEBT (continued) (8) On February 11, 2022, Xi’an App-Chem, entered into another loan agreement with China Resources Shenzhen International Investment Trust to borrow RMB 566,667 79,661 as working capital for two years, with maturity date on February 12, 2024 12.6 166,667 22,844 On March 1, 2022, Tianjin YHX, entered into a loan agreement with China Resources Shenzhen International Investment Trust, to borrow RMB 0.7 99,576 as working capital for 24 months, with maturity date on February 20, 2024 16.2 (9) On April 3, 2020, Xi’an App-Chem, obtained a line of credit approval from Huaxia Bank for a maximum of RMB 15 2.1 3 0.4 9 12 1.7 6.6 2.0 0.3 as working capital for three years, with the interest rate of 6.6 April 16, 2023 3.0 0.4 8.5 On May 30, 2023, Xi’an App-Chem, obtained a RMB 2 274,123 5.0 200,000 27,412 On May 30, 2023, Xi’an App-Chem, obtained a RMB 2.4 328,947 6.5 200,000 27,412 (10) On December 10, 2020, the Company’s subsidiary, Xi’an App-Chem, obtained an approval of line of credit from Qishang Bank Co., Ltd. (“Qishang Bank”) for a maximum of RMB 13 1.8 3.0 0.4 6.65 1.5 210,867 1.5 210,867 On August 22, 2023, the Company’s subsidiary, Xi’an App-Chem, obtained a working capital loan of RMB 3.0 411,184 5.80 1,000,000 137,061 For the above-mentioned short-term and long-term loans from PRC banks and financial institutions, interest expense amounted to $ 238,224 446,884 417,266 BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
RELATED PARTY TRANSACTIONS	Sep. 30, 2023
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 11 — RELATED PARTY TRANSACTIONS SCHEDULE OF DUE FROM TO RELATED PARTIES (a) Due to related parties Related party relationship September 30, 2023 September 30, 2022 Wenhu Guo Senior Management of the Company $ 6,168 $ 3,290 Yongwei Hu Chief Executive Officer and Controlling shareholder of the Company 3,392 6,583 Jing Liu Wife of the controlling shareholder 18,925 - Sheying Wang Senior Management of the Company 3,016 3,093 Yuantao Wang 49% shareholder of Tianjin YHX 23,650 59,870 Shujie Mou Senior Management of Tianjin YHX 28,229 - Total due to related parties $ 83,380 $ 72,836 As of September 30, 2023 and 2022, the balance of due to related parties was comprised of the Company’s borrowings from related parties and was used for working capital during the Company’s normal course of business. Such advance was non-interest bearing and due on demand. (b) Due from related parties Related party relationship September 30, 2023 September 30, 2022 Wenjuan Chen Senior Management of the Company $ 8,358 $ - Lu Jiang Employee of the Company 53 - Total due from related parties $ 8,411 $ - As of September 30, 2023 and 2022, the balance of due from related parties was mainly comprised of advance to the employees for business purposes. (c) Loan guarantee provided by related parties In connection with the Company’s short-term and long-term loans borrowed from PRC banks and other financial institutions, the Company’s controlling shareholder, Mr. Yongwei Hu pledged his proportionate ownership interest in Xi’an App-chem, and his personal bank savings as collateral to safeguard the Company’s borrowings from the banks and financial institutions. Mr. Yongwei Hu and his wife Ms. Jing Liu also jointly pledged their personal residence property to guarantee the Company’s certain loans (see Note 10). BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

TAXES

TAXES	12 Months Ended
TAXES	Sep. 30, 2023
Income Tax Disclosure [Abstract]
TAXES	NOTE 12 — TAXES (a) Corporate Income Taxes (“CIT”) Cayman Islands Under the current tax laws of the Cayman Islands, Bon Natural Life Limited (“Bon Natural Life”) is not subject to tax on its income or capital gains. In addition, no Cayman Islands withholding tax will be imposed upon the payment of dividends by the Company to its shareholders. Hong Kong Tea Essence Limited (“Tea Essence”) is incorporated in Hong Kong and is subject to profit taxes in Hong Kong at a rate of 16.5 no PRC Under PRC CIT Law, domestic enterprises and Foreign Investment Enterprises (“FIEs”) are usually subject to a unified 25 Under this preferential tax treatment, HNTEs are entitled to an income tax rate of 15 CIT is typically governed by the local tax authority in PRC. Each local tax authority at times may grant tax holidays to local enterprises as a way to encourage entrepreneurship and stimulate local economy. The corporate income taxes for the years ended September 30, 2023, 2022 and 2021 were reported at a blended reduced rate as a result of Xi’an App-chem being approved as a HNTE and enjoying a 15% reduced income tax rate, but subsidiaries of Xi’an App-chem are subject to a 25% income tax rate. The impact of the tax holidays noted above decreased foreign taxes by $ 667,258 825,899 514,327 1.50 1.00 0.80 1-for-10 BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 12 — TAXES (continued) The following table reconciles the China statutory rates to the Company’s effective tax rate for the years ended September 30, 2023, 2022 and 2021: SCHEDULE OF EFFECTIVE TAX RATE For the Years Ended September 30, 2023 2022 2021 PRC statutory income tax rate 25.0 % 25.0 % 25.0 % Effect of income tax holiday (12.0 )% (11.0 )% (9.5 )% Permanent difference 0.6 % 0.1 % 0.5 % Research and development deduction (5.4 )% (4.2 )% (3.4 )% Change in valuation allowance 9.8 % 7.0 % 2.5 % Effective tax rate 18.0 % 16.9 % 15.1 % The components of the income tax provision (benefit) are as follows: SCHEDULE OF COMPONENTS OF THE INCOME TAX PROVISION (BENEFIT) For the Years Ended September 30, 2023 2022 2021 Current tax provision: Cayman Islands $ - $ - $ - Hong Kong - - China 1,000,887 1,248,013 791,822 Sub-total 1,000,887 1,248,013 791,822 Current tax provision 1,000,887 1,248,013 791,822 Deferred tax provision (benefit): Cayman Islands - - - Hong Kong - - - China 1,411 19,012 29,109 Sub-total 1,411 19,012 29,109 Deferred tax provision (benefit) 1,411 19,012 29,109 ) Income tax provision $ 1,002,298 $ 1,267,025 $ 820,931 Deferred tax assets The Company’s deferred tax assets are comprised of the following: SCHEDULE OF DEFERRED TAX ASSETS September 30, 2023 September 30, 2022 Deferred tax assets derived from allowance for doubtful accounts and net operating losses (“NOL”) $ 300,846 $ 257,947 Less: valuation allowance (299,511 ) (255,179 ) Deferred tax assets $ 1,335 $ 2,768 The Company follows ASC 740, “Income Taxes”, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates, applicable to the periods in which the differences are expected to affect taxable income. BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 12 — TAXES (continued) A valuation allowance is provided against deferred tax assets when the Company determines that it is more likely than not that the deferred tax assets will not be utilized in the future. The Company has subsidiaries in the PRC, among which 7 entities, including Xi’an CMIT, App-Chem Ag-tech, App-Chem Guangzhou, Tongchuan DT, Xi’an DT, Tianjin YHX and Gansu BMK, reported recurring operating losses since their inception and the chances for these subsidiaries that suffered recurring losses in prior period to become profitable in the foreseeable near future and to utilize their net operating loss carry forwards were remote. Accordingly, the Company provided valuation allowance of $ 299,511 255,179 As of September 30, 2023, all of the Company’s tax returns of its PRC subsidiaries remain open for statutory examination by PRC tax authorities. (b) Taxes payable Taxes payable consist of the following: SCHEDULE OF TAXED PAYABLE September 30, 2023 September 30, 2022 Income tax payable $ 1,296,206 $ 576,098 Value added tax payable 1,338,800 572,306 Other taxes payable 83,681 91,304 Total taxes payable $ 2,718,687 $ 1,239,708 As of September 30, 2023 and 2022, Company had accrued tax liabilities of approximately $ 2.7 1.2 BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

OPERATING LEASE

OPERATING LEASE	12 Months Ended
OPERATING LEASE	Sep. 30, 2023
Operating Lease
OPERATING LEASE	NOTE 13 - OPERATING LEASE The Company entered into following lease agreements to lease its factory in Dali County, Shaanxi Province of China and its office spaces in Xi’an City, Shaanxi Province of China. The Company intend to continue these leases for the next three years. On April 6, 2022, the Company entered into a three 97,351 Balance sheet information related to the operating lease is as follows: SCHEDULE OF BALANCE SHEET INFORMATION RELATED OPERATING LEASE September 30, 2023 September 30, 2022 Operating lease assets: Operating lease right of use assets $ 312,067 $ 546,690 Total operating lease assets 312,067 546,690 　　 Operating lease obligations: Current operating lease liabilities 227,297 230,182 Non-current operating lease liabilities 91,720 327,202 Total operating lease obligations $ 319,017 $ 557,384 BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 13 - OPERATING LEASE (continued) The weighted-average remaining lease term and the weighted-average discount rate of leases are as follows: SCHEDULE OF WEIGHTED-AVERAGE OF OPERATING LEASE September 30, 2023 Weighted-average remaining lease term 1.4 Weighted-average discount rate 4.75 % The following table summarizes the maturity of operating lease liabilities as of September 30, 2023: SCHEDULE OF MATURITY OF OPERATING LEASE LIABILITIES 12 months ending March 31, US$ 2024 $ 236,512 2025 92,580 2026 - Total lease payments 329,091 Less: imputed interest (10,074 ) Total lease liabilities $ 319,017

SHAREHOLDERS_ EQUITY

SHAREHOLDERS’ EQUITY	12 Months Ended
SHAREHOLDERS’ EQUITY	Sep. 30, 2023
Equity [Abstract]
SHAREHOLDERS’ EQUITY	NOTE 14— SHAREHOLDERS’ EQUITY Ordinary Shares Bon Natural Life Limited (“Bon Natural Life”, or the “Company”) was incorporated under the laws of Cayman Islands on December 11, 2019. The initial authorized number of ordinary shares was 500,000,000 shares with par value of US$ 0.0001 each. On March 9, 2024, the Company adopted an amendment of Memorandum of Association to amend the capital of the Company into (a) 270,000,000 0.001 30,000,000 0.001 On June 17, 2020, the Company’s shareholders approved a reverse split of the outstanding ordinary shares at a ratio of 1-for-3 shares 1,033,333 1,550,000 516,667 516,667 BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 14— SHAREHOLDERS’ EQUITY (continued) On June 28, 2021, the Company closed its initial public offering (“IPO”) of 220,000 0.001 50.00 33,000 0.001 50.00 In connection with the Company’s IPO, the Company agreed to issue to the underwriters with warrants to purchase up to a total of 10,120 five years 50.00 5,060 2,038 5,060 3,185 On January 17, 2023, the Company closed a private offering of ordinary shares and warrants to purchase ordinary shares. A total of 275,000 8.00 2,200,000 8.80 24 275,000 168,532 On March 9, 2024, the shareholders of the Company approved a reverse split at a ratio of 1-for10 1,173,867 839,623 Underwriter warrants In connection with the Company’s IPO, the Company also agreed to issue to the underwriters and to register herein warrants to purchase up to a total of 10,120 4 These warrants have warrant term of five years 50.00 50.00 5 The warrants are exercisable at any time, and from time to time, in whole or in part, commencing 180 days from the closing of the IPO. Management determined that these warrants meet the requirements for equity classification under ASC 815-40. On October 1, 2021, the underwriters elected to exercise 5,060 2,038 5,060 3,185 A summary of warrants activity for the years ended September 30, 2023, 2022 and 2021 was as follows: SCHEDULE OF WARRANT ACTIVITY Number of warrants* Weighted Weighted Outstanding, September 30, 2021 10,120 $ 50.00 - Granted - - - Forfeited - - - Exercised (10,120 ) 50.00 - Exercisable, September 30, 2022 - $ - - Granted 275,000 8.80 1.3 Forfeited - - - Exercised - - - Outstanding, September 30, 2023 275,000 $ 8.80 1.3 Exercisable, September 30, 2023 275,000 $ 8.80 1.3 (* Retroactively restated to reflect the Company’s 1-for-10 BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 14— SHAREHOLDERS’ EQUITY (continued) Non-controlling interest The Company’s subsidiary, Xi’an App-chem, owns majority of the equity interest in the following two entities: Xi’an Dietary Therapy Medical Technology Co., Ltd (“Xi’an DT”) and Tianjin Yonghexiang Bio(Tech) Co., Ltd. (“Tianjin YHX”) Non-controlling interests represent minority shareholders’ 25 49 SCHEDULE OF NON-CONTROLLING INTEREST Xi’an DT Tianjin YHX Total As of September 30, 2022 $ 472,812 $ 57,680 $ 530,492 Non-controlling interest, beginning $ 472,812 $ 57,680 $ 530,492 Net loss attributable to non-controlling interest (5,700 ) (37,600 ) (43,300 ) Foreign currency translation adjustment 1,315 8,674 9,989 As of September 30, 2023 $ 468,427 $ 28,754 $ 497,181 Non-controlling interest, ending $ 468,427 $ 28,754 $ 497,181 Statutory reserve and restricted net assets Relevant PRC laws and regulations restrict the Company’s PRC subsidiaries from transferring a portion of their net assets, equivalent to their statutory reserves and their share capital, to the Company in the form of loans, advances or cash dividends. Only PRC entities’ accumulated profits may be distributed as dividends to the Company without the consent of a third party. The Company is required to make appropriations to certain reserve funds, comprising the statutory surplus reserve and the discretionary surplus reserve, based on after-tax net income determined in accordance with generally accepted accounting principles of the PRC (“PRC GAAP”). Appropriations to the statutory surplus reserve are required to be at least 10% of the after-tax net income determined in accordance with PRC GAAP until the reserve is equal to 50% of the entity’s registered capital. The payment of dividends by entities organized in China is subject to limitations, procedures and formalities. Regulations in the PRC currently permit payment of dividends only out of accumulated profits as determined in accordance with accounting standards and regulations in China. The results of operations reflected in the consolidated financial statements prepared in accordance with U.S GAAP differ from those in the statutory financial statements of the WFOE and its subsidiaries. Remittance of dividends by a wholly foreign-owned company out of China is subject to examination by the banks designated by State Administration of Foreign Exchange. In light of the foregoing restrictions, the Company’s WFOE Xi’an CMIT and subsidiaries are restricted in their ability to transfer their net assets to the Company. Foreign exchange and other regulations in the PRC may further restrict the WFOE and its subsidiaries from transferring funds to the Company in the form of dividends, loans and advances. As of September 30, 2023 and 2022, the restricted amounts as determined pursuant to PRC statutory laws totaled $ 2,372,871 1,804,116 20,556,190 17,516,406 BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION	12 Months Ended
SHARE-BASED COMPENSATION	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
SHARE-BASED COMPENSATION	NOTE 15 - SHARE-BASED COMPENSATION On June 23, 2020, the Company entered into consulting service agreements with three third-party consultants (collectively the “Consultants”), pursuant to which, the Consultants provided public listing related consulting services to the Company in connection with the Company’s intended IPO effort. The Company issued 63,333 63,333 633,333 The Company applied ASC 718 and related interpretations in accounting for measuring the cost of share-based compensation over the period during which the consultants are required to provide services in exchange for the issued shares. For the years ended September 30, 2023, 2022 and 2021, Nil Nil 422,221 On May 31, 2023, the Company entered into consulting agreements with a third-party consultant, which provide financial and acquisition consulting services. The Company issued 50,000 50,000 174,904 On August 2, 2023, the Company issued 7,000 7,000 43,400 Pursuant to the Director Service Agreements with the Company’s independent directors and following the completion of the Company’s IPO, on June 23, 2021, the Company granted stock options to three independent directors to purchase an aggregate of 3,600 0.001 0.10 179,640 On June 28, 2022 and July 1, 2022, independent directors were granted options to purchase 2,244 2,960 0.10 BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 15 - SHARE-BASED COMPENSATION (continued) SHARE-BASED COMPENSATION AWARDS MEASURED AT GRANT DATE FAIR VALUE On August 3, 2023, two independent directors were granted options to purchase 1,875 0.10 SHARE-BASED COMPENSATION AWARDS MEASURED AT GRANT DATE FAIR VALUE For the Years Ended September 30, 2023 2022 Exercise price* $ 0.10 $ 0.10 Expected term (years) 1 1 Expected stock price volatility 158.2 % 114.1 % Risk-free rate of interest 4.35 % 4.35 % Expected dividend rate 0 % 0 % For the years ended September 30, 2023, 2022 and 2021, stock-based compensation associated with amortization of stock option expense was $ 131,092 170,883 44,910 The following table summarizes the Company’s stock option activities: SUMMARY OF STOCK OPTION Number of options* Weighted Average Exercise Price* Weighted Average Remaining Contractual Term Outstanding, September 30, 2021 3,600 $ 0.10 9.75 Granted 5,204 0.10 10.00 Forfeited - - Exercised (1,400 ) 0.10 - Outstanding, September 30, 2022 7,404 $ 0.10 9.25 Granted 3,750 0.10 10.00 Forfeited - - - Exercised (2,244 ) 0.10 - Outstanding, September 30, 2023 8,910 $ 0.10 9.03 Exercisable, September 30, 2023 5,785 $ 0.10 8.51 (* Retroactively restated to reflect the Company’s 1-for-10 BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

CONCENTRATION

CONCENTRATION	12 Months Ended
CONCENTRATION	Sep. 30, 2023
Risks and Uncertainties [Abstract]
CONCENTRATION	NOTE 16 - CONCENTRATION A majority of the Company’s revenue and expense transactions are denominated in RMB and a significant portion of the Company and its subsidiaries’ assets and liabilities are denominated in RMB. RMB is not freely convertible into foreign currencies. In the PRC, certain foreign exchange transactions are required by law to be transacted only by authorized financial institutions at exchange rates set by the People’s Bank of China (“PBOC”). Remittances in currencies other than RMB by the Company in China must be processed through the PBOC or other China foreign exchange regulatory bodies which require certain supporting documentation in order to affect the remittance. For the years ended September 30, 2023, 2022 and 2021, the Company’s substantial assets were located in the PRC and the Company’s substantial revenues were derived from its subsidiaries located in the PRC. As of September 30, 2023 and 2022, $ 106,719 835,462 The Company sells its products primarily through direct distributors in the People’s Republic of China (the “PRC”) and to some extent, the overseas customers in European countries, North America and Middle East. For the year ended September 30, 2023, three customers accounted for 41.8 29.5 11.1 35.5 23.9 15.4 35.5 26.1 As of September 30, 2023, three customers accounted for approximately 42.7 24.7 13.2 38.1 33.7 17.9 For the years ended September 30, 2023 three suppliers accounted for approximately 41.8 29.5 11.1 24.6 15.0 11.9 10.7 30.1 13.4

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
COMMITMENTS AND CONTINGENCIES	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 17 - COMMITMENTS AND CONTINGENCIES From time to time, the Company is a party to various legal actions arising in the ordinary course of business. The Company accrues costs associated with these matters when they become probable and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. For the years ended September 30, 2023, 2022 and 2021, the Company did not have any material legal claims or litigation that, individually or in aggregate, could have a material adverse impact on the Company’s consolidated financial position, results of operations and cash flows. The Company has an ongoing CIP project associated with the construction of a new manufacturing facility. As of September 30, 2023, future minimum capital expenditures on the Company’s CIP project amounted to $ 5 BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DISAGGREGATION OF REVENUES

DISAGGREGATION OF REVENUES	12 Months Ended
DISAGGREGATION OF REVENUES	Sep. 30, 2023
Segment Reporting [Abstract]
DISAGGREGATION OF REVENUES	NOTE 18— DISAGGREGATION OF REVENUES Revenue by region SCHEDULE OF SEGMENT REPORTING REVENUE BY REGION 2023 2022 2021 For Years ended September 30, 2023 2022 2021 PRC $ 28,971,115 $ 28,756,333 $ 23,704,259 Overseas 551,238 1,152,228 1,790,305 Total revenue $ 29,522,353 $ 29,908,561 $ 25,494,564 Revenue by product categories The summary of our total revenues by product categories for the years ended September 30, 2023, 2022 and 2021 was as follows: SCHEDULE OF SEGMENT REPORTING REVENUE BY PRODUCT CATEGORIES 2023 2022 2021 For Years ended September 30, 2023 2022 2021 Fragrance compounds $ 14,315,810 $ 13,710,556 $ 12,744,029 Health supplements (solid drinks) 8,704,468 7,145,708 6,655,982 Bioactive food ingredients 6,502,075 9,052,297 6,094,553 Total revenue $ 29,522,353 $ 29,908,561 $ 25,494,564 BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
SUBSEQUENT EVENTS	Sep. 30, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 19 - SUBSEQUENT EVENTS (1). Bank Loans On January 15, 2024, the Company’s subsidiary, Xi’an App-Chem, entered into a loan agreement with China Bohai Bank to borrow RMB 4.0 0.5 3.9 January 21, 2025 (2) Issuance of Shares for Stock-based Compensation On October 2, 2023, the Company issued a total of 155,000 10,000 1-for-10 BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FINANCIAL INFORMATION OF THE PA

FINANCIAL INFORMATION OF THE PARENT COMPANY	12 Months Ended
FINANCIAL INFORMATION OF THE PARENT COMPANY	Sep. 30, 2023
Condensed Financial Information Disclosure [Abstract]
FINANCIAL INFORMATION OF THE PARENT COMPANY	NOTE 20— FINANCIAL INFORMATION OF THE PARENT COMPANY Rule 12-04(a), 5-04(c) and 4-08(e)(3) of Regulation S-X require the financial information of the parent company to be filed when the restricted net assets of consolidated subsidiaries exceed 25 percent of consolidated net assets as of the end of the most recently completed fiscal year. The Company performed a test on the restricted net assets of consolidated subsidiaries in accordance with such requirement and concluded that it was applicable to the Company as the restricted net assets of the Company’s PRC subsidiaries exceeded 25% of the consolidated net assets of the Company, therefore, the financial statements for the parent company are included herein. For purposes of the above test, restricted net assets of consolidated subsidiaries shall mean that amount of the Company’s proportionate share of net assets of consolidated subsidiaries (after intercompany eliminations) which as of the end of the most recent fiscal year may not be transferred to the parent company by subsidiaries in the form of loans, advances or cash dividends without the consent of a third party. The financial information of the parent company has been prepared using the same accounting policies as set out in the Company’s consolidated financial statements except that the parent company used the equity method to account for investment in its subsidiaries. Such investment is presented on the balance sheets as “Investment in subsidiaries” and the respective profit or loss as “Equity in earnings of subsidiaries” on the statements of comprehensive income. The footnote disclosures contain supplemental information relating to the operations of the Company and, as such, these statements should be read in conjunction with the notes to the consolidated financial statements of the Company. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S GAAP have been or omitted. The Company did not pay any dividend for the periods presented. As of September 30, 2023 and 2022, there were no material contingencies, significant provisions for long-term obligations, or guarantees of the Company, except for those which have been separately disclosed in the consolidated financial statements, if any. BON NATURAL LIFE LIMITED AND SUBSIDIARIES PARENT COMPANY BALANCE SHEETS SCHEDULE OF PARENT COMPANY FINANCIAL STATEMENTS September 30, 2023 September 30, 2022 ASSETS CURRENT ASSETS Cash $ 867 $ 1,221 Acquisition deposit 1,000,000 1,000,000 Due from subsidiaries 10,998,557 9,402,525 Prepaid expenses and other current assets (22,920 ) 42,749 TOTAL CURRENT ASSETS 11,976,504 10,446,495 NON-CURRENT ASSETS Investment in subsidiaries 23,507,948 19,115,509 TOTAL ASSETS $ 35,484,452 $ 29,562,004 LIABILITIES AND SHAREHOLDERS’ EQUITY LIABILITIES $ - $ - COMMITMENTS AND CONTINGENCIES - SHAREHOLDERS’ EQUITY Ordinary shares, ($ 0.001 270,000,000 1,173,867 839,623 * $ 1,117 $ 840 Additional paid-in capital 18,182,202 15,711,450 Retained earnings 20,980,978 16,480,885 Accumulated other comprehensive income (loss) (3,679,845 ) (2,631,171 ) Total Bon Natural Life Limited shareholders’ equity 35,484,452 29,562,004 Total liabilities and Bon Natural Life Limited shareholders’ equity $ 35,484,452 $ 29,562,004 * Retroactively restated to reflect the Company’s 1-for-10 BON NATURAL LIFE LIMITED AND SUBSIDIARIES PARENT COMPANY STATEMENTS OF COMPREHENSIVE INCOME 2023 2022 2021 For the Years Ended September 30, 2023 2022 2021 General and administrative expenses $ (846,930 ) $ (972,215 ) $ (68,722 Interest income 2 5 13 Equity in earnings of subsidiaries and VIEs 5,442,910 7,209,698 4,659,512 NET INCOME ATTRIBUTABLE TO BON NATURAL LIFE LIMITED 4,595,982 6,237,488 4,590,803 Foreign currency translation adjustment (1,050,274 ) (2,853,392 ) 610,323 COMPREHENSIVE INCOME ATTRIBUTABLE TO BON NATURAL LIFE LIMITED $ 3,545,708 $ 3,384,096 $ 5,201,126 BON NATURAL LIFE LIMITED AND SUBSIDIARIES PARENT COMPANY STATEMENTS OF CASH FLOWS 2023 2022 2021 For the Years Ended September 30, 2023 2022 2021 CASH FLOWS FROM OPERATING ACTIVITIES: Net income $ 4,595,982 $ 6,237,488 $ 4,590,803 Adjustments to reconcile net cash flows from operating activities: Equity in earnings of subsidiaries and VIEs (5,442,910 ) (7,209,698 ) (4,659,512 ) Amortization of stock-based compensation 131,092 170,883 44,910 Issuance of ordinary shares for services 218,304 - - Changes in operating assets and liabilities: Payables due to subsidiaries (1,596,032 ) 597,475 Prepaid expenses and other current assets 65,669 (40,148 ) (2,600 Net cash used in operating activities (2,027,898 ) (244,000 ) (26,399 CASH FLOWS FROM INVESTING ACTIVITIES: Payment of acquisition deposit - - (1,000,000 Net cash used in investing activities - - (1,000,000 CASH FLOWS FROM FINANCING ACTIVITIES: Net proceeds from issuance of ordinary shares 2,027,544 - 11,271,480 Proceeds from exercise of stock options - 140 Cash lent to subsidiaries and VIE - - (10,000,000 Net cash provided by (used in) financing activities 2,027,544 140 1,271,480 CHANGES IN CASH (354 ) (243,860 ) 245,081 CASH beginning of year 1,221 245,081 - CASH, end of year $ 867 $ 1,221 $ 245,081 BON NATURAL LIFE LIMITED AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) March 31, 2024 September 30, 2023 As of March 31, 2024 September 30, 2023 ASSETS CURRENT ASSETS Cash $ 717,879 $ 112,751 Short-term investments - 65 Accounts receivable, net 8,108,271 4,602,466 Inventories, net 1,437,180 987,287 Advance to suppliers, net 15,414,883 15,117,191 Acquisition deposit 1,000,000 1,000,000 Prepaid expenses and other current assets 1,583,606 2,363,704 TOTAL CURRENT ASSETS 28,261,819 24,183,464 Property, plant and equipment, net 20,613,211 21,064,043 Intangible assets, net 992,544 995,227 Right-of-use lease assets, net 199,679 312,067 Deferred tax assets, net 12,672 1,335 TOTAL ASSETS $ 50,079,925 $ 46,556,136 LIABILITIES AND EQUITY CURRENT LIABILITIES Short-term loans $ 4,617,414 $ 2,509,890 Current portion of long-term loans 473,111 419,610 Accounts payable 1,284,816 1,404,937 Due to related parties 188,640 83,380 Taxes payable 2,523,163 2,718,687 Deferred revenue 497,937 106,514 Accrued expenses and other current liabilities 1,797,826 2,140,900 Operating lease liability, current 202,552 227,297 TOTAL CURRENT LIABILITIES 11,585,459 9,611,215 Long-term loans 1,176,624 871,368 Operating lease liability, noncurrent - 91,720 TOTAL LIABILITIES $ 12,762,083 $ 10,574,303 COMMITMENTS AND CONTINGENCIES EQUITY Ordinary shares, ($ 0.001 270,000,000 1,413,867 1,173,867 * 1,414 1,174 Additional paid in capital 19,097,652 18,088,056 Statutory reserve 2,372,871 2,372,871 Retained earnings 18,693,477 18,703,996 Accumulated other comprehensive income (3,470,975 ) (3,681,445 ) TOTAL BON NATURAL LIFE LIMITED SHAREHOLDERS’ EQUITY 36,694,439 35,484,652 Non-controlling interest 623,403 497,181 TOTAL SHAREHOLDERS’ EQUITY 37,317,842 35,981,833 TOTAL LIABILITIES AND EQUITY $ 50,079,925 $ 46,556,136 * Retroactively restated to reflect the Company’s 1-for-10 BON NATURAL LIFE LIMITED AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (UNAUDITED) 2024 2023 For the six months ended March 31, 2024 2023 REVENUE $ 10,183,553 $ 14,149,967 COST OF REVENUE (7,215,116 ) (9,432,619 ) GROSS PROFIT 2,968,437 4,717,348 OPERATING EXPENSES Selling expenses (103,096 ) (136,164 ) General and administrative expenses (1,890,452 ) (1,465,955 ) Research and development expenses (890,384 ) (129,995 ) Total operating expenses (2,883,932 ) (1,732,114 ) INCOME FROM OPERATIONS 84,505 2,985,234 OTHER INCOME (EXPENSES) Interest income 161 8,732 Interest expense (143,747 ) (178,557 ) Unrealized foreign transaction exchange loss (gain) (2,747 ) 8,452 Government subsidies 61,081 11,916 Income from short-term investments - - Other income (expenses) 49,683 (223,044 ) Total other expenses, net (35,569 ) (372,501 ) INCOME BEFORE INCOME TAX PROVISION 48,936 2,612,733 INCOME TAX PROVISION (90,734 ) (510,077 ) NET (LOSS) INCOME (41,798 ) 2,102,656 Less: net loss attributable to non-controlling interest (31,279 ) (17,104 ) NET (LOSS) INCOME ATTRIBUTABLE TO BON NATURAL LIFE LIMITED $ (10,519 ) $ 2,119,760 NET (LOSS) INCOME $ (41,798 ) $ 2,102,656 OTHER COMPREHENSIVE INCOME Total foreign currency translation adjustment 367,971 1,071,621 TOTAL COMPREHENSIVE INCOME 326,173 3,174,277 Less: comprehensive loss attributable to non-controlling interest 126,222 (17,104 ) COMPREHENSIVE INCOME ATTRIBUTABLE TO BON NATURAL LIFE LIMITED $ 199,951 $ 3,191,381 (LOSS) EARNINGS PER SHARE ATTRIBUTABLE TO BON NATURAL LIFE LIMITED Basic * $ (0.03 ) $ 2.36 Diluted * $ (0.03 ) $ 2.34 WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING Basic * 1,285,702 891,831 Diluted * 1,285,702 897,924 * Retroactively restated to reflect the Company’s 1-for-10 BON NATURAL LIFE LIMITED AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY FOR THE SIX MONTHS ENDED MARCH 31, 2024 AND 2023 (UNAUDITED) Common shares Additional paid-in Statutory Retained Accumulated other comprehensive Total shareholders’ Non- controlling Total Shares* Amount capital reserve earnings loss equity interest equity Balance at September 30, 2022 839,623 $ 840 $ 15,711,450 $ 1,804,116 $ 14,676,769 $ (2,631,171 ) $ 29,562,004 $ 530,492 $ 30,092,496 Issuance of ordinary shares in a private placement, net 275,000 275 2,199,725 2,200,000 2,220,000 Share-based compensation 35,000 35,000 35,000 Net income - 2,119,760 2,119,760 (17,104 ) 2,102,656 Foreign currency translation adjustment 1,071,621 1,071,621 1,071,621 Balance at March 31, 2023 1,114,623 $ 1,115 $ 17,946,175 $ 1,804,116 $ 16,796,529 $ (1,559,550 ) $ 34,988,384 $ 513,387 $ 35,501,771 Balance at September 30, 2023 1,173,867 $ 1,174 $ 18,088,056 $ 2,372,871 $ 18,703,996 $ (3,681,445 ) $ 35,484,652 $ 497,181 $ 35,981,833 Share-based compensation 240,000 240 1,009,596 1,009,836 1,009,836 Net loss (10,519 ) (10,519 ) (31,279 ) (41,798 ) Net income (loss) - (10,519 ) (10,519 ) (31,279 ) (41,798 ) Foreign currency translation adjustment 210,470 210,470 157,501 367,971 Balance at March 31, 2024 1,413,867 $ 1,414 $ 19,097,652 $ 2,372,871 $ 18,693,477 $ (3,470,975 ) $ 36,694,439 $ 623,403 $ 37,317,842 * Retroactively restated to reflect the Company’s 1-for-10 share consolidation effective on April 11, 2024. BON NATURAL LIFE LIMITED AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) For the six months ended March 31, 2024 2023 Cash flows from operating activities Net (loss) income $ (41,798 ) $ 2,102,656 Adjustments to reconcile net income to cash provided by operating activities Allowance for doubtful accounts 21,441 - Depreciation and amortization 686,038 282,888 Inventory reserve 58,349 105,314 Deferred income tax (11,345 ) (25,749 ) Amortization of operating lease right-of-use assets 115,882 114,179 Share-based compensation 1,009,836 35,000 Unrealized foreign currency exchange loss (gain) 2,747 (8,452 ) Changes in operating assets and liabilities: Accounts receivable (3,464,205 ) (2,198,450 ) Inventories (498,736 ) (124,601 ) Advance to suppliers, net (160,908 ) (3,353,433 ) Prepaid expenses and other current assets 801,781 (3,595,458 ) Accounts payable (135,111 ) 100,386 Operating lease liabilities (120,040 ) (115,170 ) Taxes payable (224,459 ) 386,510 Deferred revenue 391,057 781,183 Accrued expenses and other current liabilities (314,702 ) 3,335,205 Net cash used in operating activities (1,884,173 ) (2,177,992 ) Cash flows from investing activities Purchase of property and equipment (693 ) (15,131 ) Capital expenditures on construction-in-progress - (2,970 ) Net cash used in investing activities (693 ) (18,101 ) Cash flows from financing activities Net proceeds from issuance of ordinary shares - 2,200,000 Proceeds from short-term loans 3,619,267 259,767 Proceeds from long-term loans 854,514 - Repayment of short-term loans (1,534,052 ) (79,165 ) Repayment of long-term loans (508,629 ) (437,412 ) Proceeds from (repayment of) borrowings from related parties 80,752 (1,038 ) Repayment of capital lease - (27,236 ) Net cash provided by financing activities 2,511,853 1,914,916 Effect of changes of foreign exchange rates on cash (21,858 ) (17,412 ) Net increase (decrease) in cash 605,128 (298,589 ) Cash, beginning of period 112,751 840,861 Cash, end of period $ 717,879 $ 542,272 Supplemental disclosure of cash flow information Cash paid for interest expense $ 143,747 $ 178,557 Cash paid for income tax $ - $ 500,251 Supplemental disclosure of non-cash investing and financing activities Amortization of share-based compensation for initial public offering services $ 24,000 $ 35,000 Right-of-use assets obtained in exchange for operating lease obligations $ - $ 458,181

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The accompanying consolidated financial statements include the financial statements of the Company, and its wholly owned subsidiaries. All inter-company balances and transactions are eliminated upon consolidation.
Non-controlling interests	Non-controlling interests Non-controlling interests represent minority shareholders’ 25 49
Uses of estimates	Uses of estimates In preparing the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“US GAAP”), management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates are based on information as of the date of the consolidated financial statements. Significant estimates required to be made by management include, but are not limited to, the allowance for estimated uncollectible receivables, realizability of advance to suppliers, inventory valuations, useful lives of property, plant and equipment, intangible assets, the recoverability of long-lived assets, provision necessary for contingent liabilities, fair value of stock-based compensation, revenue recognition and realization of deferred tax assets. The inputs into the Company’s judgments and estimates consider the economic implications of COVID-19 on the Company’s critical and significant accounting estimates. Actual results could differ from those estimates.
Risks and Uncertainties	Risks and Uncertainties The main operation of the Company is located in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by political, economic, and legal environments in the PRC, as well as by the general state of the PRC economy. The Company’s results may be adversely affected by changes in the political, regulatory and social conditions in the PRC. Although the Company has not experienced losses from these situations and believes that it is in compliance with existing laws and regulations including its organization and structure disclosed in Note 1, this may not be indicative of future results. The development and commercialization of natural and healthy extracts and compounds products is highly competitive, and the industry currently is characterized by rapidly changing technologies, significant competition and a strong emphasis on intellectual property. The Company may face competition with respect to its current and future pharmaceutical product candidates from major pharmaceutical companies in China. Since March 2023, the Company has recovered from the COVID-19 pandemic. However, the Company’s operations may be further affected by the ongoing outbreak of COVID-19 pandemic, A COVID-19 resurgence could negatively affect the execution of customer contracts, the collection of customer payments, or disruption of the Company’s supply chain. The continued uncertainties associated with COVID-19 may cause the Company’s revenue and cash flows to underperform in the next 12 months. The extent of the future impact of COVID-19 is still highly uncertain and cannot be predicted as of the date the Company’s consolidated financial statements are released.
Cash	Cash Cash includes currency on hand and deposits held by banks that can be added or withdrawn without limitation. The Company maintains most of its bank accounts in the PRC. Cash balances in bank accounts in PRC are insured by the PRC regulation and are not insured by the Federal Deposit Insurance Corporation (see Note 16)
Accounts receivable, net	Accounts receivable, net The Company determines the adequacy of reserves for doubtful accounts based on individual account analysis and historical collection trend. The Company establishes a provision for doubtful receivables when there is objective evidence that the Company may not be able to collect amounts due. The allowance is based on management’s best estimate of specific losses on individual exposures, as well as a provision on historical trends of collections. Actual amounts received may differ from management’s estimate of credit worthiness and the economic environment. Delinquent account balances are written-off against the allowance for doubtful accounts after management has determined that the collection is not probable, Nil Nil 99,528 13,004 13,337 BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Advances to Suppliers, net	Advances to Suppliers, net Advances to suppliers consist of balances paid to suppliers for inventory raw materials and construction materials associated with the Company’s construction-in-progress projects that have not been provided or received. Advances to suppliers are reviewed periodically to determine whether their carrying value has become impaired. The Company considers the assets to be impaired if the collectability of the advance becomes doubtful. The Company uses the aging method to estimate the allowance for unrealizable balances. In addition, at each reporting date, the Company generally determines the adequacy of allowance for doubtful accounts by evaluating all available information, and then records specific allowances for those advances based on the specific facts and circumstances. As of September 30, 2023 and 2022, no
Inventories, net	Inventories, net Inventories are stated at net realizable value using weighted average method. Costs include the cost of raw materials, freight, direct labor and related production overhead. Any excess of the cost over the net realizable value of each item of inventories is recognized as a provision for diminution in the value of inventories. Net realizable value is the estimated selling price in the normal course of business less any costs to complete and sell products. The Company evaluates inventories on a quarterly basis for its net realizable value adjustments, and reduces the carrying value of those inventories that are obsolete or in excess of the forecasted usage to their estimated net realizable value based on various factors including aging, expiration dates, as applicable, taking into consideration historical and expected future product sales. The Company recorded inventory reserve of $ 1,079 6,869
Short-term investments	Short-term investments The Company’s short-term investments consist of wealth management financial products purchased from PRC banks, which can be redeemed at any time. The banks invest the Company’s fund in certain financial instruments including money market funds, bonds or mutual funds, with floating interest rates. The carrying values of the Company’s short-term investments approximate fair value because of their short-term maturities. The interest earned is recognized in the consolidated statements of income and comprehensive income over the contractual term of these investments. As of September 30, 2023 and 2022, short-term investments consisted of the following: SCHEDULE OF SHORT-TERM INVESTMENT September 30, 2023 September 30, 2022 Beginning balance $ - $ 1,703,314 Add: purchase wealth management financial products 65 5,097,816 Less: proceeds received upon maturity of short-term investments - (6,776,385 ) Foreign currency translation adjustments - (24,745 ) Ending balance of short-term investments $ 65 $ - BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) Investment income generated from short-term investments amounted to Nil 20,343 565
Fair value of financial instruments	Fair value of financial instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy prioritizes the inputs used to measure fair value. The hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: ● Level 1 — inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. ● Level 2 — inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted market prices for identical or similar assets in markets that are not active, inputs other than quoted prices that are observable and inputs derived from or corroborated by observable market data. ● Level 3 — inputs to the valuation methodology are unobservable. Unless otherwise disclosed, the fair value of the Company’s cash, short-term investment, accounts receivable, inventories, advance to suppliers, prepaid expenses and other current assets, accounts payable, short-term bank loans, accrued expenses and other current liabilities, taxes payable and due to related parties, approximate the fair value of the respective assets and liabilities as of September 30, 2023 and 2022 based upon the short-term nature of the assets and liabilities. The Company believes that the carrying amount of long-term loans approximates fair value at September 30, 2023 and 2022 based on the terms of the borrowings and current market rates as the rates of the borrowings are reflective of the current market rates.
Property, plant and equipment, net	Property, plant and equipment, net Property, plant and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization of property and equipment is provided using the straight-line method over their expected useful lives, as follows: SCHEDULE OF USEFUL LIVES OF PROPERTY, PLANT AND EQUIPMENT Useful life Buildings 20 Machinery and equipment 5 10 Automobiles 8 Office and electric equipment 3 5 Expenditures for maintenance and repairs, which do not materially extend the useful lives of the assets, are charged to expense as incurred. Expenditures for major renewals and betterments which substantially extend the useful life of assets are capitalized. The cost and related accumulated depreciation of assets retired or sold are removed from the respective accounts, and any gain or loss is recognized in the consolidated statements of income and comprehensive income in other income or expenses.
Construction-in-Progress (“CIP”)	Construction-in-Progress (“CIP”) Construction-in-progress represents property and buildings under construction and consists of construction expenditures, equipment procurement, and other direct costs attributable to the construction. Construction-in-progress is not depreciated. Upon completion and ready for intended use, construction-in-progress is reclassified to the appropriate category within property, plant and equipment. BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Intangible assets, net	Intangible assets, net The Company’s intangible assets primarily include two land use rights. A land use right in the PRC represents an exclusive right to occupy, use and develop a piece of land during the contractual term of the land use right. The cost of a land use right is usually paid in one lump sum at the date the right is granted. The prepayment usually covers the entire period of the land use right. The lump sum advance payment is capitalized and recorded as land use right and then charged to expense on a straight-line basis over the period of the right, which is normally 50 The Company acquired the first land use right of 4.1 acres located at Tongchuan City, Shaanxi Province of China at cost of approximately $ 0.2 8.2 0.3
Impairment of long-lived Assets	Impairment of long-lived Assets Long-lived assets, such as property, plant and equipment, land use rights and long-term investment, are reviewed for impairment when events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. Recoverability of a long-lived asset or asset group to be held and used is measured by a comparison of the carrying amount of an asset or asset group to the estimated undiscounted future cash flows expected to be generated by the asset or asset group. If the carrying value of an asset or asset group exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount that the carrying value exceeds the estimated fair value of the asset or asset group. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. Assets to be disposed are reported at the lower of carrying amount or fair value less costs to sell, and are no longer depreciated. No
Leases	Leases ASC 842 requires that lessees recognize ROU assets and lease liabilities calculated based on the present value of lease payments for all lease agreements with terms that are greater than twelve months. ASC 842 distinguishes leases as either a finance lease or an operating lease that affects how the leases are measured and presented in the statement of operations and statement of cash flows. For operating leases, the Company calculated ROU assets and lease liabilities based on the present value of the remaining lease payments as of the date of adoption. There were no changes in the Company’s capital lease portfolio, which are now titled “finance leases” under ASC 842. Upon the adoption of the new guidance on October 1, 2020, the Company recognized operating lease right of use assets and operating lease liabilities of approximately $ 0.2 BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Foreign Currency Translation	Foreign Currency Translation The functional currency for Bon Natural is the U.S Dollar (“US$”). Tea Essence uses Hong Kong dollar as its functional currency. However, Bon Natural, and Tea Essence currently only serve as the holding companies and did not have active operations as of September 30, 2023. The Company operates its business through its subsidiaries in the PRC as of September 30, 2023. The functional currency of the Company’s subsidiaries is the Chinese Yuan (“RMB”). The Company’s consolidated financial statements have been translated into US$. Assets and liabilities accounts are translated using the exchange rate at each reporting period end date. Equity accounts are translated at historical rates. Income and expense accounts are translated at the average rate of exchange during the reporting period. The resulting translation adjustments are reported under other comprehensive income. Gains and losses resulting from the translations of foreign currency transactions and balances are reflected in the results of operations. The RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into US$ at the rates used in translation. The following table outlines the currency exchange rates that were used in creating the consolidated financial statements: SCHEDULE OF CURRENCY EXCHANGE RATES September 30, 2023 September 30, 2022 September 30, 2021 Period-end spot rate US$ 1 7.2960 US$ 1 7.1135 US$ 1 6.4580 Average rate US$ 1 7.0533 US$ 1 6.5532 US$ 1 6.5095
Revenue recognition	Revenue recognition To determine revenue recognition for contracts with customers, the Company performs the following five steps : (i) identify the contract(s) with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable that a significant future reversal will not In accordance to ASC 606, the Company recognizes revenue when it transfers its goods and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange. The Company accounts for the revenue generated from sales of its products to its customers, in which the Company is acting as a principal in these transactions, is subject to inventory risk, has latitude in establishing prices, and is responsible for fulfilling the promise to provide customers the specified goods. All of the Company’s contracts have single performance obligation as the promise is to transfer the individual goods to customers, and there are no other separately identifiable promises in the contracts. The Company’s revenue streams are recognized at a point in time when title and risk of loss passes and the customer accepts the goods, which generally occurs at delivery. The Company’s products are sold with no right of return and the Company does not provide other credits or sales incentive to customers. The Company’s sales are net of value added tax (“VAT”) and business tax and surcharges collected on behalf of tax authorities in respect of product sales. BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Contract Assets and Liabilities	Contract Assets and Liabilities Payment terms are established on the Company’s pre-established credit requirements based upon an evaluation of customers’ credit. The Company did not have contract assets as of September 30, 2023 and 2022. The Company’s contract liability primarily relates to unsatisfied performance obligations when payment has been received from customers before the Company’s products are delivered, and are recorded as deferred revenue on the consolidated balance sheets. Costs of fulfilling customers’ purchase orders, such as shipping, handling and delivery, which occur prior to the transfer of control, are recognized in selling, general and administrative expense when incurred. Deferred revenue amounted to $ 106,514 188,745 1,096,101 133,533 1,080,178 403,399
Disaggregation of Revenues	Disaggregation of Revenues The Company disaggregates its revenue from contracts by product types, as the Company believes it best depicts how the nature, amount, timing and uncertainty of the revenue and cash flows are affected by economic factors. The Company’s disaggregation of revenues for the years ended September 30, 2023, 2022 and 2021 are disclosed in Note 18 of the consolidation financial statements.
Research and development expenses	Research and development expenses The Company expenses all internal research and development costs as incurred, which primarily comprise employee costs, internal and external costs related to execution of studies, including manufacturing costs, facility costs of the research center, and amortization and depreciation to intangible assets and property, plant and equipment used in the research and development activities. For the years ended September 30, 2023, 2022 and 2021, research and development expense were approximately $ 298,469 424,558 249,050
Selling, General and Administrative Expenses	Selling, General and Administrative Expenses Selling expenses represents primarily costs of payroll, benefits, commissions for sales representatives and advertising expenses. General and administrative expenses represent primarily payroll and benefits costs for administrative employees, rent and operating costs of office premises, depreciation and amortization of office facilities, professional fees and other administrative expenses.
Advertising expense	Advertising expense Advertising expenses primarily relate to promotion of the Company’s brand name and products through outdoor billboards and social media such as Weibo and WeChat. Advertising expenses are included in selling expenses in the consolidated statements of income and comprehensive income. Advertising expenses amounted to $ 11,344 41,578 25,397
Government subsidies	Government subsidies Government subsidies primarily relate to local government’s cash award to High and New Technology Enterprises (“HNTEs”) to encourage entrepreneurship and stimulate local economy. Such awards are granted on a case-by-case basis by local government. The Company’s subsidiary, Xi’an App-chem was approved as a HNTE and received government subsidy in the form of export sales refund and cash awards based on annual financial performance. BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) The Company recognizes government subsidies as other operating income when they are received because they are not subject to any past or future conditions, there are no performance conditions or conditions of use, and they are not subject to future refunds. Government subsidies received and recognized as other operating income totaled $ 25,415 1,306,627 449,972
Income taxes	Income taxes The Company accounts for current income taxes in accordance with the laws of the relevant tax authorities. Deferred income taxes are recognized when temporary differences exist between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period including the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. An uncertain tax position is recognized only if it is “more likely than not” that the tax position would be sustained in a tax examination. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the period incurred. As of September 30, 2023, the Company had income tax payable of $ 1,041,862 The Company’s subsidiaries in China are subject to the income tax laws of the PRC. No significant income was generated outside the PRC for the years ended September 30, 2023, 2022 and 2021. As of September 30, 2023 and 2022, all of the Company’s tax returns of its PRC subsidiaries remain open for statutory examination by PRC tax authorities.
Value added tax (“VAT”)	Value added tax (“VAT”) Sales revenue represents the invoiced value of goods, net of VAT. The VAT is based on gross sales price and VAT rates range up to 17% (starting from May 1, 2018, VAT rate was lowered to 16%, and starting from April 1, 2019, VAT rate was further lowered to 13%) 1,338,800 For export sales, VAT is not imposed on gross sales price, and the VAT related to purchasing raw materials is refunded after the export is completed. BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Employee Defined Contribution Plan	Employee Defined Contribution Plan The Company’s subsidiaries in the PRC participate in a government-mandated multi-employer defined contribution plan pursuant to which pension, work-related injury benefits, maternity insurance, medical insurance, unemployment benefit and housing fund are provided to eligible full-time employees. The relevant labor regulations require the Company’s subsidiaries in the PRC to pay the local labor and social welfare authorities monthly contributions based on the applicable benchmarks and rates stipulated by the local government. The contributions to the plan are expensed as incurred. Employee social security and welfare benefits included as expenses in the accompanying consolidated statements of income and comprehensive income amounted to $ 93,190 80,150 54,189
Share Based Compensation	Share Based Compensation The Company accounts for share-based payment awards exchanged for services at the estimated grant date fair value of the award. The Company issued 57,000 63,333 Nil 3,600 2,244 2,960 3,750 1-for-10 The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. Expected Term - The expected term of options represents the period that the Company’s stock-based awards are expected to be outstanding based on the simplified method, which is the half-life from vesting to the end of its contractual term. Expected Volatility - The Company computes stock price volatility over expected terms based on its historical common stock trading prices. Risk-Free Interest Rate - The Company bases the risk-free interest rate on the benchmark interest rate for loans from financial institutions provided by the People’s Bank of China with an equivalent remaining term. Expected Dividend - The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models. BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Earnings per Share	Earnings per Share The Company computes earnings per share (“EPS”) in accordance with ASC 260, “Earnings per Share” (“ASC 260”). ASC 260 requires companies with complex capital structures to present basic and diluted EPS. Basic EPS is measured as net income divided by the weighted average common shares outstanding for the period. Diluted presents the dilutive effect on a per share basis of potential common shares (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. For the years ended September 30, 2023, 5,851 3,529 3,600 10,120 The following table sets forth the computation of basic and diluted earnings per share for the years ended September 30, 2023, 2022 and 2021: SCHEDULE OF EARNINGS PER SHARE 2023 2022 2021 For the Years ended September 30, 2023 2022 2021 Numerator: Net income attributable to ordinary shareholders $ 4,595,982 $ 6,237,488 $ 4,590,803 Denominator: Weighted-average number of ordinary shares outstanding – basic * 913,960 836,077 661,583 Outstanding options * 5,851 3,529 3,597 Outstanding warrants * - - 5,444 Potentially dilutive shares from outstanding options and warrants * 5,851 3,529 9,041 Weighted-average number of ordinary shares outstanding – diluted * 919,811 839,606 670,624 Earnings per share – basic * $ 5.03 $ 7.47 $ 6.94 Earnings per share – diluted * $ 5.00 $ 7.43 $ 6.85 * Retroactively restated to reflect the Company’s 1-for-10
Comprehensive income	Comprehensive income Comprehensive income consists of two components, net income and other comprehensive income (loss). The foreign currency translation gain or loss resulting from translation of the financial statements expressed in RMB to US$ is reported in other comprehensive income (loss) in the consolidated statements of income and comprehensive income.
Statement of Cash Flows	Statement of Cash Flows In accordance with ASC 230, “Statement of Cash Flows”, cash flows from the Company’s operations are formulated based upon the local currencies. As a result, amounts related to assets and liabilities reported on the consolidated statements of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets BON NATURAL LIFE LIMITED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), which requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost. ASU 2016-13 was subsequently amended by ASU 2018-19, ASU 2019-04, ASU 2019-05, ASU 2019-10 and ASU 2020-02. For public entities, ASU 2016-13 and its amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. For all other entities, this guidance and its amendments will be effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early application will be permitted for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is currently evaluating the effects of the guidance on the Company’s consolidated financial statements and related disclosures. In October 2020, the FASB issued ASU 2020-10, “Codification Improvements to Subtopic 205-10, presentation of financial statements”. The amendments in this Update improve the codification by ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to financial statements is codified in the disclosure section of the codification. That reduce the likelihood that the disclosure requirement would be missed. ASU 2020-10 is effective for the Company for annual and interim reporting periods beginning January 1, 2022. Early application of the amendments is permitted for any annual or interim period for which financial statements are available to be issued. The amendments in this Update should be applied retrospectively. An entity should apply the amendments at the beginning of the period that includes the adoption date. The Company is currently evaluating the impact of this new standard on Company’s consolidated financial statements and related disclosures.

ORGANIZATION AND BUSINESS DES_2

ORGANIZATION AND BUSINESS DESCRIPTION (Tables)	12 Months Ended
ORGANIZATION AND BUSINESS DESCRIPTION (Tables)	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
SCHEDULE OF SUBSIDIARIES COMPANY	Details of the subsidiaries of the Company as of September 30, 2023 were set out below: SCHEDULE OF SUBSIDIARIES COMPANY Name of Entity Date of Incorporation Place of Incorporation % of Ownership Principal Activities Bon Natural Life December 11, 2019 Cayman Islands Parent, 100 Investment holding Bon Natural Life U.S.A. February 7, 2023 U.S.A. 100 Investment holding Tea Essence January 9, 2020 Hong Kong 100 Investment holding Xi’an CMIT April 9, 2020 Xi.an City, PRC 100 WFOE, Investment holding Xi’an Youpincui September 8, 2021 Xi.an City, PRC 100 WFOE, Investment holding PRC Subsidiaries: Xi’an App- Chem Bio (Tech) April 23, 2006 Xi’an City, PRC 100 General administration and sales of the Company’s products to customers Xi’an YH September 15, 2009 Xi’an City, PRC 91 Research and development of product Bon Operating Companies (owned by Xi’an App-Chem) App-Chem Health April 17, 2006 Tongchuan City, PRC 100 Registered owner of land with an area of 12,904.5 square meters, no other business activities App-Chem Ag-tech April 19, 2013 Dali County, PRC 100 Product manufacturing App-Chem Guangzhou April 27, 2018 Guangzhou City, PRC 100 Raw material purchase Tongchuan DT May 22, 2017 Tongchuan City, PRC 100 Product manufacturing Xi’an DT April 24, 2015 Xi’an City, PRC 75 Research and development of product Tianjin YHX September 16, 2019 Tianjin City, PRC 51 Raw material purchase Gansu BMK March 11, 2020 Jiuquan City, PRC 100 Product manufacturing Bozhou DT March 9, 2023 Bozhou City, PRC 100 Product manufacturing

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	Sep. 30, 2023
Accounting Policies [Abstract]
SCHEDULE OF SHORT-TERM INVESTMENT	SCHEDULE OF SHORT-TERM INVESTMENT September 30, 2023 September 30, 2022 Beginning balance $ - $ 1,703,314 Add: purchase wealth management financial products 65 5,097,816 Less: proceeds received upon maturity of short-term investments - (6,776,385 ) Foreign currency translation adjustments - (24,745 ) Ending balance of short-term investments $ 65 $ -
SCHEDULE OF USEFUL LIVES OF PROPERTY, PLANT AND EQUIPMENT	Property, plant and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization of property and equipment is provided using the straight-line method over their expected useful lives, as follows: SCHEDULE OF USEFUL LIVES OF PROPERTY, PLANT AND EQUIPMENT Useful life Buildings 20 Machinery and equipment 5 10 Automobiles 8 Office and electric equipment 3 5
SCHEDULE OF CURRENCY EXCHANGE RATES	The following table outlines the currency exchange rates that were used in creating the consolidated financial statements: SCHEDULE OF CURRENCY EXCHANGE RATES September 30, 2023 September 30, 2022 September 30, 2021 Period-end spot rate US$ 1 7.2960 US$ 1 7.1135 US$ 1 6.4580 Average rate US$ 1 7.0533 US$ 1 6.5532 US$ 1 6.5095
SCHEDULE OF EARNINGS PER SHARE	The following table sets forth the computation of basic and diluted earnings per share for the years ended September 30, 2023, 2022 and 2021: SCHEDULE OF EARNINGS PER SHARE 2023 2022 2021 For the Years ended September 30, 2023 2022 2021 Numerator: Net income attributable to ordinary shareholders $ 4,595,982 $ 6,237,488 $ 4,590,803 Denominator: Weighted-average number of ordinary shares outstanding – basic * 913,960 836,077 661,583 Outstanding options * 5,851 3,529 3,597 Outstanding warrants * - - 5,444 Potentially dilutive shares from outstanding options and warrants * 5,851 3,529 9,041 Weighted-average number of ordinary shares outstanding – diluted * 919,811 839,606 670,624 Earnings per share – basic * $ 5.03 $ 7.47 $ 6.94 Earnings per share – diluted * $ 5.00 $ 7.43 $ 6.85 * Retroactively restated to reflect the Company’s 1-for-10

ACCOUNTS RECEIVABLE, NET (Table

ACCOUNTS RECEIVABLE, NET (Tables)	12 Months Ended
ACCOUNTS RECEIVABLE, NET (Tables)	Sep. 30, 2023
Credit Loss [Abstract]
SCHEDULE OF ACCOUNTS RECEIVABLE, NET	Accounts receivable, net, consists of the following: SCHEDULE OF ACCOUNTS RECEIVABLE, NET September 30, 2023 September 30, 2022 Accounts receivable $ 4,615,470 $ 6,797,644 Less: allowance for doubtful accounts (13,004 ) (13,337 ) Accounts receivable, net $ 4,602,466 $ 6,784,307
SCHEDULE OF ACCOUNTS RECEIVABLE AND SUBSEQUENT COLLECTION BY AGING BUCKET	The following table summarizes the Company’s accounts receivable and subsequent collection by aging bucket: SCHEDULE OF ACCOUNTS RECEIVABLE AND SUBSEQUENT COLLECTION BY AGING BUCKET Accounts Receivable by aging bucket Balance as of September 30, 2023 Subsequent collection % of subsequent collection Less than 3 months $ 4,603,299 $ 3,487,207 75.8 % From 4 to 6 months - - - % From 7 to 9 months - - - % From 10 to 12 months - - - % Over 1 year 12,171 - - % Total gross accounts receivable 4,615,470 3,487,207 75.8 % Allowance for doubtful accounts (13,004 ) Accounts Receivable, net $ 4,602,466 $ 3,487,207 75.8 %
SCHEDULE OF ALLOWANCE FOR DOUBTFUL ACCOUNTS	Allowance for doubtful accounts movement is as follows: SCHEDULE OF ALLOWANCE FOR DOUBTFUL ACCOUNTS September 30, 2023 September 30, 2022 Beginning balance $ 13,337 $ 14,691 Additions - - Write-off uncollectible balance - - Foreign currency translation adjustments (334 ) (1,354 ) Ending balance $ 13,004 $ 13,337

INVENTORIES, NET (Tables)

INVENTORIES, NET (Tables)	12 Months Ended
INVENTORIES, NET (Tables)	Sep. 30, 2023
Inventory Disclosure [Abstract]
SCHEDULE OF INVENTORIES	Inventories, net, consist of the following: SCHEDULE OF INVENTORIES September 30, 2023 September 30, 2022 Raw materials $ 12,715 $ 677,042 Finished goods 975,651 1,051,947 Inventory valuation allowance (1,079 ) (6,869 ) Total inventory, net $ 987,287 $ 1,722,120

ADVANCES TO SUPPLIERS, NET (Tab

ADVANCES TO SUPPLIERS, NET (Tables)	12 Months Ended
ADVANCES TO SUPPLIERS, NET (Tables)	Sep. 30, 2023
Advances To Suppliers Net
SCHEDULE OF ADVANCES TO SUPPLIERS	Advances to suppliers, net, consist of the following: SCHEDULE OF ADVANCES TO SUPPLIERS Schedule of Advances to suppliers: September 30, 2023 September 30, 2022 Raw materials purchase $ 6,406,488 $ 3,654,520 Construction of the CIP 6,716,009 2,105 Machinery and equipment 1,918,860 - Others 75,834 435,365 Less: allowance for doubtful accounts - - Advances to suppliers, net $ 15,117,191 $ 4,091,990

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT, NET (Tables)	12 Months Ended
PROPERTY, PLANT AND EQUIPMENT, NET (Tables)	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY, PLANT, AND EQUIPMENT	Property, plant and equipment, net, consists of the following: SCHEDULE OF PROPERTY, PLANT, AND EQUIPMENT September 30, 2023 September 30, 2022 Buildings $ 11,621,665 $ 967,530 Machinery, equipment and furniture 6,207,931 1,866,760 Motor Vehicles 210,201 201,537 Construction-in-progress (“CIP”) (1) 5,582,213 20,274,698 Subtotal 23,622,010 23,310,525 Less: accumulated depreciation (2,557,967 ) (1,686,088 ) Property, plant and equipment, net $ 21,064,043 $ 21,624,437 Depreciation expense was $ 945,507 210,916 219,906 (1) Construction-in-progress (“CIP”) represents direct costs of construction incurred for the Company’s manufacturing facilities. On August 16, 2017, the Company’s subsidiary, Xi’an App-Chem Bio (Tech) Co.,Ltd. started to construct a new manufacturing plant in Tongchuan City (“Tongchuan Project”), Shaanxi Province, with total budget of RMB 95.0 13.4 114.0 16.0 10,678,336 4,305,847
SCHEDULE OF FUTURE MINIMUM CAPITAL EXPENDITURES ON THE CONSTRUCTION-IN-PROGRESS	As of September 30, 2023, future minimum capital expenditures on the Company’s the CIP project are estimated as follows: SCHEDULE OF FUTURE MINIMUM CAPITAL EXPENDITURES ON THE CONSTRUCTION-IN-PROGRESS Years ending September 30, Yumen 2024 $ 5,000,000 2025 - 2026 - 2027 - Total $ 5,000,000

INTANGIBLE ASSETS, NET (Tables)

INTANGIBLE ASSETS, NET (Tables)	12 Months Ended
INTANGIBLE ASSETS, NET (Tables)	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
SCHEDULE OF INTANGIBLE ASSETS	Intangible assets, net mainly consist of the following: SCHEDULE OF INTANGIBLE ASSETS September 30, 2023 September 30, 2022 Land use rights $ 1,067,134 $ 430,985 Less: accumulated amortization (71,907 ) (64,818 ) Land use rights, net $ 995,227 $ 366,167
SCHEDULE OF AMORTIZATION EXPENSES	SCHEDULE OF AMORTIZATION EXPENSES Years ending September 30, Amortization expense 2024 $ 21,649 2025 21,649 2026 21,649 2027 21,649 2028 21,649 Thereafter 886,982 Total $ 995,227

DEBT (Tables)

DEBT (Tables)	12 Months Ended
DEBT (Tables)	Sep. 30, 2023
Debt Disclosure [Abstract]
SCHEDULE OF SHORT-TERM LOANS	(a) Short-term loans: SCHEDULE OF SHORT-TERM LOANS September 30, 2023 September 30, 2022 China Construction Bank (“CCB’) (1) $ 42,785 $ 34,765 Shanghai Pudong Development Bank (“SPD Bank”) (2) 1,370,614 1,405,777 China Construction Bank (3) 137,061 140,578 Beijing Bank (4) 822,368 843,467 Industrial and Commercial Bank of China (5) 137,061 - Total short-term loans $ 2,509,890 $ 2,424,587
SCHEDULE OF LONG -TERM LOANS	(b) Long-term loans: SCHEDULE OF LONG -TERM LOANS September 30, 2023 September 30, 2022 Xi’an High-Tech Emerging Industry Investment Fund Partnership (6) $ 44,747 $ 1,082,449 Webank Co., Ltd. (7) 209,133 262,813 China Resources Shenzhen International Investment Trust (8) 22,844 179,237 Huaxia Bank (9) 603,070 590,426 Qishang Bank (10) 411,184 210,867 Total 1,290,978 2,325,792 Less: current portion of long-term loans (419,610 ) (2,135,979 ) Total long-term loans $ 871,368 $ 189,813

RELATED PARTY TRANSACTIONS (Tab

RELATED PARTY TRANSACTIONS (Tables)	12 Months Ended
RELATED PARTY TRANSACTIONS (Tables)	Sep. 30, 2023
Related Party Transactions [Abstract]
SCHEDULE OF DUE FROM TO RELATED PARTIES	SCHEDULE OF DUE FROM TO RELATED PARTIES (a) Due to related parties Related party relationship September 30, 2023 September 30, 2022 Wenhu Guo Senior Management of the Company $ 6,168 $ 3,290 Yongwei Hu Chief Executive Officer and Controlling shareholder of the Company 3,392 6,583 Jing Liu Wife of the controlling shareholder 18,925 - Sheying Wang Senior Management of the Company 3,016 3,093 Yuantao Wang 49% shareholder of Tianjin YHX 23,650 59,870 Shujie Mou Senior Management of Tianjin YHX 28,229 - Total due to related parties $ 83,380 $ 72,836 As of September 30, 2023 and 2022, the balance of due to related parties was comprised of the Company’s borrowings from related parties and was used for working capital during the Company’s normal course of business. Such advance was non-interest bearing and due on demand. (b) Due from related parties Related party relationship September 30, 2023 September 30, 2022 Wenjuan Chen Senior Management of the Company $ 8,358 $ - Lu Jiang Employee of the Company 53 - Total due from related parties $ 8,411 $ - As of September 30, 2023 and 2022, the balance of due from related parties was mainly comprised of advance to the employees for business purposes.

TAXES (Tables)

TAXES (Tables)	12 Months Ended
TAXES (Tables)	Sep. 30, 2023
Income Tax Disclosure [Abstract]
SCHEDULE OF EFFECTIVE TAX RATE	The following table reconciles the China statutory rates to the Company’s effective tax rate for the years ended September 30, 2023, 2022 and 2021: SCHEDULE OF EFFECTIVE TAX RATE For the Years Ended September 30, 2023 2022 2021 PRC statutory income tax rate 25.0 % 25.0 % 25.0 % Effect of income tax holiday (12.0 )% (11.0 )% (9.5 )% Permanent difference 0.6 % 0.1 % 0.5 % Research and development deduction (5.4 )% (4.2 )% (3.4 )% Change in valuation allowance 9.8 % 7.0 % 2.5 % Effective tax rate 18.0 % 16.9 % 15.1 %
SCHEDULE OF COMPONENTS OF THE INCOME TAX PROVISION (BENEFIT)	The components of the income tax provision (benefit) are as follows: SCHEDULE OF COMPONENTS OF THE INCOME TAX PROVISION (BENEFIT) For the Years Ended September 30, 2023 2022 2021 Current tax provision: Cayman Islands $ - $ - $ - Hong Kong - - China 1,000,887 1,248,013 791,822 Sub-total 1,000,887 1,248,013 791,822 Current tax provision 1,000,887 1,248,013 791,822 Deferred tax provision (benefit): Cayman Islands - - - Hong Kong - - - China 1,411 19,012 29,109 Sub-total 1,411 19,012 29,109 Deferred tax provision (benefit) 1,411 19,012 29,109 ) Income tax provision $ 1,002,298 $ 1,267,025 $ 820,931
SCHEDULE OF DEFERRED TAX ASSETS	The Company’s deferred tax assets are comprised of the following: SCHEDULE OF DEFERRED TAX ASSETS September 30, 2023 September 30, 2022 Deferred tax assets derived from allowance for doubtful accounts and net operating losses (“NOL”) $ 300,846 $ 257,947 Less: valuation allowance (299,511 ) (255,179 ) Deferred tax assets $ 1,335 $ 2,768
SCHEDULE OF TAXED PAYABLE	Taxes payable consist of the following: SCHEDULE OF TAXED PAYABLE September 30, 2023 September 30, 2022 Income tax payable $ 1,296,206 $ 576,098 Value added tax payable 1,338,800 572,306 Other taxes payable 83,681 91,304 Total taxes payable $ 2,718,687 $ 1,239,708

OPERATING LEASE (Tables)

OPERATING LEASE (Tables)	12 Months Ended
OPERATING LEASE (Tables)	Sep. 30, 2023
Operating Lease
SCHEDULE OF BALANCE SHEET INFORMATION RELATED OPERATING LEASE	Balance sheet information related to the operating lease is as follows: SCHEDULE OF BALANCE SHEET INFORMATION RELATED OPERATING LEASE September 30, 2023 September 30, 2022 Operating lease assets: Operating lease right of use assets $ 312,067 $ 546,690 Total operating lease assets 312,067 546,690 　　 Operating lease obligations: Current operating lease liabilities 227,297 230,182 Non-current operating lease liabilities 91,720 327,202 Total operating lease obligations $ 319,017 $ 557,384
SCHEDULE OF WEIGHTED-AVERAGE OF OPERATING LEASE	The weighted-average remaining lease term and the weighted-average discount rate of leases are as follows: SCHEDULE OF WEIGHTED-AVERAGE OF OPERATING LEASE September 30, 2023 Weighted-average remaining lease term 1.4 Weighted-average discount rate 4.75 %
SCHEDULE OF MATURITY OF OPERATING LEASE LIABILITIES	The following table summarizes the maturity of operating lease liabilities as of September 30, 2023: SCHEDULE OF MATURITY OF OPERATING LEASE LIABILITIES 12 months ending March 31, US$ 2024 $ 236,512 2025 92,580 2026 - Total lease payments 329,091 Less: imputed interest (10,074 ) Total lease liabilities $ 319,017

SHAREHOLDERS_ EQUITY (Tables)

SHAREHOLDERS’ EQUITY (Tables)	12 Months Ended
SHAREHOLDERS’ EQUITY (Tables)	Sep. 30, 2023
Equity [Abstract]
SCHEDULE OF WARRANT ACTIVITY	A summary of warrants activity for the years ended September 30, 2023, 2022 and 2021 was as follows: SCHEDULE OF WARRANT ACTIVITY Number of warrants* Weighted Weighted Outstanding, September 30, 2021 10,120 $ 50.00 - Granted - - - Forfeited - - - Exercised (10,120 ) 50.00 - Exercisable, September 30, 2022 - $ - - Granted 275,000 8.80 1.3 Forfeited - - - Exercised - - - Outstanding, September 30, 2023 275,000 $ 8.80 1.3 Exercisable, September 30, 2023 275,000 $ 8.80 1.3 (* Retroactively restated to reflect the Company’s 1-for-10
SCHEDULE OF NON-CONTROLLING INTEREST	SCHEDULE OF NON-CONTROLLING INTEREST Xi’an DT Tianjin YHX Total As of September 30, 2022 $ 472,812 $ 57,680 $ 530,492 Non-controlling interest, beginning $ 472,812 $ 57,680 $ 530,492 Net loss attributable to non-controlling interest (5,700 ) (37,600 ) (43,300 ) Foreign currency translation adjustment 1,315 8,674 9,989 As of September 30, 2023 $ 468,427 $ 28,754 $ 497,181 Non-controlling interest, ending $ 468,427 $ 28,754 $ 497,181

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	12 Months Ended
SHARE-BASED COMPENSATION (Tables)	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
SHARE-BASED COMPENSATION AWARDS MEASURED AT GRANT DATE FAIR VALUE	SHARE-BASED COMPENSATION AWARDS MEASURED AT GRANT DATE FAIR VALUE For the Years Ended September 30, 2023 2022 Exercise price* $ 0.10 $ 0.10 Expected term (years) 1 1 Expected stock price volatility 158.2 % 114.1 % Risk-free rate of interest 4.35 % 4.35 % Expected dividend rate 0 % 0 %
SUMMARY OF STOCK OPTION	The following table summarizes the Company’s stock option activities: SUMMARY OF STOCK OPTION Number of options* Weighted Average Exercise Price* Weighted Average Remaining Contractual Term Outstanding, September 30, 2021 3,600 $ 0.10 9.75 Granted 5,204 0.10 10.00 Forfeited - - Exercised (1,400 ) 0.10 - Outstanding, September 30, 2022 7,404 $ 0.10 9.25 Granted 3,750 0.10 10.00 Forfeited - - - Exercised (2,244 ) 0.10 - Outstanding, September 30, 2023 8,910 $ 0.10 9.03 Exercisable, September 30, 2023 5,785 $ 0.10 8.51 (* Retroactively restated to reflect the Company’s 1-for-10

DISAGGREGATION OF REVENUES (Tab

DISAGGREGATION OF REVENUES (Tables)	12 Months Ended
DISAGGREGATION OF REVENUES (Tables)	Sep. 30, 2023
Segment Reporting [Abstract]
SCHEDULE OF SEGMENT REPORTING REVENUE BY REGION	SCHEDULE OF SEGMENT REPORTING REVENUE BY REGION 2023 2022 2021 For Years ended September 30, 2023 2022 2021 PRC $ 28,971,115 $ 28,756,333 $ 23,704,259 Overseas 551,238 1,152,228 1,790,305 Total revenue $ 29,522,353 $ 29,908,561 $ 25,494,564
SCHEDULE OF SEGMENT REPORTING REVENUE BY PRODUCT CATEGORIES	The summary of our total revenues by product categories for the years ended September 30, 2023, 2022 and 2021 was as follows: SCHEDULE OF SEGMENT REPORTING REVENUE BY PRODUCT CATEGORIES 2023 2022 2021 For Years ended September 30, 2023 2022 2021 Fragrance compounds $ 14,315,810 $ 13,710,556 $ 12,744,029 Health supplements (solid drinks) 8,704,468 7,145,708 6,655,982 Bioactive food ingredients 6,502,075 9,052,297 6,094,553 Total revenue $ 29,522,353 $ 29,908,561 $ 25,494,564

FINANCIAL INFORMATION OF THE _2

FINANCIAL INFORMATION OF THE PARENT COMPANY (Tables)	12 Months Ended
FINANCIAL INFORMATION OF THE PARENT COMPANY (Tables)	Sep. 30, 2023
Condensed Financial Information Disclosure [Abstract]
SCHEDULE OF PARENT COMPANY FINANCIAL STATEMENTS	SCHEDULE OF PARENT COMPANY FINANCIAL STATEMENTS September 30, 2023 September 30, 2022 ASSETS CURRENT ASSETS Cash $ 867 $ 1,221 Acquisition deposit 1,000,000 1,000,000 Due from subsidiaries 10,998,557 9,402,525 Prepaid expenses and other current assets (22,920 ) 42,749 TOTAL CURRENT ASSETS 11,976,504 10,446,495 NON-CURRENT ASSETS Investment in subsidiaries 23,507,948 19,115,509 TOTAL ASSETS $ 35,484,452 $ 29,562,004 LIABILITIES AND SHAREHOLDERS’ EQUITY LIABILITIES $ - $ - COMMITMENTS AND CONTINGENCIES - SHAREHOLDERS’ EQUITY Ordinary shares, ($ 0.001 270,000,000 1,173,867 839,623 * $ 1,117 $ 840 Additional paid-in capital 18,182,202 15,711,450 Retained earnings 20,980,978 16,480,885 Accumulated other comprehensive income (loss) (3,679,845 ) (2,631,171 ) Total Bon Natural Life Limited shareholders’ equity 35,484,452 29,562,004 Total liabilities and Bon Natural Life Limited shareholders’ equity $ 35,484,452 $ 29,562,004 * Retroactively restated to reflect the Company’s 1-for-10 BON NATURAL LIFE LIMITED AND SUBSIDIARIES PARENT COMPANY STATEMENTS OF COMPREHENSIVE INCOME 2023 2022 2021 For the Years Ended September 30, 2023 2022 2021 General and administrative expenses $ (846,930 ) $ (972,215 ) $ (68,722 Interest income 2 5 13 Equity in earnings of subsidiaries and VIEs 5,442,910 7,209,698 4,659,512 NET INCOME ATTRIBUTABLE TO BON NATURAL LIFE LIMITED 4,595,982 6,237,488 4,590,803 Foreign currency translation adjustment (1,050,274 ) (2,853,392 ) 610,323 COMPREHENSIVE INCOME ATTRIBUTABLE TO BON NATURAL LIFE LIMITED $ 3,545,708 $ 3,384,096 $ 5,201,126 BON NATURAL LIFE LIMITED AND SUBSIDIARIES PARENT COMPANY STATEMENTS OF CASH FLOWS 2023 2022 2021 For the Years Ended September 30, 2023 2022 2021 CASH FLOWS FROM OPERATING ACTIVITIES: Net income $ 4,595,982 $ 6,237,488 $ 4,590,803 Adjustments to reconcile net cash flows from operating activities: Equity in earnings of subsidiaries and VIEs (5,442,910 ) (7,209,698 ) (4,659,512 ) Amortization of stock-based compensation 131,092 170,883 44,910 Issuance of ordinary shares for services 218,304 - - Changes in operating assets and liabilities: Payables due to subsidiaries (1,596,032 ) 597,475 Prepaid expenses and other current assets 65,669 (40,148 ) (2,600 Net cash used in operating activities (2,027,898 ) (244,000 ) (26,399 CASH FLOWS FROM INVESTING ACTIVITIES: Payment of acquisition deposit - - (1,000,000 Net cash used in investing activities - - (1,000,000 CASH FLOWS FROM FINANCING ACTIVITIES: Net proceeds from issuance of ordinary shares 2,027,544 - 11,271,480 Proceeds from exercise of stock options - 140 Cash lent to subsidiaries and VIE - - (10,000,000 Net cash provided by (used in) financing activities 2,027,544 140 1,271,480 CHANGES IN CASH (354 ) (243,860 ) 245,081 CASH beginning of year 1,221 245,081 - CASH, end of year $ 867 $ 1,221 $ 245,081 BON NATURAL LIFE LIMITED AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) March 31, 2024 September 30, 2023 As of March 31, 2024 September 30, 2023 ASSETS CURRENT ASSETS Cash $ 717,879 $ 112,751 Short-term investments - 65 Accounts receivable, net 8,108,271 4,602,466 Inventories, net 1,437,180 987,287 Advance to suppliers, net 15,414,883 15,117,191 Acquisition deposit 1,000,000 1,000,000 Prepaid expenses and other current assets 1,583,606 2,363,704 TOTAL CURRENT ASSETS 28,261,819 24,183,464 Property, plant and equipment, net 20,613,211 21,064,043 Intangible assets, net 992,544 995,227 Right-of-use lease assets, net 199,679 312,067 Deferred tax assets, net 12,672 1,335 TOTAL ASSETS $ 50,079,925 $ 46,556,136 LIABILITIES AND EQUITY CURRENT LIABILITIES Short-term loans $ 4,617,414 $ 2,509,890 Current portion of long-term loans 473,111 419,610 Accounts payable 1,284,816 1,404,937 Due to related parties 188,640 83,380 Taxes payable 2,523,163 2,718,687 Deferred revenue 497,937 106,514 Accrued expenses and other current liabilities 1,797,826 2,140,900 Operating lease liability, current 202,552 227,297 TOTAL CURRENT LIABILITIES 11,585,459 9,611,215 Long-term loans 1,176,624 871,368 Operating lease liability, noncurrent - 91,720 TOTAL LIABILITIES $ 12,762,083 $ 10,574,303 COMMITMENTS AND CONTINGENCIES EQUITY Ordinary shares, ($ 0.001 270,000,000 1,413,867 1,173,867 * 1,414 1,174 Additional paid in capital 19,097,652 18,088,056 Statutory reserve 2,372,871 2,372,871 Retained earnings 18,693,477 18,703,996 Accumulated other comprehensive income (3,470,975 ) (3,681,445 ) TOTAL BON NATURAL LIFE LIMITED SHAREHOLDERS’ EQUITY 36,694,439 35,484,652 Non-controlling interest 623,403 497,181 TOTAL SHAREHOLDERS’ EQUITY 37,317,842 35,981,833 TOTAL LIABILITIES AND EQUITY $ 50,079,925 $ 46,556,136 * Retroactively restated to reflect the Company’s 1-for-10 BON NATURAL LIFE LIMITED AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (UNAUDITED) 2024 2023 For the six months ended March 31, 2024 2023 REVENUE $ 10,183,553 $ 14,149,967 COST OF REVENUE (7,215,116 ) (9,432,619 ) GROSS PROFIT 2,968,437 4,717,348 OPERATING EXPENSES Selling expenses (103,096 ) (136,164 ) General and administrative expenses (1,890,452 ) (1,465,955 ) Research and development expenses (890,384 ) (129,995 ) Total operating expenses (2,883,932 ) (1,732,114 ) INCOME FROM OPERATIONS 84,505 2,985,234 OTHER INCOME (EXPENSES) Interest income 161 8,732 Interest expense (143,747 ) (178,557 ) Unrealized foreign transaction exchange loss (gain) (2,747 ) 8,452 Government subsidies 61,081 11,916 Income from short-term investments - - Other income (expenses) 49,683 (223,044 ) Total other expenses, net (35,569 ) (372,501 ) INCOME BEFORE INCOME TAX PROVISION 48,936 2,612,733 INCOME TAX PROVISION (90,734 ) (510,077 ) NET (LOSS) INCOME (41,798 ) 2,102,656 Less: net loss attributable to non-controlling interest (31,279 ) (17,104 ) NET (LOSS) INCOME ATTRIBUTABLE TO BON NATURAL LIFE LIMITED $ (10,519 ) $ 2,119,760 NET (LOSS) INCOME $ (41,798 ) $ 2,102,656 OTHER COMPREHENSIVE INCOME Total foreign currency translation adjustment 367,971 1,071,621 TOTAL COMPREHENSIVE INCOME 326,173 3,174,277 Less: comprehensive loss attributable to non-controlling interest 126,222 (17,104 ) COMPREHENSIVE INCOME ATTRIBUTABLE TO BON NATURAL LIFE LIMITED $ 199,951 $ 3,191,381 (LOSS) EARNINGS PER SHARE ATTRIBUTABLE TO BON NATURAL LIFE LIMITED Basic * $ (0.03 ) $ 2.36 Diluted * $ (0.03 ) $ 2.34 WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING Basic * 1,285,702 891,831 Diluted * 1,285,702 897,924 * Retroactively restated to reflect the Company’s 1-for-10 BON NATURAL LIFE LIMITED AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY FOR THE SIX MONTHS ENDED MARCH 31, 2024 AND 2023 (UNAUDITED) Common shares Additional paid-in Statutory Retained Accumulated other comprehensive Total shareholders’ Non- controlling Total Shares* Amount capital reserve earnings loss equity interest equity Balance at September 30, 2022 839,623 $ 840 $ 15,711,450 $ 1,804,116 $ 14,676,769 $ (2,631,171 ) $ 29,562,004 $ 530,492 $ 30,092,496 Issuance of ordinary shares in a private placement, net 275,000 275 2,199,725 2,200,000 2,220,000 Share-based compensation 35,000 35,000 35,000 Net income - 2,119,760 2,119,760 (17,104 ) 2,102,656 Foreign currency translation adjustment 1,071,621 1,071,621 1,071,621 Balance at March 31, 2023 1,114,623 $ 1,115 $ 17,946,175 $ 1,804,116 $ 16,796,529 $ (1,559,550 ) $ 34,988,384 $ 513,387 $ 35,501,771 Balance at September 30, 2023 1,173,867 $ 1,174 $ 18,088,056 $ 2,372,871 $ 18,703,996 $ (3,681,445 ) $ 35,484,652 $ 497,181 $ 35,981,833 Share-based compensation 240,000 240 1,009,596 1,009,836 1,009,836 Net loss (10,519 ) (10,519 ) (31,279 ) (41,798 ) Net income (loss) - (10,519 ) (10,519 ) (31,279 ) (41,798 ) Foreign currency translation adjustment 210,470 210,470 157,501 367,971 Balance at March 31, 2024 1,413,867 $ 1,414 $ 19,097,652 $ 2,372,871 $ 18,693,477 $ (3,470,975 ) $ 36,694,439 $ 623,403 $ 37,317,842 * Retroactively restated to reflect the Company’s 1-for-10 share consolidation effective on April 11, 2024. BON NATURAL LIFE LIMITED AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) For the six months ended March 31, 2024 2023 Cash flows from operating activities Net (loss) income $ (41,798 ) $ 2,102,656 Adjustments to reconcile net income to cash provided by operating activities Allowance for doubtful accounts 21,441 - Depreciation and amortization 686,038 282,888 Inventory reserve 58,349 105,314 Deferred income tax (11,345 ) (25,749 ) Amortization of operating lease right-of-use assets 115,882 114,179 Share-based compensation 1,009,836 35,000 Unrealized foreign currency exchange loss (gain) 2,747 (8,452 ) Changes in operating assets and liabilities: Accounts receivable (3,464,205 ) (2,198,450 ) Inventories (498,736 ) (124,601 ) Advance to suppliers, net (160,908 ) (3,353,433 ) Prepaid expenses and other current assets 801,781 (3,595,458 ) Accounts payable (135,111 ) 100,386 Operating lease liabilities (120,040 ) (115,170 ) Taxes payable (224,459 ) 386,510 Deferred revenue 391,057 781,183 Accrued expenses and other current liabilities (314,702 ) 3,335,205 Net cash used in operating activities (1,884,173 ) (2,177,992 ) Cash flows from investing activities Purchase of property and equipment (693 ) (15,131 ) Capital expenditures on construction-in-progress - (2,970 ) Net cash used in investing activities (693 ) (18,101 ) Cash flows from financing activities Net proceeds from issuance of ordinary shares - 2,200,000 Proceeds from short-term loans 3,619,267 259,767 Proceeds from long-term loans 854,514 - Repayment of short-term loans (1,534,052 ) (79,165 ) Repayment of long-term loans (508,629 ) (437,412 ) Proceeds from (repayment of) borrowings from related parties 80,752 (1,038 ) Repayment of capital lease - (27,236 ) Net cash provided by financing activities 2,511,853 1,914,916 Effect of changes of foreign exchange rates on cash (21,858 ) (17,412 ) Net increase (decrease) in cash 605,128 (298,589 ) Cash, beginning of period 112,751 840,861 Cash, end of period $ 717,879 $ 542,272 Supplemental disclosure of cash flow information Cash paid for interest expense $ 143,747 $ 178,557 Cash paid for income tax $ - $ 500,251 Supplemental disclosure of non-cash investing and financing activities Amortization of share-based compensation for initial public offering services $ 24,000 $ 35,000 Right-of-use assets obtained in exchange for operating lease obligations $ - $ 458,181

SCHEDULE OF SUBSIDIARIES COMPAN

SCHEDULE OF SUBSIDIARIES COMPANY (Details)	12 Months Ended
SCHEDULE OF SUBSIDIARIES COMPANY (Details)	Sep. 30, 2023	Mar. 29, 2023	Feb. 07, 2023	Mar. 11, 2020	Jan. 09, 2020	Sep. 16, 2019	Apr. 24, 2015
Date of Incorporation	Dec. 11, 2019
Bon Natural Life [Member]
Date of Incorporation	Dec. 11, 2019
Place of Incorporation	Cayman Islands
% of Ownership	100%
Principal activities	Investment holding
Bon Natural Life U S A [Member]
Date of Incorporation	Feb. 07, 2023
Place of Incorporation	U.S.A.
% of Ownership	100%
Principal activities	Investment holding
Tea Essence Limited [Member]
Date of Incorporation	Jan. 09, 2020
Place of Incorporation	Hong Kong
% of Ownership	100%		100%		100%
Principal activities	Investment holding
Xian Cmit [Member]
Date of Incorporation	Apr. 09, 2020
Place of Incorporation	Xi.an City, PRC
% of Ownership	100%
Principal activities	WFOE, Investment holding
Xian Youpincui [Member]
Date of Incorporation	Sep. 08, 2021
Place of Incorporation	Xi.an City, PRC
% of Ownership	100%
Principal activities	WFOE, Investment holding
Xian App Chem Bio Tech [Member]
Date of Incorporation	Apr. 23, 2006
Place of Incorporation	Xi’an City, PRC
% of Ownership	100%
Principal activities	General administration and sales of the Company’s products to customers
Xian Y H [Member]
Date of Incorporation	Sep. 15, 2009
Place of Incorporation	Xi’an City, PRC
% of Ownership	91%
Principal activities	Research and development of product
App Chem Health [Member]
Date of Incorporation	Apr. 17, 2006
Place of Incorporation	Tongchuan City, PRC
% of Ownership	100%	100%		100%
Principal activities	Registered owner of land with an area of 12,904.5 square meters, no other business activities
App Chem Agtech [Member]
Date of Incorporation	Apr. 19, 2013
Place of Incorporation	Dali County, PRC
% of Ownership	100%
Principal activities	Product manufacturing
App Chem Guangzhou [Member]
Date of Incorporation	Apr. 27, 2018
Place of Incorporation	Guangzhou City, PRC
% of Ownership	100%
Principal activities	Raw material purchase
Tongchuan D T [Member]
Date of Incorporation	May 22, 2017
Place of Incorporation	Tongchuan City, PRC
% of Ownership	100%
Principal activities	Product manufacturing
Xi'an DT [Member]
Date of Incorporation	Apr. 24, 2015
Place of Incorporation	Xi’an City, PRC
% of Ownership	75%						75%
Principal activities	Research and development of product
Tianjin YHX [Member]
Date of Incorporation	Sep. 16, 2019
Place of Incorporation	Tianjin City, PRC
% of Ownership	51%					51%
Principal activities	Raw material purchase
Gansu B M K [Member]
Date of Incorporation	Mar. 11, 2020
Place of Incorporation	Jiuquan City, PRC
% of Ownership	100%
Principal activities	Product manufacturing
Bozhou D T [Member]
Date of Incorporation	Mar. 09, 2023
Place of Incorporation	Bozhou City, PRC
% of Ownership	100%
Principal activities	Product manufacturing

ORGANIZATION AND BUSINESS DES_3

ORGANIZATION AND BUSINESS DESCRIPTION (Details Narrative) - USD ($)

6 Months Ended

12 Months Ended

Apr. 11, 2024

Mar. 09, 2024

Sep. 28, 2021

Jul. 02, 2021

Jun. 28, 2021

Jun. 17, 2020

Mar. 31, 2023

Sep. 30, 2023

Mar. 29, 2023

Feb. 07, 2023

Sep. 30, 2022

Sep. 27, 2021

Sep. 08, 2021

Mar. 11, 2020

Jan. 09, 2020

Dec. 11, 2019

Sep. 16, 2019

Apr. 24, 2015

Apr. 23, 2006

Entity date of incorporation

Dec. 11, 2019

Ordinary shares, par value

$ 0.001

$ 0.0001

Gross proceeds from issuance initial public offering and over-allotment shares

$ 2,220,000

$ 2,027,574

Reverse stock split, description

1-for-10

1-for10

1-for-3 shares

Xian App Chem Bio Tech [Member]

Variable interest entity ownership percentage

100%

IPO [Member]

Ordinary shares, shares issued

220,000

Ordinary shares, par value

$ 0.001

Shares issued, price per share

$ 50

Over-Allotment Option [Member]

Ordinary shares, shares issued

33,000

Ordinary shares, par value

$ 0.001

Shares issued, price per share

$ 50

Initial Public Offering And Over Allotment Option [Member]

Gross proceeds from issuance initial public offering and over-allotment shares

$ 12,650,000

Underwriting discounts and other related expenses

$ 11,300,000

Balikun [Member]

Disposal operation, assets

$ 1

Tea Essence Limited [Member]

Entity date of incorporation

Jan. 09, 2020

Equity ownership

100%

Xian App Chem [Member]

Equity ownership

100%

Xi'an DT [Member]

Entity date of incorporation

Apr. 24, 2015

Equity ownership

75%

Tianjin YHX [Member]

Entity date of incorporation

Sep. 16, 2019

Equity ownership

51%

App Chem Health [Member]

Entity date of incorporation

Apr. 17, 2006

Equity ownership

100%

Tianjin Yonghexiang Bio Tech Co Ltd [Member]

Equity ownership

100%

SCHEDULE OF SHORT-TERM INVESTME

SCHEDULE OF SHORT-TERM INVESTMENT (Details) - USD ($)	12 Months Ended
SCHEDULE OF SHORT-TERM INVESTMENT (Details) - USD ($)	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Beginning balance
Add: purchase wealth management financial products	67	$ 5,097,816	$ 2,159,920
Less: proceeds received upon maturity of short-term investments		(6,776,385)	(470,082)
Foreign currency translation adjustments	9,989
Ending balance of short-term investments	65
Short-Term Investments [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Beginning balance		1,703,314
Add: purchase wealth management financial products	65	5,097,816
Less: proceeds received upon maturity of short-term investments		(6,776,385)
Foreign currency translation adjustments		(24,745)
Ending balance of short-term investments	$ 65		$ 1,703,314

SCHEDULE OF USEFUL LIVES OF PRO

SCHEDULE OF USEFUL LIVES OF PROPERTY, PLANT AND EQUIPMENT (Details)	Sep. 30, 2023
Building [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	20 years
Machinery and Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	5 years
Machinery and Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	10 years
Automobiles [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	8 years
Office and Electric Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Office and Electric Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	5 years

SCHEDULE OF CURRENCY EXCHANGE R

SCHEDULE OF CURRENCY EXCHANGE RATES (Details)	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2021
Period-End Spot Rate [Member]
Debt Instrument [Line Items]
Exchange rate	1	1	1
Period-End Spot Rate [Member] \| RMB [Member]
Debt Instrument [Line Items]
Exchange rate	7.2960	7.1135	6.4580
Average Rate [Member]
Debt Instrument [Line Items]
Exchange rate	1	1	1
Average Rate [Member] \| RMB [Member]
Debt Instrument [Line Items]
Exchange rate	7.0533	6.5532	6.5095

SCHEDULE OF EARNINGS PER SHARE

SCHEDULE OF EARNINGS PER SHARE (Details) - USD ($)		6 Months Ended				12 Months Ended
SCHEDULE OF EARNINGS PER SHARE (Details) - USD ($)		Mar. 31, 2024		Mar. 31, 2023		Sep. 30, 2023		Sep. 30, 2022		Sep. 30, 2021
Accounting Policies [Abstract]
Net income attributable to ordinary shareholders		$ (10,519)		$ 2,119,760		$ 4,595,982		$ 6,237,488		$ 4,590,803
Weighted-average number of ordinary shares outstanding – basic		1,285,702	[1]	891,831	[1]	913,960	[2],[3]	836,077	[2],[3]	661,583	[2],[3]
Outstanding options	[2]					5,851		3,529		3,597
Outstanding warrants	[2]									5,444
Potentially dilutive shares from outstanding options and warrants	[2]					5,851		3,529		9,041
Weighted-average number of ordinary shares outstanding – diluted		1,285,702	[1]	897,924	[1]	919,811	[2],[3]	839,606	[2],[3]	670,624	[2],[3]
Earnings per share – basic		$ (0.03)	[1]	$ 2.36	[1]	$ 5.03	[2],[3]	$ 7.47	[2],[3]	$ 6.94	[2],[3]
Earnings per share – diluted		$ (0.03)	[1]	$ 2.34	[1]	$ 5	[2],[3]	$ 7.43	[2],[3]	$ 6.85	[2],[3]

[1]Retroactively restated to reflect the Company’s 1-for-10 1-for-10 1-for-10

SCHEDULE OF EARNINGS PER SHAR_2

SCHEDULE OF EARNINGS PER SHARE (Details) (Parenthetical)	Apr. 11, 2024	Mar. 09, 2024	Jun. 17, 2020
Accounting Policies [Abstract]
Reverse stock split, description	1-for-10	1-for10	1-for-3 shares

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)						1 Months Ended				6 Months Ended		12 Months Ended
		Apr. 11, 2024	Mar. 09, 2024	May 10, 2021 USD ($) ft²	Jun. 17, 2020	Aug. 31, 2023 shares	Jul. 31, 2022 shares	Jun. 30, 2022 shares	Jun. 30, 2021 shares	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Sep. 30, 2023 USD ($) shares	Sep. 30, 2022 USD ($) shares	Sep. 30, 2021 USD ($) shares	Sep. 30, 2011 USD ($)	Oct. 01, 2020 USD ($)
Uncollectable account receivable written-off														$ 99,528
Allowance for uncollectable balances												13,004	13,337	14,691
Allowance for doubtful accounts
Inventory reserve												1,079	6,869
Short term investments													20,343	565
Estimated useful lives of intangible assets												50 years
Payments to acquire property, plant, and equipment										693	15,131	$ 61,906	27,695	51,878
Land acquired \| ft²				8.2
Impairment of long-lived assets												0	0
Operating lease right of use assets										199,679		312,067	546,690			$ 200,000
Operating lease liabilities												319,017	557,384			$ 200,000
Deferred revenue										497,937		106,514	188,745	1,096,101
Deferred revenue, revenue recognized												133,533	1,080,178	403,399
Research and development expense										890,384	129,995	298,469	424,558	249,050
Government subsidies										$ 61,081	$ 11,916	$ 25,415	1,306,627	449,972
Value added tax rate description												17% (starting from May 1, 2018, VAT rate was lowered to 16%, and starting from April 1, 2019, VAT rate was further lowered to 13%)
Employee defined cost												$ 93,190	$ 80,150	$ 54,189
Grant stock option directors to purchase, shares \| shares	[1]											3,750	5,204
Reverse stock split, description		1-for-10	1-for10		1-for-3 shares
Antidilutive shares \| shares	[2]											5,851	3,529	9,041
Option Shares [Member]
Antidilutive shares \| shares												5,851	3,529	3,600
Underwriter Warrants [Member]
Antidilutive shares \| shares														10,120
Third Party Consultants [Member]
Number of ordianary shares \| shares												57,000	63,333
Director [Member]
Grant stock option directors to purchase, shares \| shares						3,750	2,960	2,244	3,600
VAT [Member]
Income tax payable												$ 1,338,800
CHINA
Income tax payable												1,041,862
Tongchuan CIP Project [Member]
Payments to acquire property, plant, and equipment															$ 200,000
Yumen CIP Project [Member]
Payments to acquire property, plant, and equipment				$ 300,000
Other Income [Member]
Short term investments													$ 20,343	$ 565
Selling and Marketing Expense [Member]
Advertising expenses												$ 11,344	$ 41,578	$ 25,397
Xi'an DT [Member]
Non-controlling interests rate												25%
Tianjin YHX [Member]
Non-controlling interests rate												49%	49%

[1]Retroactively restated to reflect the Company’s 1-for-10 1-for-10

LIQUIDITY (Details Narrative)

LIQUIDITY (Details Narrative) - USD ($)			1 Months Ended	6 Months Ended		12 Months Ended
LIQUIDITY (Details Narrative) - USD ($)	Jan. 17, 2022	Jun. 30, 2021	Jan. 31, 2023	Mar. 31, 2024	Mar. 31, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]
Construction in progress gross						$ 5,000,000
Unpaid tax liabilities						2,700,000
Proceeds from initial public offering	$ 2,000,000	$ 11,300,000			$ 2,200,000	2,027,544		$ 11,271,480
Cash				717,879		112,751	840,861
Accounts receivable related parties current				8,108,271		$ 4,602,466	6,784,307
Accounts receivable percentage						75.80%
Short-term bank loans				4,617,414		$ 2,509,890	2,424,587
Long-term bank loans current				473,111		419,610	2,135,979
Long-term bank loans non-current				$ 1,176,624		871,368	$ 189,813
Proceeds from issuance of private placement			$ 2,000,000
Unused lines of Credit [Member]
Defined Benefit Plan Disclosure [Line Items]
Unused line of credit						1,700,000
PRC Banks [Member]
Defined Benefit Plan Disclosure [Line Items]
Loans Payables						3,800,000
Short-term bank loans						2,500,000
Long-term bank loans current						400,000
Long-term bank loans non-current						900,000
PRC Banks and Financial Institutions [Member]
Defined Benefit Plan Disclosure [Line Items]
Lines of credit									$ 1,700,000
Related Party [Member]
Defined Benefit Plan Disclosure [Line Items]
Accounts receivable related parties current						$ 3,500,000

SCHEDULE OF ACCOUNTS RECEIVABLE

SCHEDULE OF ACCOUNTS RECEIVABLE, NET (Details) - USD ($)	Mar. 31, 2024	Sep. 30, 2023	Sep. 30, 2022
Credit Loss [Abstract]
Accounts receivable		$ 4,615,470	$ 6,797,644
Less: allowance for doubtful accounts		(13,004)	(13,337)
Accounts receivable, net	$ 8,108,271	$ 4,602,466	$ 6,784,307

SCHEDULE OF ACCOUNTS RECEIVAB_2

SCHEDULE OF ACCOUNTS RECEIVABLE AND SUBSEQUENT COLLECTION BY AGING BUCKET (Details) - USD ($)	Mar. 31, 2024	Sep. 30, 2023	Sep. 30, 2022
Total gross accounts receivable		$ 4,615,470
Allowance for doubtful accounts		(13,004)	$ (13,337)
Accounts Receivable, net	$ 8,108,271	4,602,466	$ 6,784,307
Subsequent Collection [Member]
Total gross accounts receivable		$ 3,487,207
Percentage of subsequent collection		75.80%
Accounts Receivable, net		$ 3,487,207
% of account receivable subsequent collection		75.80%
Less than 3 Months [Member]
Total gross accounts receivable		$ 4,603,299
Less than 3 Months [Member] \| Subsequent Collection [Member]
Total gross accounts receivable		$ 3,487,207
Percentage of subsequent collection		75.80%
From 4 to 6 Months [Member]
Total gross accounts receivable
From 4 to 6 Months [Member] \| Subsequent Collection [Member]
Total gross accounts receivable
From 7 to 9 Months [Member]
Total gross accounts receivable
From 7 to 9 Months [Member] \| Subsequent Collection [Member]
Total gross accounts receivable
From 10 to 12 Months [Member]
Total gross accounts receivable
From 10 to 12 Months [Member] \| Subsequent Collection [Member]
Total gross accounts receivable
Over 1 Year [Member]
Total gross accounts receivable		12,171
Over 1 Year [Member] \| Subsequent Collection [Member]
Total gross accounts receivable

SCHEDULE OF ALLOWANCE FOR DOUBT

SCHEDULE OF ALLOWANCE FOR DOUBTFUL ACCOUNTS (Details) - USD ($)	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Credit Loss [Abstract]
Beginning balance	$ 13,337	$ 14,691
Additions
Write-off uncollectible balance
Foreign currency translation adjustments	(334)	(1,354)
Ending balance	$ 13,004	$ 13,337

ACCOUNTS RECEIVABLE, NET (Detai

ACCOUNTS RECEIVABLE, NET (Details Narrative) - USD ($)	12 Months Ended
ACCOUNTS RECEIVABLE, NET (Details Narrative) - USD ($)	Sep. 30, 2023	Mar. 31, 2024	Sep. 30, 2022
Product Information [Line Items]
Accounts receivable, net	$ 4,602,466	$ 8,108,271	$ 6,784,307
Account receivable, percentage	75.80%
Accounts Receivable [Member]
Product Information [Line Items]
Accounts receivable, net	$ 3,500,000
Account receivable, percentage	75.80%

SCHEDULE OF INVENTORIES (Detail

SCHEDULE OF INVENTORIES (Details) - USD ($)	Mar. 31, 2024	Sep. 30, 2023	Sep. 30, 2022
Inventory Disclosure [Abstract]
Raw materials		$ 12,715	$ 677,042
Finished goods		975,651	1,051,947
Inventory valuation allowance		(1,079)	(6,869)
Total inventory, net	$ 1,437,180	$ 987,287	$ 1,722,120

SCHEDULE OF ADVANCES TO SUPPLIE

SCHEDULE OF ADVANCES TO SUPPLIERS (Details) - USD ($)	Mar. 31, 2024	Sep. 30, 2023	Sep. 30, 2022
Advances To Suppliers Net
Raw materials purchase		$ 6,406,488	$ 3,654,520
Less: allowance for doubtful accounts
Advances to suppliers, net	$ 15,414,883	$ 15,117,191	$ 4,091,990

ADVANCES TO SUPPLIERS, NET (Det

ADVANCES TO SUPPLIERS, NET (Details Narrative) $ in Millions	12 Months Ended
	Sep. 30, 2023 USD ($)
Defined Benefit Plan Disclosure [Line Items]
Prepaid inventory, percentage	18.70%
Related Party [Member]
Defined Benefit Plan Disclosure [Line Items]
Due from related parties current	$ 2.8

ACQUISITION DEPOSIT (Details Na

ACQUISITION DEPOSIT (Details Narrative) - USD ($)	12 Months Ended
ACQUISITION DEPOSIT (Details Narrative) - USD ($)	Sep. 30, 2023	Mar. 31, 2024	Sep. 30, 2022	Sep. 30, 2021	Jul. 06, 2021
Business Acquisition [Line Items]
Business combination, consideration transferred	$ 30,000
Acquisition deposit	1,000,000	$ 1,000,000	$ 1,000,000
The consulting firm Global Capital LP [Member]
Business Acquisition [Line Items]
Deposit assets				$ 1,000,000	$ 1,500,000
Acquisition deposit	$ 1,500,000

SCHEDULE OF PROPERTY, PLANT, AN

SCHEDULE OF PROPERTY, PLANT, AND EQUIPMENT (Details) - USD ($)		Mar. 31, 2024	Sep. 30, 2023	Sep. 30, 2022
Property, Plant and Equipment [Line Items]
Subtotal			$ 23,622,010	$ 23,310,525
Less: accumulated depreciation			(2,557,967)	(1,686,088)
Property, plant and equipment, net		$ 20,613,211	21,064,043	21,624,437
Building [Member]
Property, Plant and Equipment [Line Items]
Subtotal			11,621,665	967,530
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Subtotal			6,207,931	1,866,760
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Subtotal			210,201	201,537
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Subtotal	[1]		$ 5,582,213	$ 20,274,698

[1]Construction-in-progress (“CIP”) represents direct costs of construction incurred for the Company’s manufacturing facilities. On August 16, 2017, the Company’s subsidiary, Xi’an App-Chem Bio (Tech) Co.,Ltd. started to construct a new manufacturing plant in Tongchuan City (“Tongchuan Project”), Shaanxi Province, with total budget of RMB 95.0 13.4 114.0 16.0 10,678,336 4,305,847

SCHEDULE OF PROPERTY, PLANT, _2

SCHEDULE OF PROPERTY, PLANT, AND EQUIPMENT (Details) (Parenthetical) - Sep. 30, 2023 ¥ in Millions	USD ($)	CNY (¥)
Property, Plant and Equipment [Line Items]
Future minimum capital expenditures on construction in progress	$ 16,000,000	¥ 114
Bulidings And Machinaery [Member]
Property, Plant and Equipment [Line Items]
Construction in progress	10,678,336
Equipment And Furniture [Member]
Property, Plant and Equipment [Line Items]
Construction in progress	4,305,847
Xian App Chem Bio Tech Co Ltd [Member]
Property, Plant and Equipment [Line Items]
Construction in progress	$ 13,400,000	¥ 95

SCHEDULE OF FUTURE MINIMUM CAPI

SCHEDULE OF FUTURE MINIMUM CAPITAL EXPENDITURES ON THE CONSTRUCTION-IN-PROGRESS (Details) - Yumen CIP Project [Member]	Sep. 30, 2023 USD ($)
Property, Plant and Equipment [Line Items]
Total	$ 5,000,000
2024
2025
2026

PROPERTY, PLANT AND EQUIPMENT_3

PROPERTY, PLANT AND EQUIPMENT, NET (Details Narrative) ¥ in Thousands		12 Months Ended
		Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2023 CNY (¥)	May 10, 2021 USD ($)	May 10, 2021 CNY (¥)
Property, Plant and Equipment [Line Items]
Depreciation		$ 945,507	$ 210,916	$ 219,906
Future minimum capital expenditures on construction in progress		16,000,000			¥ 114,000
Property plant and equipment gross		23,622,010	23,310,525
Tongchuan & Yumen CIP Project [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment gross		5,600,000
Future minimum capital expenditures on construction in progress next twelve months		5,000,000
Yumen CIP Project [Member]
Property, Plant and Equipment [Line Items]
Future minimum capital expenditures on construction in progress						$ 5,600,000	¥ 200,000
Future minimum capital expenditures on construction in progress next twelve months		5,000,000
Yumen CIP Project [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Future minimum capital expenditures on construction in progress \| ¥							¥ 40,000
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment gross	[1]	5,582,213	$ 20,274,698
Addition construction in progress		6,700,000
Equipment [Member]
Property, Plant and Equipment [Line Items]
Addition construction in progress		$ 1,900,000

[1]Construction-in-progress (“CIP”) represents direct costs of construction incurred for the Company’s manufacturing facilities. On August 16, 2017, the Company’s subsidiary, Xi’an App-Chem Bio (Tech) Co.,Ltd. started to construct a new manufacturing plant in Tongchuan City (“Tongchuan Project”), Shaanxi Province, with total budget of RMB 95.0 13.4 114.0 16.0 10,678,336 4,305,847

SCHEDULE OF INTANGIBLE ASSETS (

SCHEDULE OF INTANGIBLE ASSETS (Details) - USD ($)	Sep. 30, 2023	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Land use rights	$ 1,067,134	$ 430,985
Less: accumulated amortization	(71,907)	(64,818)
Land use rights, net	$ 995,227	$ 366,167

SCHEDULE OF AMORTIZATION EXPENS

SCHEDULE OF AMORTIZATION EXPENSES (Details) - USD ($)	Mar. 31, 2024	Sep. 30, 2023	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
2024		$ 21,649
2025		21,649
2026		21,649
2027		21,649
2028		21,649
Thereafter		886,982
Total	$ 992,544	$ 995,227	$ 366,167

INTANGIBLE ASSETS, NET (Details

INTANGIBLE ASSETS, NET (Details Narrative) - USD ($)	12 Months Ended
INTANGIBLE ASSETS, NET (Details Narrative) - USD ($)	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 9,010	$ 7,610	$ 8,641

SCHEDULE OF SHORT-TERM LOANS (D

SCHEDULE OF SHORT-TERM LOANS (Details) - USD ($)	Mar. 31, 2024	Sep. 30, 2023	Sep. 30, 2022
Short-Term Debt [Line Items]
Total short-term loans	$ 4,617,414	$ 2,509,890	$ 2,424,587
Xian Xinchang Micro Lending Co Ltd [Member]
Short-Term Debt [Line Items]
Total short-term loans		42,785	34,765
China Construction Bank One [Member]
Short-Term Debt [Line Items]
Total short-term loans		1,370,614	1,405,777
Shanghai Pudong Development Bank [Member]
Short-Term Debt [Line Items]
Total short-term loans		137,061	140,578
China Construction Bank Two [Member]
Short-Term Debt [Line Items]
Total short-term loans		822,368	843,467
Beijing Bank [Member]
Short-Term Debt [Line Items]
Total short-term loans		$ 137,061

SCHEDULE OF LONG -TERM LOANS (D

SCHEDULE OF LONG -TERM LOANS (Details) - USD ($)	Mar. 31, 2024	Sep. 30, 2023	Sep. 30, 2022
Debt Instrument [Line Items]
Total		$ 1,290,978	$ 2,325,792
Less: current portion of long-term loans	$ (473,111)	(419,610)	(2,135,979)
Total long-term loans	$ 1,176,624	871,368	189,813
Xian High Tech Emerging Industry Investment Fund Partnership [Member]
Debt Instrument [Line Items]
Total		44,747	1,082,449
We Bank Co Ltd [Member]
Debt Instrument [Line Items]
Total		209,133	262,813
China Resources Shenzhen International Investment Trust One [Member]
Debt Instrument [Line Items]
Total		22,844	179,237
Huaxia Bank [Member]
Debt Instrument [Line Items]
Total		603,070	590,426
Qishang Bank [Member]
Debt Instrument [Line Items]
Total		$ 411,184	$ 210,867

DEBT (Details Narrative)

DEBT (Details Narrative)																								1 Months Ended		6 Months Ended		12 Months Ended
DEBT (Details Narrative)	Sep. 15, 2023 USD ($)	Aug. 23, 2023 USD ($)	May 15, 2023 USD ($)	May 11, 2023 USD ($)	Mar. 14, 2023 USD ($)	Jan. 16, 2023 USD ($)	Jan. 12, 2023 USD ($)	Dec. 30, 2022 USD ($)	Sep. 30, 2022 CNY (¥)	Sep. 29, 2022 USD ($)	Jun. 23, 2022 USD ($)	May 18, 2022 USD ($)	Mar. 14, 2022 USD ($)	Mar. 01, 2022 USD ($)	Feb. 11, 2022 USD ($)	Feb. 10, 2022 USD ($)	Jan. 13, 2022 USD ($)	Jan. 10, 2022 USD ($)	Jan. 10, 2022 USD ($)	Jun. 20, 2021 USD ($)	Jun. 20, 2021 USD ($)	Apr. 16, 2020 USD ($)	Jun. 26, 2017 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2022 CNY (¥)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2023 CNY (¥)	Sep. 15, 2023 CNY (¥)	Aug. 23, 2023 CNY (¥)	Aug. 22, 2023 USD ($)	Aug. 22, 2023 CNY (¥)	May 30, 2023 USD ($)	May 30, 2023 CNY (¥)	May 15, 2023 CNY (¥)	May 11, 2023 CNY (¥)	Mar. 14, 2023 CNY (¥)	Jan. 16, 2023 CNY (¥)	Jan. 12, 2023 CNY (¥)	Dec. 31, 2022	Dec. 30, 2022 CNY (¥)	Sep. 30, 2022 CNY (¥)	Jun. 23, 2022 CNY (¥)	May 18, 2022 CNY (¥)	Mar. 14, 2022 CNY (¥)	Mar. 01, 2022 CNY (¥)	Feb. 11, 2022 CNY (¥)	Feb. 10, 2022 CNY (¥)	Jan. 13, 2022 CNY (¥)	Jan. 10, 2022 CNY (¥)	Dec. 06, 2021 USD ($)	Dec. 06, 2021 CNY (¥)	Jul. 07, 2021 USD ($)	Jul. 07, 2021 CNY (¥)	Jun. 20, 2021 CNY (¥)	Dec. 15, 2020 USD ($)	Dec. 15, 2020 CNY (¥)	Dec. 10, 2020 USD ($)	Dec. 10, 2020 CNY (¥)	Apr. 16, 2020 CNY (¥)	Apr. 03, 2020 USD ($)	Apr. 03, 2020 CNY (¥)	Jun. 26, 2017 CNY (¥)
Short-Term Debt [Line Items]
Short-term bank loans																								$ 2,424,587		$ 4,617,414		$ 2,509,890	$ 2,424,587
Long term debt																								2,325,792				1,290,978	2,325,792
Repayment of long term debt																										$ 508,629	$ 437,412	2,143,046	637,147	$ 2,522,101
Interest Expense, Operating and Nonoperating																												$ 238,224	446,884	$ 417,266
Beijing Bank [Member]
Short-Term Debt [Line Items]
% of Ownership				100%							100%																												100%							100%
Spd Bank [Member]
Short-Term Debt [Line Items]
Line of credit, collateral						A third-party Xi’an Financial Guarantee Co., Ltd. provided guarantee to this loan and the Company paid $15,260 for the guarantee service. In addition, the Company pledged its 100% ownership interest in App-Chem Health and certain free patent owned by the Company as collateral to guarantee this loan													A third-party Xi’an Financial Guarantee Co., Ltd. provided guarantee to this loan and the Company paid $15,260 for the guarantee service. In addition, the Company pledged its 100% ownership interest in App-Chem Health and certain free patent owned by the Company as collateral to guarantee this loan
Line of credit remaining borrowing capacity																		$ 700,000	$ 700,000																																		¥ 5,000,000
Spd Bank [Member]
Short-Term Debt [Line Items]
Debt maturity date																		Jan. 10, 2023
Line of credit, maximum borrowing capacity						$ 1,400,000												$ 1,400,000	$ 1,400,000																						¥ 10,000,000												¥ 10,000,000	$ 2,100,000	¥ 15,000,000
Line of credit interest rate						4.30%												5%	5%																						4.30%												5%
Huaxia Bank [Member]
Short-Term Debt [Line Items]
Debt maturity date																						Apr. 16, 2023
Interest rate																						6.60%																																									6.60%
Line of credit, maximum borrowing capacity																																				$ 274,123	¥ 2,000,000																											$ 2,100,000	¥ 15,000,000
Huaxia Bank [Member] \| One Year With 9% [Member]
Short-Term Debt [Line Items]
Line of credit, maximum borrowing capacity																																																																$ 400,000	¥ 3,000,000
Line of credit interest rate																																																																9%	9%
Huaxia Bank [Member] \| Three Year With 6.6% [Member]
Short-Term Debt [Line Items]
Line of credit, maximum borrowing capacity																																																																$ 1,700,000	¥ 12,000,000
Line of credit interest rate																																																																6.60%	6.60%
Huaxia Bank [Member] \| Five Point Zero Percentage [Member]
Short-Term Debt [Line Items]
Line of credit interest rate																																				5%	5%
Huaxia Bank [Member]
Short-Term Debt [Line Items]
Line of credit, maximum borrowing capacity																																				$ 328,947	¥ 2,400,000
Huaxia Bank [Member] \| Six Point Five Percentage [Member]
Short-Term Debt [Line Items]
Line of credit interest rate																																				6.50%	6.50%
Loan Agreement [Member]
Short-Term Debt [Line Items]
Interest rate																																											3.95%
Loan Agreement [Member] \| Beijing Bank [Member]
Short-Term Debt [Line Items]
Short-term bank loans				$ 800,000							$ 800,000																												¥ 6,000,000							¥ 6,000,000
Debt maturity date				May 10, 2024							Jun. 22, 2023
Interest rate				5.17%							5.22%																												5.17%							5.22%
Loan Agreement [Member] \| Xian High Tech Emerging Industry Investment Fund Partnership [Member]
Short-Term Debt [Line Items]
Debt maturity date, description																							as working capital for three years, with maturity date on June 25, 2020					The Company has negotiated with the Lender to extend the loan repayment date to December 25, 2022 in accordance with a COVID-19 relief notice issued by local government, with adjusted interest rate of 4.75% per annum during the period from June 26, 2020 to June 25, 2021, and 5.225% per annum during the period from June 26, 2021 to December 31, 2023
Debt maturity date							Jan. 20, 2025						Mar. 20, 2024								Jun. 20, 2023		Jun. 25, 2020
Interest rate																							3.80%																																											3.80%
Long term debt																							$ 1,200,000																																											¥ 8,000,000
Repayment of long term debt									¥ 7,300,000	$ 1,100,000
Loan Agreement [Member] \| Xian Xinchang Micro Lending Co Ltd [Member]
Short-Term Debt [Line Items]
Debt instrument face amount										$ 50,000																																			¥ 300,000
Loan Agreement [Member] \| We Bank Co Ltd [Member]
Short-Term Debt [Line Items]
Debt maturity date, description	as working capital for 24 months, with maturity date on September 15, 2025	as working capital for 24 months, with maturity date on August 20, 2025														as working capital for two years, with maturity date on February 12, 2024
Interest rate	14.76%	14.76%														8.10%																14.76%	14.76%																		8.10%
Long term debt	$ 3,701	$ 68,531														$ 212,808																¥ 27,000	¥ 500,000																		¥ 1,510,000
Loan Agreement [Member] \| China Resources Shenzhen International Investment Trust One [Member]
Short-Term Debt [Line Items]
Debt maturity date, description														as working capital for 24 months, with maturity date on February 20, 2024	as working capital for two years, with maturity date on February 12, 2024
Interest rate														16.20%	12.60%																																		16.20%	12.60%
Long term debt														$ 99,576	$ 79,661																																		¥ 700,000	¥ 566,667
Loan Agreement [Member] \| China Construction Bank One [Member]
Short-Term Debt [Line Items]
Short-term bank loans								$ 42,785									$ 34,765																											¥ 312,159								¥ 247,300
Debt maturity date, description								as working capital for one year, with maturity date on December 30, 2023									as working capital for one year, with maturity date on January 13, 2023
Debt maturity date								Dec. 30, 2023									Jan. 13, 2023
Interest rate																	3.8525%																																			3.8525%
Loan Agreement [Member] \| China Construction Bank Two [Member]
Short-Term Debt [Line Items]
Short-term bank loans			$ 137,061		$ 137,061							$ 140,578																										¥ 1,000,000		¥ 1,000,000							¥ 1,000,000
Debt maturity date, description			as working capital for one year, with maturity date on May 15, 2024		as working capital for one year, with maturity date on March 13, 2024							as working capital for one year, with maturity date on May 18, 2023
Debt maturity date			May 15, 2024									May 18, 2023
Interest rate			3.80%		3.70%							3.96%																										3.80%		3.70%							3.96%
Loan Agreement [Member] \| We Bank Co Ltd [Member]
Short-Term Debt [Line Items]
Debt maturity date, description							as working capital for 24 months, with maturity date on January 20, 2025						as working capital for 24 months, with maturity date on March 20, 2024							as working capital for 24 months, with maturity date on June 20, 2023
Interest rate							13.77%						15.39%							14.40%	14.40%																					13.77%						15.39%										14.40%
Long term debt	$ 34,265	$ 34,265					$ 20,559						$ 12,652			$ 85,435				$ 96,005	$ 96,005											¥ 13,500	¥ 250,000									¥ 150,000						¥ 90,000			¥ 623,333							¥ 620,000
Loan Agreement [Member] \| China Resources Shenzhen International Investment Trust One [Member]
Short-Term Debt [Line Items]
Long term debt															$ 22,844																																			¥ 166,667
Loan Agreement [Member] \| Huaxia Bank [Member]
Short-Term Debt [Line Items]
Debt maturity date, description																						as working capital for three years, with the interest rate of 6.6% per annum and maturity date on April 16, 2023
Line of credit, maximum borrowing capacity																												$ 27,412			¥ 200,000																									$ 400,000	¥ 3,000,000
Line of credit interest rate																																																								8.50%	8.50%
Long term debt																						$ 300,000																																									¥ 2,000,000
Loan Agreement [Member] \| Huaxia Bank [Member]
Short-Term Debt [Line Items]
Line of credit, maximum borrowing capacity																												27,412			200,000
Loan Agreement [Member] \| Qishang Bank [Member]
Short-Term Debt [Line Items]
Interest rate																																																											6.65%	6.65%
Long term debt																																																											$ 400,000	¥ 3,000,000	$ 1,800,000	¥ 13,000,000
Debt instrument face amount																								210,867					$ 210,867																¥ 1,500,000
Repayment of debt																								$ 210,867	¥ 1,500,000
Working Capital Loan [Member] \| Qishang Bank [Member]
Short-Term Debt [Line Items]
Interest rate																																		5.80%	5.80%
Long term debt																																		$ 411,184	¥ 3,000,000
Debt instrument face amount																												$ 137,061			¥ 1,000,000

SCHEDULE OF DUE FROM TO RELATED

SCHEDULE OF DUE FROM TO RELATED PARTIES (Details) - USD ($)	12 Months Ended
SCHEDULE OF DUE FROM TO RELATED PARTIES (Details) - USD ($)	Sep. 30, 2023	Sep. 30, 2022
Wenhu Guo [Member]
Related Party Transaction [Line Items]
Related party relationship description	Senior Management of the Company	Senior Management of the Company
Due to related parties	$ 6,168	$ 3,290
Yongwei Hu [Member]
Related Party Transaction [Line Items]
Related party relationship description	Chief Executive Officer and Controlling shareholder of the Company	Chief Executive Officer and Controlling shareholder of the Company
Due to related parties	$ 3,392	$ 6,583
Jing Liu [Member]
Related Party Transaction [Line Items]
Related party relationship description	Wife of the controlling shareholder	Wife of the controlling shareholder
Due to related parties	$ 18,925
Sheying Wang [Member]
Related Party Transaction [Line Items]
Related party relationship description	Senior Management of the Company	Senior Management of the Company
Due to related parties	$ 3,016	$ 3,093
Yuantao Wang [Member]
Related Party Transaction [Line Items]
Related party relationship description	49% shareholder of Tianjin YHX	49% shareholder of Tianjin YHX
Due to related parties	$ 23,650	$ 59,870
Shujie Mou [Member]
Related Party Transaction [Line Items]
Related party relationship description	Senior Management of Tianjin YHX	Senior Management of Tianjin YHX
Due to related parties	$ 28,229
Related Party [Member]
Related Party Transaction [Line Items]
Due to related parties	83,380	72,836
Due from related parties	$ 8,411
Wenjuan Chen [Member]
Related Party Transaction [Line Items]
Related party relationship description	Senior Management of the Company	Senior Management of the Company
Due from related parties	$ 8,358
Lu Jiang [Member]
Related Party Transaction [Line Items]
Related party relationship description	Employee of the Company	Employee of the Company
Due from related parties	$ 53

SCHEDULE OF EFFECTIVE TAX RATE

SCHEDULE OF EFFECTIVE TAX RATE (Details)	12 Months Ended
SCHEDULE OF EFFECTIVE TAX RATE (Details)	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2021
Income Tax Disclosure [Abstract]
PRC statutory income tax rate	25%	25%	25%
Effect of income tax holiday	(12.00%)	(11.00%)	(9.50%)
Permanent difference	0.60%	0.10%	0.50%
Research and development deduction	(5.40%)	(4.20%)	(3.40%)
Change in valuation allowance	9.80%	7%	2.50%
Effective tax rate	18%	16.90%	15.10%

SCHEDULE OF COMPONENTS OF THE I

SCHEDULE OF COMPONENTS OF THE INCOME TAX PROVISION (BENEFIT) (Details) - USD ($)	6 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2021
Current tax provision			$ 1,000,887	$ 1,248,013	$ 791,822
Deferred tax provision (benefit)	$ (11,345)	$ (25,749)	1,411	19,012	29,109
Income tax provision	$ 90,734	$ 510,077	1,002,298	1,267,025	820,931
CAYMAN ISLANDS
Current tax provision
Deferred tax provision (benefit)
HONG KONG
Current tax provision
Deferred tax provision (benefit)
CHINA
Current tax provision			1,000,887	1,248,013	791,822
Deferred tax provision (benefit)			$ 1,411	$ 19,012	$ 29,109

SCHEDULE OF DEFERRED TAX ASSETS

SCHEDULE OF DEFERRED TAX ASSETS (Details) - USD ($)	Sep. 30, 2023	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Deferred tax assets derived from allowance for doubtful accounts and net operating losses (“NOL”)	$ 300,846	$ 257,947
Less: valuation allowance	(299,511)	(255,179)
Deferred tax assets	$ 1,335	$ 2,768

SCHEDULE OF TAXED PAYABLE (Deta

SCHEDULE OF TAXED PAYABLE (Details) - USD ($)	Mar. 31, 2024	Sep. 30, 2023	Sep. 30, 2022
Total taxes payable	$ 2,523,163	$ 2,718,687	$ 1,239,708
Income Tax [Member]
Total taxes payable		1,296,206	576,098
Value Added Tax VAT [Member]
Total taxes payable		1,338,800	572,306
Other Taxes [Member]
Total taxes payable		$ 83,681	$ 91,304

TAXES (Details Narrative)

TAXES (Details Narrative) - USD ($)				6 Months Ended		12 Months Ended
TAXES (Details Narrative) - USD ($)	Apr. 11, 2024	Mar. 09, 2024	Jun. 17, 2020	Mar. 31, 2024	Mar. 31, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2021
Provision for income taxes				$ 90,734	$ 510,077	$ 1,002,298	$ 1,267,025	$ 820,931
Income tax description						Under this preferential tax treatment, HNTEs are entitled to an income tax rate of 15%, subject to a requirement that they re-apply for their HNTE status every three years. The Company’s subsidiary, Xi’an App-Chem was approved as a HNTE and is entitled to a reduced income tax rate of 15% beginning October 18, 2017, which is valid for three years. In December 2020, Xi’an App-Chem successfully renewed its HNTE Certificate with local government and will continue to enjoy the reduced income tax rate of 15% for another three years by December 1, 2023.
Changes in income taxes						$ 667,258	$ 825,899	$ 514,327
Benefit of tax holidays on net income per share						$ 1.50	$ 1	$ 0.80
Reverse stock split, description	1-for-10	1-for10	1-for-3 shares
Deferred tax assets valuation allowance						$ 299,511	$ 255,179
Accrued tax liabilities				$ 2,523,163		$ 2,718,687	1,239,708
High And New Technology Enterprises [Member]
Effective income tax rate						15%
CHINA
Effective income tax rate						25%
Accrued tax liabilities						$ 2,700,000	1,200,000
Tea Essence Limited [Member] \| HONG KONG
Effective income tax rate						16.50%
Provision for income taxes						$ 0	$ 0	$ 0

SCHEDULE OF BALANCE SHEET INFOR

SCHEDULE OF BALANCE SHEET INFORMATION RELATED OPERATING LEASE (Details) - USD ($)	Mar. 31, 2024	Sep. 30, 2023	Sep. 30, 2022	Oct. 01, 2020
Operating Lease
Operating lease right of use assets		$ 312,067	$ 546,690
Total operating lease assets	$ 199,679	312,067	546,690	$ 200,000
Current operating lease liabilities	202,552	227,297	230,182
Non-current operating lease liabilities		91,720	327,202
Total operating lease obligations		$ 319,017	$ 557,384	$ 200,000

SCHEDULE OF WEIGHTED-AVERAGE OF

SCHEDULE OF WEIGHTED-AVERAGE OF OPERATING LEASE (Details)	Sep. 30, 2023
Operating Lease
Weighted-average remaining lease term	1 year 4 months 24 days
Weighted-average discount rate	4.75%

SCHEDULE OF MATURITY OF OPERATI

SCHEDULE OF MATURITY OF OPERATING LEASE LIABILITIES (Details) - USD ($)	Sep. 30, 2023	Sep. 30, 2022	Oct. 01, 2020
Operating Lease
2024	$ 236,512
2025	92,580
2026
Total lease payments	329,091
Less: imputed interest	(10,074)
Total operating lease obligations	$ 319,017	$ 557,384	$ 200,000

OPERATING LEASE (Details Narrat

OPERATING LEASE (Details Narrative) - Three Years Lease Agreement [Member] - USD ($)		12 Months Ended
	Apr. 06, 2022	Sep. 30, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating lease, description	the Company entered into a three-years lease agreement with Xi’an Droplets Culture Ltd. to rent an office space of 1163 square meters at Xi’an City, PRC.
Lease terms	3 years
Lease rental payment		$ 97,351

SCHEDULE OF WARRANT ACTIVITY (D

SCHEDULE OF WARRANT ACTIVITY (Details) - Warrant [Member] - shares		12 Months Ended
		Sep. 30, 2023	Sep. 30, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Warrants, Outstanding, Beginning	[1]		10,120
Weighted Average Exercise Price, Outstanding, Ending	[1]		50
Number of Warrants, Granted	[1]	275,000
Weighted Average Exercise Price, Granted	[1]	8.80
Number of Warrants, Forfeited	[1]
Weighted Average Exercise Price, Forfeited	[1]
Number of Warrants, Exercised	[1]		(10,120)
Weighted Average Exercise Price, Exercised	[1]		50
Weighted Average Remaining Contractual Term, Outstanding, Ending		1 year 3 months 18 days	1 year 3 months 18 days
Number of Warrants, Outstanding, Ending	[1]	275,000
Weighted Average Exercise Price, Outstanding, Ending	[1]	8.80
Number of Warrants, Exercisable, Ending	[1]	275,000
Weighted Average Exercise Price, Exercisable, Ending	[1]	8.80
Weighted Average Remaining Contractual Term, Exercisable, Ending		1 year 3 months 18 days

[1]Retroactively restated to reflect the Company’s 1-for-10

SCHEDULE OF WARRANT ACTIVITY _2

SCHEDULE OF WARRANT ACTIVITY (Details) (Parenthetical)	Apr. 11, 2024	Mar. 09, 2024	Jun. 17, 2020
Equity [Abstract]
Reverse stock split, description	1-for-10	1-for10	1-for-3 shares

SCHEDULE OF NON-CONTROLLING INT

SCHEDULE OF NON-CONTROLLING INTEREST (Details) - USD ($)	6 Months Ended		12 Months Ended
SCHEDULE OF NON-CONTROLLING INTEREST (Details) - USD ($)	Mar. 31, 2024	Mar. 31, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2021
Non-controlling interest, beginning	$ 497,181	$ 530,492	$ 530,492
Net loss attributable to non-controlling interest	(31,279)	(17,104)	(43,300)	$ 4,936	$ 18,650
Foreign currency translation adjustment			9,989
Non-controlling interest, ending	623,403		497,181	530,492
Xi'an DT [Member]
Non-controlling interest, beginning	468,427	472,812	472,812
Net loss attributable to non-controlling interest			(5,700)
Foreign currency translation adjustment			1,315
Non-controlling interest, ending			468,427	472,812
Tianjin YHX [Member]
Non-controlling interest, beginning	$ 28,754	$ 57,680	57,680
Net loss attributable to non-controlling interest			(37,600)
Foreign currency translation adjustment			8,674
Non-controlling interest, ending			$ 28,754	$ 57,680

SHAREHOLDERS_ EQUITY (Details N

SHAREHOLDERS’ EQUITY (Details Narrative) - USD ($)											6 Months Ended		12 Months Ended
SHAREHOLDERS’ EQUITY (Details Narrative) - USD ($)		Apr. 11, 2024	Mar. 09, 2024	Jan. 17, 2023	Jul. 13, 2022	Oct. 01, 2021	Jul. 02, 2021	Jun. 28, 2021	Jun. 28, 2021	Jun. 17, 2020	Mar. 31, 2023		Sep. 30, 2023		Sep. 30, 2022	Mar. 31, 2024	Jun. 24, 2020	Dec. 11, 2019
Subsidiary, Sale of Stock [Line Items]
Ordinary shares, shares authorized			270,000,000										270,000,000		270,000,000			500,000,000
Ordinary stock, par value			$ 0.001										$ 0.001		$ 0.001			$ 0.0001
Preferred stock, shares authorized			30,000,000
Reverse stock split, description		1-for-10	1-for10							1-for-3 shares
Redemption of shares during period										1,033,333
Ordinary shares, shares issued				275,000						1,550,000			1,173,867		839,623		516,667
Ordinary shares, shares outstanding				275,000									1,173,867		839,623	1,413,867	516,667
Total subscription proceeds											$ 2,220,000		$ 2,027,574
Commission paid				$ 168,532
Reverse split, shares issued													1,173,867		839,623
Reverse split, shares outstanding													1,173,867		839,623
Statutory surplus reserve, description													Appropriations to the statutory surplus reserve are required to be at least 10% of the after-tax net income determined in accordance with PRC GAAP until the reserve is equal to 50% of the entity’s registered capital.
Restricted cash equivalents													$ 2,372,871		$ 1,804,116
Restricted net assets													$ 20,556,190		$ 17,516,406
Xi'an DT [Member]
Subsidiary, Sale of Stock [Line Items]
Non-controlling interests rate													25%
Tianjin YHX [Member]
Subsidiary, Sale of Stock [Line Items]
Non-controlling interests rate													49%		49%
Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Ordinary shares, issued											275,000	[1]	275,000	[2]
Total subscription proceeds											$ 275		$ 275
Common Stock [Member] \| Five Investors [Member]
Subsidiary, Sale of Stock [Line Items]
Ordinary shares, issued				275,000
Subscription price per share				$ 8
Total subscription proceeds				$ 2,200,000
Common Stock [Member] \| Investor [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant exercise price				$ 8.80
Exercisable term				24 months
Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants exercised	[3]														10,120
Exercisable term													1 year 3 months 18 days
IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Ordinary stock, par value								$ 0.001	$ 0.001
Ordinary shares, shares issued					3,185	2,038
Warrants terms								5 years	5 years
Warrant exercise price								$ 50	$ 50
Ordinary shares, issued									220,000
Subscription price per share								$ 50	$ 50
Ordinary shares sold percentage								4%
Offering price								$ 50	$ 50
Warrants exercisable year								5 years
IPO [Member] \| Maximum [Member]
Subsidiary, Sale of Stock [Line Items]
Number of warrants issued								10,120	10,120
IPO [Member] \| Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Ordinary stock, par value								$ 0.001	$ 0.001
Sale of stock, shares issued								220,000
Sale of stock, price per share								$ 50	$ 50
IPO [Member] \| Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants exercised					5,060	5,060		5,060
Over-Allotment Option [Member]
Subsidiary, Sale of Stock [Line Items]
Ordinary stock, par value							$ 0.001
Ordinary shares, issued							33,000
Subscription price per share							$ 50
Over-Allotment Option [Member] \| Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Ordinary stock, par value							$ 0.001
Sale of stock, shares issued							33,000
Sale of stock, price per share							$ 50

[1]Retroactively restated to reflect the Company’s 1-for-10 share consolidation effective on April 11, 2024.[2]Retroactively restated to reflect the Company’s 1-for-10 1-for-10

SHARE-BASED COMPENSATION AWARDS

SHARE-BASED COMPENSATION AWARDS MEASURED AT GRANT DATE FAIR VALUE (Details) - $ / shares	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Exercise price	$ 0.10	$ 0.10
Expected term (years)	1 year	1 year
Expected stock price volatility	158.20%	114.10%
Risk-free rate of interest	4.35%	4.35%
Expected dividend rate	0%	0%

SUMMARY OF STOCK OPTION (Detail

SUMMARY OF STOCK OPTION (Details) - $ / shares		12 Months Ended
SUMMARY OF STOCK OPTION (Details) - $ / shares		Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2021
Share-Based Payment Arrangement [Abstract]
Number of options, Outstanding, Beginning	[1]	7,404	3,600
Weighted Average Exercise Price, Outstanding, Beginning	[1]	$ 0.10	$ 0.10
Weighted Average Remaining Contractual Term, Outstanding, Ending		9 years 10 days	9 years 3 months	9 years 9 months
Number of options, Granted	[1]	3,750	5,204
Weighted Average Exercise Price, Granted	[1]	$ 0.10	$ 0.10
Weighted Average Remaining Contractual Term, Granted		10 years	10 years
Number of options, Forfeited	[1]
Weighted Average Exercise Price, Forfeited	[1]
Number of options, Exercised	[1]	(2,244)	(1,400)
Weighted Average Exercise Price, Exercised	[1]	$ 0.10	$ 0.10
Number of options, Outstanding, Ending	[1]	8,910	7,404	3,600
Weighted Average Exercise Price, Outstanding, Ending	[1]	$ 0.10	$ 0.10	$ 0.10
Number of options, Exercisable	[1]	5,785
Weighted Average Exercise Price, Exercisable	[1]	$ 0.10
Weighted Average Remaining Contractual Term, Exercisable		8 years 6 months 3 days

[1]Retroactively restated to reflect the Company’s 1-for-10

SUMMARY OF STOCK OPTION (Deta_2

SUMMARY OF STOCK OPTION (Details) (Parenthetical)	Apr. 11, 2024	Mar. 09, 2024	Jun. 17, 2020
Share-Based Payment Arrangement [Abstract]
Reverse stock split, description	1-for-10	1-for10	1-for-3 shares

SHARE-BASED COMPENSATION (Detai

SHARE-BASED COMPENSATION (Details Narrative) - USD ($)

6 Months Ended

12 Months Ended

Aug. 03, 2023

Aug. 02, 2023

May 31, 2023

Jul. 01, 2022

Jun. 28, 2022

Jun. 23, 2021

Jun. 23, 2020

Mar. 31, 2024

Mar. 31, 2023

Sep. 30, 2023

Sep. 30, 2022

Sep. 30, 2021

Mar. 09, 2024

Dec. 11, 2019

Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]

Number of stock issued, services, value

$ 218,304

Share based compensation

$ 422,221

Common stock, par value

$ 0.001

$ 0.0001

Exercise price

[1]

$ 0.10

Number of shares granted options to purchase

[1]

5,785

Share based compensation

$ 1,009,836

$ 35,000

$ 218,304

General and Administrative Expense [Member]

Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]

Share based compensation

$ 131,092

$ 170,883

$ 44,910

Consultant [Member]

Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]

Number of stock issued, services, shares

63,333

Number of stock issued, services, value

$ 633,333

Consultant [Member] | Acquisition Consulting Services [Member]

Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]

Number of stock issued, services, shares

50,000

Number of stock issued, services, value

$ 174,904

Consultant [Member] | Legal Advice Services [Member]

Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]

Number of stock issued, services, shares

7,000

Number of stock issued, services, value

$ 43,400

Director [Member]

Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]

Number of shares granted

3,600

Common stock, par value

$ 0.001

Exercise price

$ 0.10

Fair value of shares granted

$ 179,640

Independent Director [Member]

Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]

Exercise price

$ 0.10

Number of shares granted options to purchase

2,960

2,244

Two Independent Director [Member]

Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]

Exercise price

$ 0.10

Number of shares granted options to purchase

1,875

[1]Retroactively restated to reflect the Company’s 1-for-10

CONCENTRATION (Details Narrativ

CONCENTRATION (Details Narrative) - USD ($)	12 Months Ended
CONCENTRATION (Details Narrative) - USD ($)	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2021
Concentration Risk [Line Items]
Cash deposit at financial instutions	$ 106,719	$ 835,462
Revenue from Contract with Customer Benchmark [Member] \| Customer Concentration Risk [Member] \| Customer One [Member]
Concentration Risk [Line Items]
Concentration risk percentage	41.80%	35.50%	35.50%
Revenue from Contract with Customer Benchmark [Member] \| Customer Concentration Risk [Member] \| Customer Two [Member]
Concentration Risk [Line Items]
Concentration risk percentage	29.50%	23.90%	26.10%
Revenue from Contract with Customer Benchmark [Member] \| Customer Concentration Risk [Member] \| Customer Three [Member]
Concentration Risk [Line Items]
Concentration risk percentage	11.10%	15.40%
Accounts Receivable [Member] \| Customer Concentration Risk [Member] \| Customer One [Member]
Concentration Risk [Line Items]
Concentration risk percentage	42.70%	38.10%
Accounts Receivable [Member] \| Customer Concentration Risk [Member] \| Customer Two [Member]
Concentration Risk [Line Items]
Concentration risk percentage	24.70%	33.70%
Accounts Receivable [Member] \| Customer Concentration Risk [Member] \| Customer Three [Member]
Concentration Risk [Line Items]
Concentration risk percentage	13.20%	17.90%
Purchase [Member] \| Supplier Concentration Risk [Member] \| Supplier One [Member]
Concentration Risk [Line Items]
Concentration risk percentage	41.80%	24.60%	30.10%
Purchase [Member] \| Supplier Concentration Risk [Member] \| Supplier Two [Member]
Concentration Risk [Line Items]
Concentration risk percentage	29.50%	15%	13.40%
Purchase [Member] \| Supplier Concentration Risk [Member] \| Supplier Three [Member]
Concentration Risk [Line Items]
Concentration risk percentage	11.10%	11.90%
Purchase [Member] \| Supplier Concentration Risk [Member] \| Supplier Four [Member]
Concentration Risk [Line Items]
Concentration risk percentage		10.70%

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) $ in Millions	Sep. 30, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Future minimum capital expenditures on construction in progress	$ 5

SCHEDULE OF SEGMENT REPORTING R

SCHEDULE OF SEGMENT REPORTING REVENUE BY REGION (Details) - USD ($)	6 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	$ 10,183,553	$ 14,149,967	$ 29,522,353	$ 29,908,561	$ 25,494,564
CHINA
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue			28,971,115	28,756,333	23,704,259
Overseas [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue			$ 551,238	$ 1,152,228	$ 1,790,305

SCHEDULE OF SEGMENT REPORTING_2

SCHEDULE OF SEGMENT REPORTING REVENUE BY PRODUCT CATEGORIES (Details) - USD ($)	6 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2021
Revenue from External Customer [Line Items]
Total revenue	$ 10,183,553	$ 14,149,967	$ 29,522,353	$ 29,908,561	$ 25,494,564
Fragrance Compounds [Member]
Revenue from External Customer [Line Items]
Total revenue			14,315,810	13,710,556	12,744,029
Health Supplements (Solid Drinks) [Member]
Revenue from External Customer [Line Items]
Total revenue			8,704,468	7,145,708	6,655,982
Bioactive Food Ingredients [Member]
Revenue from External Customer [Line Items]
Total revenue			$ 6,502,075	$ 9,052,297	$ 6,094,553

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) ¥ in Millions, $ in Millions	Apr. 11, 2024	Mar. 09, 2024	Oct. 02, 2023 shares	Jan. 16, 2023 USD ($)	Jun. 17, 2020	Jan. 16, 2023 CNY (¥)	Dec. 31, 2022
Subsequent Event [Line Items]
Reverse stock split, description	1-for-10	1-for10			1-for-3 shares
Subsequent Event [Member] \| Employees and Consultants [Member] \| 2022 Equity Incentive Plan [Member]
Subsequent Event [Line Items]
Issuance of ordinary shares in a private placement, shares			155,000
Subsequent Event [Member] \| Chief Executive Officer [Member] \| 2022 Equity Incentive Plan [Member]
Subsequent Event [Line Items]
Number of shares issued as compensation			10,000
Loan Agreement [Member]
Subsequent Event [Line Items]
Interest rate							3.95%
Loan Agreement [Member] \| Shanghai Pudong Development Bank [Member]
Subsequent Event [Line Items]
Borrowings				$ 0.5		¥ 4
Interest rate				3.90%		3.90%
Debt maturity date				Jan. 21, 2025

SCHEDULE OF PARENT COMPANY BALA

SCHEDULE OF PARENT COMPANY BALANCE SHEETS (Details) - USD ($)		Mar. 31, 2024		Sep. 30, 2023		Mar. 31, 2023	Sep. 30, 2022		Sep. 30, 2021	Oct. 01, 2020	Sep. 30, 2020
CURRENT ASSETS
Cash		$ 717,879		$ 112,751			$ 840,861
Acquisition deposit		1,000,000		1,000,000			1,000,000
Prepaid expenses and other current assets				2,355,293			277,509
TOTAL CURRENT ASSETS		28,261,819		24,183,464			14,716,787
NON-CURRENT ASSETS
TOTAL ASSETS		50,079,925		46,556,136			37,256,849
LIABILITIES AND EQUITY
LIABILITIES		12,762,083		10,574,303			7,164,353
COMMITMENTS AND CONTINGENCIES
EQUITY
Ordinary shares, ($0.001 par value, 270,000,000 shares authorized, 1,413,867 and 1,173,867 shares issued and outstanding as of March 31, 2024 and September 30, 2023, respectively)		1,414	[1]	1,174	[1],[2]		840	[2]
Retained earnings		18,693,477		18,703,996			14,676,769
Accumulated other comprehensive income		(3,470,975)		(3,681,445)			(2,631,171)
TOTAL BON NATURAL LIFE LIMITED SHAREHOLDERS’ EQUITY		36,694,439		35,484,652			29,562,004
TOTAL LIABILITIES AND EQUITY		50,079,925		46,556,136			37,256,849
Short-term investments				65
Accounts receivable, net		8,108,271		4,602,466			6,784,307
Inventories, net		1,437,180		987,287			1,722,120
Advance to suppliers, net		15,414,883		15,117,191			4,091,990
Property, plant and equipment, net		20,613,211		21,064,043			21,624,437
Intangible assets, net		992,544		995,227			366,167
Right-of-use lease assets, net		199,679		312,067			546,690			$ 200,000
Deferred tax assets, net		12,672		1,335			2,768
CURRENT LIABILITIES
Short-term loans		4,617,414		2,509,890			2,424,587
Current portion of long-term loans		473,111		419,610			2,135,979
Accounts payable		1,284,816		1,404,937			214,585
Due to related parties		188,640		83,380
Taxes payable		2,523,163		2,718,687			1,239,708
Deferred revenue		497,937		106,514			188,745		$ 1,096,101
Accrued expenses and other current liabilities		1,797,826		2,140,900			114,431
Operating lease liability, current		202,552		227,297			230,182
TOTAL CURRENT LIABILITIES		11,585,459		9,611,215			6,647,338
Long-term loans		1,176,624		871,368			189,813
Operating lease liability, noncurrent				91,720			327,202
TOTAL LIABILITIES		12,762,083		10,574,303			7,164,353
Additional paid in capital		19,097,652		18,088,056			15,711,450
Statutory reserve		2,372,871		2,372,871			1,804,116
Non-controlling interest		623,403		497,181			530,492
TOTAL SHAREHOLDERS’ EQUITY		37,317,842		35,981,833		$ 35,501,771	30,092,496		$ 26,534,749		$ 11,023,009
Related Party [Member]
CURRENT ASSETS
Due from subsidiaries				8,411
EQUITY
Accounts receivable, net				3,500,000
Prepaid expenses and other current assets		$ 1,583,606		2,363,704
CURRENT LIABILITIES
Due to related parties				83,380			72,836
Parent Company [Member]
CURRENT ASSETS
Cash				867			1,221
Acquisition deposit				1,000,000			1,000,000
Prepaid expenses and other current assets				(22,920)			42,749
TOTAL CURRENT ASSETS				11,976,504			10,446,495
NON-CURRENT ASSETS
Investment in subsidiaries				23,507,948			19,115,509
TOTAL ASSETS				35,484,452			29,562,004
LIABILITIES AND EQUITY
LIABILITIES
COMMITMENTS AND CONTINGENCIES
EQUITY
Ordinary shares, ($0.001 par value, 270,000,000 shares authorized, 1,413,867 and 1,173,867 shares issued and outstanding as of March 31, 2024 and September 30, 2023, respectively)	[3]			1,117			840
Additional paid-in capital				18,182,202			15,711,450
Retained earnings				20,980,978			16,480,885
Accumulated other comprehensive income				(3,679,845)			(2,631,171)
TOTAL BON NATURAL LIFE LIMITED SHAREHOLDERS’ EQUITY				35,484,452			29,562,004
TOTAL LIABILITIES AND EQUITY				35,484,452			29,562,004
CURRENT LIABILITIES
TOTAL LIABILITIES
Parent Company [Member] \| Related Party [Member]
CURRENT ASSETS
Due from subsidiaries				$ 10,998,557			$ 9,402,525

[1]Retroactively restated to reflect the Company’s 1-for-10 1-for-10 1-for-10

SCHEDULE OF PARENT COMPANY BA_2

SCHEDULE OF PARENT COMPANY BALANCE SHEETS (Details) (Parenthetical) - $ / shares	Apr. 11, 2024	Mar. 09, 2024	Jun. 17, 2020	Mar. 31, 2024	Sep. 30, 2023	Jan. 17, 2023	Sep. 30, 2022	Jun. 24, 2020	Dec. 11, 2019
Condensed Financial Statements, Captions [Line Items]
Ordinary shares, par value		$ 0.001			$ 0.001		$ 0.001		$ 0.0001
Common Stock, Shares Authorized		270,000,000			270,000,000		270,000,000		500,000,000
Common Stock, Shares, Issued			1,550,000		1,173,867	275,000	839,623	516,667
Common Stock, Shares, Outstanding				1,413,867	1,173,867	275,000	839,623	516,667
Reverse stock split, description	1-for-10	1-for10	1-for-3 shares
Parent Company [Member]
Condensed Financial Statements, Captions [Line Items]
Ordinary shares, par value					$ 0.001		$ 0.001
Common Stock, Shares Authorized					270,000,000		270,000,000
Common Stock, Shares, Issued					1,173,867		839,623
Common Stock, Shares, Outstanding					1,173,867		839,623

SCHEDULE OF PARENT COMPANY STAT

SCHEDULE OF PARENT COMPANY STATEMENTS OF COMPREHENSIVE INCOME (Details) - USD ($)	6 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2021
Condensed Financial Statements, Captions [Line Items]
General and administrative expenses	$ (1,890,452)	$ (1,465,955)	$ (2,329,198)	$ (2,239,967)	$ (1,323,726)
Interest income	161	8,732	9,419	1,392	3,207
NET INCOME ATTRIBUTABLE TO BON NATURAL LIFE LIMITED	(10,519)	2,119,760	4,595,982	6,237,488	4,590,803
Foreign currency translation adjustment	367,971	1,071,621	(1,040,285)	(2,855,701)	612,806
COMPREHENSIVE INCOME ATTRIBUTABLE TO BON NATURAL LIFE LIMITED	$ 199,951	$ 3,191,381	3,502,408	3,389,032	5,219,776
Parent Company [Member]
Condensed Financial Statements, Captions [Line Items]
General and administrative expenses			(846,930)	(972,215)	(68,722)
Interest income			2	5	13
Equity in earnings of subsidiaries and VIEs			5,442,910	7,209,698	4,659,512
NET INCOME ATTRIBUTABLE TO BON NATURAL LIFE LIMITED			4,595,982	6,237,488	4,590,803
Foreign currency translation adjustment			(1,050,274)	(2,853,392)	610,323
COMPREHENSIVE INCOME ATTRIBUTABLE TO BON NATURAL LIFE LIMITED			$ 3,545,708	$ 3,384,096	$ 5,201,126

SCHEDULE OF PARENT COMPANY ST_2

SCHEDULE OF PARENT COMPANY STATEMENTS OF CASH FLOWS (Details) - USD ($)			6 Months Ended		12 Months Ended
	Jan. 17, 2022	Jun. 30, 2021	Mar. 31, 2024	Mar. 31, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities
Net income			$ (10,519)	$ 2,119,760	$ 4,595,982	$ 6,237,488	$ 4,590,803
Adjustments to reconcile net income to cash provided by operating activities
Amortization of stock-based compensation					131,092	170,883	44,910
Changes in operating assets and liabilities:
Advance to suppliers, net			(160,908)	(3,353,433)	(11,510,450)	(407,022)	(399,262)
Prepaid expenses and other current assets			801,781	(3,595,458)	(2,170,541)	(265,446)	2,642
Net cash (used in) provided by operating activities			(1,884,173)	(2,177,992)	(651,912)	(187,121)	4,053,124
Cash flows from investing activities
Payment of acquisition deposit							(1,000,000)
Net cash used in investing activities			(693)	(18,101)	(1,185,665)	(3,055,651)	(7,443,745)
Cash flows from financing activities
Proceeds from exercise of stock options						140
Net cash provided by financing activities			2,511,853	1,914,916	1,155,247	2,261,516	5,352,682
Net (loss) income			(41,798)	2,102,656	4,552,682	6,242,424	4,609,453
Allowance for doubtful accounts			21,441			116	2,948
Depreciation and amortization			686,038	282,888	954,517	218,526	228,547
Inventory reserve			58,349	105,314	(5,812)	(138,354)	(312,532)
Deferred income tax			(11,345)	(25,749)	1,411	19,012	29,109
Amortization of operating lease right-of-use assets			115,882	114,179	228,552	150,978	58,147
Share-based compensation			1,009,836	35,000	218,304
Unrealized foreign currency exchange loss (gain)			2,747	(8,452)	(35,008)	(18,831)	45,124
Accounts receivable			(3,464,205)	(2,198,450)	2,081,376	(1,300,942)	(89,543)
Inventories			(498,736)	(124,601)	721,371	(157,709)	(209,011)
Accounts payable			(135,111)	100,386	833,547	(141,927)	(969,414)
Operating lease liabilities			(120,040)	(115,170)	(232,147)	(147,812)	(49,648)
Taxes payable			(224,459)	386,510	1,561,946	(3,632,922)	410,716
Deferred revenue			391,057	781,183	(80,176)	(875,295)	684,030
Accrued expenses and other current liabilities			(314,702)	3,335,205	2,097,424	97,925	(33,092)
Purchase of property and equipment			(693)	(15,131)	(61,906)	(27,695)	(51,878)
Capital expenditures on construction-in-progress				(2,970)	(460,125)	(4,708,138)	(4,432,941)
Net proceeds from issuance of ordinary shares	$ 2,000,000	$ 11,300,000		2,200,000	2,027,544		11,271,480
Proceeds from short-term loans			3,619,267	259,767	2,879,809	2,631,890	1,257,225
Proceeds from long-term loans			854,514		1,132,803	578,343	1,245,871
Repayment of short-term loans			(1,534,052)	(79,165)	(2,728,836)	(40,780)	(2,563,433)
Repayment of long-term loans			(508,629)	(437,412)	(2,143,046)	(637,147)	(2,522,101)
Proceeds from (repayment of) borrowings from related parties			80,752	(1,038)	13,482	(96,969)	(2,262,378)
Repayment of capital lease				(27,236)
Effect of changes of foreign exchange rates on cash			(21,858)	(17,412)	(45,780)	(81,750)	(111,300)
Net (decrease) increase in cash			605,128	(298,589)	(728,110)	(1,063,006)	1,850,761
Cash, beginning of year			112,751	840,861	840,861	1,903,867	53,106
Cash, end of year			717,879	542,272	112,751	840,861	1,903,867
Supplemental disclosure of cash flow information
Cash paid for interest expense			143,747	178,557	238,224	446,884	417,266
Cash paid for income tax				500,251	478,683	2,290,393	2,411
Supplemental disclosure of non-cash investing and financing activities
Amortization of share-based compensation for initial public offering services			24,000	35,000			422,221
Right-of-use assets obtained in exchange for operating lease obligations				458,181		546,323	257,564
Parent Company [Member]
Cash flows from operating activities
Net income					4,595,982	6,237,488	4,590,803
Adjustments to reconcile net income to cash provided by operating activities
Equity in earnings of subsidiaries and VIEs					(5,442,910)	(7,209,698)	(4,659,512)
Amortization of stock-based compensation					131,092	170,883	44,910
Changes in operating assets and liabilities:
Advance to suppliers, net					(1,596,032)	597,475
Prepaid expenses and other current assets					65,669	(40,148)	(2,600)
Net cash (used in) provided by operating activities					(2,027,898)	(244,000)	(26,399)
Cash flows from investing activities
Payment of acquisition deposit							(1,000,000)
Net cash used in investing activities							(1,000,000)
Cash flows from financing activities
Net proceeds from issuance of ordinary shares					2,027,544		11,271,480
Proceeds from exercise of stock options						140
Cash lent to subsidiaries and VIE							(10,000,000)
Net cash provided by financing activities					2,027,544	140	1,271,480
CHANGES IN CASH					(354)	(243,860)	245,081
CASH beginning of year			$ 867	$ 1,221	1,221	245,081
CASH, end of year					$ 867	$ 1,221	$ 245,081

SCHEDULE OF PARENT COMPANY ST_3

SCHEDULE OF PARENT COMPANY STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (Details) - USD ($)	6 Months Ended				12 Months Ended
	Mar. 31, 2024		Mar. 31, 2023		Sep. 30, 2023		Sep. 30, 2022		Sep. 30, 2021
Condensed Financial Information Disclosure [Abstract]
REVENUE	$ 10,183,553		$ 14,149,967		$ 29,522,353		$ 29,908,561		$ 25,494,564
COST OF REVENUE	(7,215,116)		(9,432,619)		(20,682,326)		(20,484,996)		(18,382,637)
GROSS PROFIT	2,968,437		4,717,348		8,840,027		9,423,565		7,111,927
OPERATING EXPENSES
Selling expenses	(103,096)		(136,164)		(293,719)		(218,822)		(138,530)
General and administrative expenses	(1,890,452)		(1,465,955)		(2,329,198)		(2,239,967)		(1,323,726)
Research and development expenses	(890,384)		(129,995)		(298,469)		(424,558)		(249,050)
Total operating expenses	(2,883,932)		(1,732,114)		(2,921,386)		(2,883,347)		(1,711,306)
INCOME FROM OPERATIONS	84,505		2,985,234		5,918,641		6,540,218		5,400,621
OTHER INCOME (EXPENSES)
Interest income	161		8,732		9,419		1,392		3,207
Interest expense	(143,747)		(178,557)		(238,224)		(446,884)		(417,266)
Unrealized foreign transaction exchange loss (gain)	(2,747)		8,452		35,008		18,831		(45,124)
Government subsidies	61,081		11,916		25,415		1,306,627		449,972
Income from short-term investments							20,343		565
Other income (expenses)	49,683		(223,044)		(195,279)		68,922		38,409
Total other expenses, net	(35,569)		(372,501)		(363,661)		969,231		29,763
INCOME BEFORE INCOME TAX PROVISION	48,936		2,612,733		5,554,980		7,509,449		5,430,384
INCOME TAX PROVISION	(90,734)		(510,077)		(1,002,298)		(1,267,025)		(820,931)
NET INCOME	(41,798)		2,102,656		4,552,682		6,242,424		4,609,453
Less: net loss attributable to non-controlling interest	(31,279)		(17,104)		(43,300)		4,936		18,650
NET INCOME ATTRIBUTABLE TO BON NATURAL LIFE LIMITED	(10,519)		2,119,760		4,595,982		6,237,488		4,590,803
OTHER COMPREHENSIVE INCOME
Total foreign currency translation adjustment	367,971		1,071,621		(1,040,285)		(2,855,701)		612,806
TOTAL COMPREHENSIVE INCOME	326,173		3,174,277		3,512,397		3,386,723		5,222,259
Less: comprehensive loss attributable to non-controlling interest	126,222		(17,104)		9,989		(2,309)		2,483
COMPREHENSIVE INCOME ATTRIBUTABLE TO BON NATURAL LIFE LIMITED	$ 199,951		$ 3,191,381		$ 3,502,408		$ 3,389,032		$ 5,219,776
(LOSS) EARNINGS PER SHARE ATTRIBUTABLE TO BON NATURAL LIFE LIMITED
Basic	$ (0.03)	[1]	$ 2.36	[1]	$ 5.03	[2],[3]	$ 7.47	[2],[3]	$ 6.94	[2],[3]
Diluted	$ (0.03)	[1]	$ 2.34	[1]	$ 5	[2],[3]	$ 7.43	[2],[3]	$ 6.85	[2],[3]
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING
Basic	1,285,702	[1]	891,831	[1]	913,960	[2],[3]	836,077	[2],[3]	661,583	[2],[3]
Diluted	1,285,702	[1]	897,924	[1]	919,811	[2],[3]	839,606	[2],[3]	670,624	[2],[3]

[1]Retroactively restated to reflect the Company’s 1-for-10 1-for-10 1-for-10

SCHEDULE OF PARENT COMPANY ST_4

SCHEDULE OF PARENT COMPANY STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (Details) (Parenthetical)	Apr. 11, 2024	Mar. 09, 2024	Jun. 17, 2020
Condensed Financial Information Disclosure [Abstract]
Reverse stock split, description	1-for-10	1-for10	1-for-3 shares

SCHEDULE OF PARENT COMPANY ST_5

SCHEDULE OF PARENT COMPANY STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Details) - USD ($)		6 Months Ended				12 Months Ended
		Mar. 31, 2024		Mar. 31, 2023		Sep. 30, 2023		Sep. 30, 2022		Sep. 30, 2021
Balance		$ 35,981,833		$ 30,092,496		$ 30,092,496		$ 26,534,749		$ 11,023,009
Issuance of ordinary shares in a private placement, net				2,220,000		2,027,574
Share-based compensation		1,009,836		35,000
Net income (loss)		(41,798)		2,102,656		4,552,682		6,242,424		4,609,453
Foreign currency translation adjustment		367,971		1,071,621		(1,040,285)		(2,855,701)		612,806
Balance		37,317,842		35,501,771		35,981,833		30,092,496		26,534,749
Common Stock [Member]
Balance		$ 1,174		$ 840		$ 840		$ 833		$ 580
Balance, shares	[2]	1,173,867	[1]	839,623	[1]	839,623	[1]	833,000		580,000
Issuance of ordinary shares in a private placement, net				$ 275		$ 275
Issuance of ordinary shares in a private placement, shares				275,000	[1]	275,000	[2]
Share-based compensation		$ 240
Net income (loss)
Foreign currency translation adjustment
Balance		$ 1,414		$ 1,115		$ 1,174		$ 840		$ 833
Balance, shares		1,413,867	[1]	1,114,623	[1]	1,173,867	[1],[2]	839,623	[1],[2]	833,000	[2]
Share-based compensation, shares	[1]	240,000
Additional Paid-in Capital [Member]
Balance		$ 18,088,056		$ 15,711,450		$ 15,711,450		$ 15,540,433		$ 5,251,205
Issuance of ordinary shares in a private placement, net				2,199,725		2,027,269
Share-based compensation		1,009,596		35,000
Net income (loss)
Foreign currency translation adjustment
Balance		19,097,652		17,946,175		18,088,056		15,711,450		15,540,433
Statutory Reserve [Member]
Balance		2,372,871		1,804,116		1,804,116		1,050,721		579,922
Issuance of ordinary shares in a private placement, net
Net income (loss)
Foreign currency translation adjustment
Balance		2,372,871		1,804,116		2,372,871		1,804,116		1,050,721
Retained Earnings [Member]
Balance		18,703,996		14,676,769		14,676,769		9,192,676		5,072,672
Issuance of ordinary shares in a private placement, net
Net income (loss)		(10,519)		2,119,760		4,595,982		6,237,488		4,590,803
Foreign currency translation adjustment
Balance		18,693,477		16,796,529		18,703,996		14,676,769		9,192,676
AOCI Attributable to Parent [Member]
Balance		(3,681,445)		(2,631,171)		(2,631,171)		222,221		(388,102)
Issuance of ordinary shares in a private placement, net
Net income (loss)
Foreign currency translation adjustment		210,470		1,071,621		(1,050,274)		(2,853,392)		610,323
Balance		(3,470,975)		(1,559,550)		(3,681,445)		(2,631,171)		222,221
Total Shareholders Equity [Member]
Balance		35,484,652		29,562,004		29,562,004		26,006,884		10,516,277
Issuance of ordinary shares in a private placement, net				2,200,000		2,027,544
Share-based compensation		1,009,836		35,000
Net income (loss)		(10,519)		2,119,760		4,595,982		6,237,488		4,590,803
Foreign currency translation adjustment		210,470		1,071,621		(1,050,274)		(2,853,392)		610,323
Balance		36,694,439		34,988,384		35,484,652		29,562,004		26,006,884
Noncontrolling Interest [Member]
Balance		497,181		530,492		530,492		527,865		506,732
Issuance of ordinary shares in a private placement, net
Net income (loss)		(31,279)		(17,104)		(43,300)		4,936		18,650
Foreign currency translation adjustment		157,501				9,989		(2,309)		2,483
Balance		$ 623,403		$ 513,387		$ 497,181		$ 530,492		$ 527,865

[1]Retroactively restated to reflect the Company’s 1-for-10 share consolidation effective on April 11, 2024.[2]Retroactively restated to reflect the Company’s 1-for-10